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Cell volume regulation is a homeostatic imperative in the brain due to the 
restrictions of the skull. To counteract an osmolarity disturbance and restore 
normal cell volume, neural cells initiate volume regulatory mechanism by 
modifying the concentration of their intracellular inorganic and organic osmolytes. 
This dissertation illustrates the important ability of GPCRs to potentiate osmolyte 
efflux in response to hypo-osmotic stress.  
I discovered that the addition of sub-nanomolar concentrations of 
thrombin, mediated via the activation of PAR-1 receptor, can robustly enhance 
the release of the organic osmolyte taurine, through the volume sensitive organic 
osmolyte and anion channel (VSOAC) from neuro-tumor cells in response to 
hypo-osmotic stress. Biochemical and pharmacological studies demonstrated 
that both intracellular Ca2+ and PKC are required for receptor-mediated, but not 
basal (swelling-induced), taurine release. The results indicated that activation of 
PAR-1 receptors by thrombin lowers the threshold osmolarity or “set-point” for 
osmolyte efflux, thereby facilitating the ability of cells to respond to small 
reductions in osmolarity. Receptor activation (PAR-1 and mAChR) also 
enhanced the release of the inorganic osmolyte, Cl- (125I- used as a tracer). The 
kinetics and magnitude of 125I- release were greater than those of taurine. 
However, both osmolytes showed similar pharmacological profiles in response to 
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VSOAC inhibitors. Although receptor stimulated-taurine efflux was inhibited by 
depletion of intracellular Ca2+ and/or inhibition of PKC, 125I- efflux was either 
unaffected or less dependent upon these two parameters. This differential 
regulation of the osmolyte release suggests either the presence of separate but 
pharmacologically similar, efflux channels or, receptor-specific activation of 
distinct signal transduction pathways that differentially contribute to the release of 
taurine and 125I-, both of which are released through a common membrane 
channel. 
I also demonstrated that cholesterol depletion with methyl-ß-cyclodextrin 
synergistically potentiated receptor-mediated taurine release. This stimulatory 
effect was not due to disruption of lipid rafts or changes in receptor signaling. 
Experiments with cholesterol analogs provided evidence that the potentiation by 
cholesterol depletion resulted from changes in the biophysical properties (fluidity) 
of the membrane. Together, the findings described in this thesis provide new 
insight into mechanisms involved in the GPCR-regulation of osmolyte efflux 









Evolutionary Conservation of Cell Volume Regulation 
Cell volume regulation is a homeostatic trait conserved in essentially all 
species throughout evolution. Bacteria readily change their intracellular 
osmolarity in response to alterations in their environment. This ability makes 
them able to survive in a wide variety of habitats (Csonka, 1989). Due to the 
presence of a rigid cell wall, fungi, algae and plants are less susceptible to small 
osmolarity changes in their environment. This cell wall, therefore, prevents cell 
swelling but not shrinkage. Normally these cells maintain their shape by the 
osmotic balance between the cytosol and their environment (turgor) (Yoshiba et 
al., 1997; Johansson et al., 2000). The osmolarity of marine invertebrates is 
matched to the concentration of surrounding sea-water by adjusting the 
intracellular concentration of ions or organic osmolytes. In other multicellular 
organisms such as fish and mammals, cells are in contact with interstitial fluid 
and each individual cell contains a variety of plasma membrane transporters and 
channels to maintain homeostatic conditions. Animal cells have flexible but 
fragile membranes which require osmotic volume regulation to prevent them from 
collapse by shrinkage or lysis by swelling (Strange, 2004). 
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Although the process of cell volume regulation has been preserved 
throughout evolution, the cellular mechanisms and the osmolyte profiles involved 
vary considerably. Protozoa achieve osmoregulation predominantly through 
efflux of amino acids, of which alanine is quantitatively the most important. In 
contrast, efflux of inorganic anions is most important in mammalian cells, and the 
most abundant amino acid involved in cell volume regulation is usually taurine 
(Krogh, 1939; Yancey, 1982). The cellular response to osmotic stress ensures 
that the content of water inside the cell is maintained within a range that is 
compatible with biologic function.  
 Approximately 60% of body weight in man consists of water with two-
thirds being present inside cells and most of the remaining water comprising the 
interstitial fluid outside cells that forms the extracellular environment. In 
mammals, protection of cells against high osmolarities is especially required in 
the kidney, where osmolarities up to 1000 mOsM can develop during antiduresis 
(Hall et al., 1996; Schliess and Haussinger, 2002). In the brain, this homeostasis 
is absolutely critical due to the spatial constraints imposed by the skull. 
Expansion of intracranial tissue can cause constriction of small blood vessels, 
episodes of anoxia, ischemia, excitotoxicity and ultimately cell mortality.  
 
Osmoregulation  
The movement of water between aqueous solutions that are separated by 
a semi-permeable membrane is driven by differences in the concentration of 
solute particles (also referred to as osmolytes) on either side of the membrane, 
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with water flowing down its concentration gradient from the solution with a lower 
osmolyte concentration into the solution with a higher concentration. This 
process, referred to as osmosis, is of fundamental and universal significance to 
all biologic organisms as they utilize a semi-permeable membrane to separate 
the intracellular milieu from the extracellular environment. The osmotic flow of 
water occurs by passive diffusion across the lipid bilayer, however some cells 
may possess water-permeable protein channels called aquaporins to accelerate 
this water transport (Agre and Kozono, 2003; King et al., 2004). 
A multitude of factors challenge the constancy of cell volume. These 
include alterations in extracellular osmolarity, changes associated with cellular 
processes such as synthesis and breakdown of macromolecules, accumulation 
of metabolites, exocytosis and dissipation of ion gradients. A challenge to cell 
volume can only be accommodated if osmotic equilibrium across the cell 
membrane is maintained by cell volume regulatory mechanisms. Cell volume 
regulation is linked to many aspects of cell function, including glucose 
metabolism, pH regulation, cell excitability, protein function and cell survival. It is 
a universal feature for cell growth and division of all cells. 
There are two types of volume changes that activate osmoregulatory 
mechanisms; anisosmotic volume changes are induced by alterations in 
extracellular osmolarity, while isosmotic volume changes are brought about by 
alterations in intracellular solute content (Kimelberg, 1995). The focus of this 




Cell Volume Adaptation 
Under steady state conditions, the osmotic concentrations of cytoplasmic 
and extracellular fluid are in equilibrium. In the face of external or internal 
challenges, cells alter the concentration of osmolytes in order to reduce the 
difference in intracellular versus extracellular concentration, eliminating any 
change in intracellular water concentration and therefore a concomitant change 
in cell volume   occurs.  This flux of water either in or out of the cell results in cell 
swelling or cell shrinkage, respectively. If the cell volume in response to osmotic 
stress is not corrected, it may cause cell damage and loss of function. For 
example, cell swelling can inhibit glycolysis, stimulate glycine oxidation and 
glutamine breakdown and form NH4 and urea from amino acids while also 
decreasing the mRNA expression of principal enzymes involved in 
gluconeogenesis (Haussinger et al., 1994a). Therefore all cells have a 
mechanism for restoration of cell volume that is accomplished by the fast 
activation of potassium (K+), sodium (Na+) and chloride (Cl-) channels, 
exchangers and cotransporters. Cell swelling, due to reduction in extracellular 
tonicity triggers Regulatory Volume Decrease (RVD) and cell shrinkage, due to 
high extracellular tonicity results in Regulatory Volume Increase (RVI) (Figure 
1.1). 
 
Regulatory Volume Decrease (RVD) 
When cells are exposed to a decrease in osmolarity (hypotonic 
environment), there is an increase in cell volume or hypo-osmotic cell swelling. 
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This volume increase is transient and is followed by a regulatory volume 
decrease (RVD). RVD is an active process that involves the release of cations 
such as K+ and anions such as Cl- via activation of separate K+ and Cl- channels 
or by activation of the K-Cl cotransporter. In a few cell types, K+ and Cl- efflux is 
mediated by activation of K+/H+ and Cl-/HCO3- exchangers. As these electrolytes 
are released from the cell they bring with them obligated water in part by 
specialized water channels called aquaporins (For review, see Verkman and 
Mitra, 2000, Agre et al., 2002). This net flux helps the cell return to its original 
volume and establish a new osmotic equilibrium.  
Finally, osmotic cell swelling also induces a rapid release of organic 
osmolytes such as taurine, alanine, inositol through a yet unidentified volume 
sensitive organic osmolyte and anion channel (VSOAC) that primarily transports 
Cl-. Since loss of inorganic osmolytes such as K+ and Cl- can be potentially 
harmful on a long-term basis, release of these electrolytes reverses with time, 
whereas the release of organic osmolytes is more sustained (Olson, 1999). The 
efflux pattern of organic osmolytes also closely parallels the time course of the 
change in cell volume, in contrast to Cl- and K+ fluxes which are faster (Cl-) or 
slower (K+) than the change in cell volume (Pasantes-Morales, 1998) 
Downregulation of the mechanisms controlling synthesis and uptake of organic 
osmolytes also contributes to the loss of the solutes. In many cases, exposure of 
cells to hypotonic media has been shown to cause a regulation of the rates of 
both efflux and influx for a range of solutes. The net flux of organic osmolytes is 










Figure 1.1. Cell volume adaptation 
Under conditions of hyperosmotic-induced cell shrinkage, NaCl influx is effected 
via the Na+/H+ and Cl-/HCO3- antiporters or by operation of the Na+/K+/2Cl- 
symporter.  Organic osmolytes (e.g., taurine or inositol) are also transported into 
the cell via Na+-dependent carriers, which increase in number. During hypotonic-
induced cell swelling, KCl is extruded via separate K+ and Cl- channels (either 
Ca2+-activated or Ca2+-independent), a K+/Cl- symporter and K+/H+ and Cl-/HCO3- 
antiporters.  The efflux of organic osmolytes occurs via a channel that primarily 










The time or rate necessary to regain cell volume varies among different 
cell types. In cultured astrocytes, RVD occurs rapidly with a 70-80% recovery 
reached within a few minutes (Pasantes-Morales, 1996). In vivo, a decrement in 
brain sodium and chloride content can be measured within 30 minutes, whereas 
a decrement in potassium is slower, measurable only at 3 hours after the onset 
of cell swelling (Melton et al., 1987; Berl, 1990; Figure 1.2). The focus of my 
thesis will be on the process of RVD. 
 
Regulatory Volume Increase (RVI) 
Exposure of a cell to an increase in osmolarity (hypertonic environment) 
results in the osmotic efflux of water and a reduction in cell volume (i.e., cell 
shrinkage).  Cell shrinkage in response to a hyperosmotic challenge stimulates a 
net uptake of Na+, K+ and Cl- ions and osmotically obligated water leading to a 
restoration of "normal" cell volume, a process known as regulatory volume 
increase (RVI) (Cserr et al., 1991). RVI in a majority of cells involves the 
concomitant activation of Na+/H+ and Cl-/HCO3- exchanger as well as the Na+ K+ 
ATPase and Na+/K+/2Cl- (NKCC) cotransporter (O’Neill, 1999; Lang et al., 
1998c). Upregulation of NKCC cotransporter may also be essential during a long-
term hyperosmotic challenge (Bildin et al., 2000). Adaptation to hyperosmolarity 
is a relatively slow process and may take several hours since accumulation of 
organic osmolytes also involves an increased gene transcription, elevated mRNA 








Figure 1.2. Regulatory volume decrease (RVD) after hypotonic swelling in 
cortical neurons. (A) Time course of cell size change during exposure to 63.5% 
hypotonic solution monitored by both cross-sectional area (CSA) and the 
fluorescence intensity of intracellular calcein. (B) Effects of Cl- channel blocker, 







In the event that biochemical homeostasis is not restored, the resulting 
disequilibrium gives rise to a wide spectrum of deleterious effects on cell function 
and ultimately results in apoptotic cell death. 
  
Experimental measurement of cell volume 
 A variety of methods are available for measuring absolute and relative cell 
volume changes under experimental conditions including electronic sizing by 
Coulter-type impedence techniques, light scattering, ion-sensitive electrode and 
radioactive tracer methods. Microscopy methods such as calcein-AM 
fluorescence microscopy can measure the intensity of fluorescent probes trapped 
within the cell and reliably track swelling and shrinkage-induced volume 
perturbations as long as the probes are not sensitive to cellular parameters such 
as pH or calcium etc  (Parkerson and Sontheimer, 2003, 2004; Inoue et al., 
2005).  
 
Osmolyte Release: Inorganic and Organic Osmolytes 
Potassium conductance 
The intracellular and extracellular concentrations of K+ in cells are 140 mM 
and 5 mM respectively. Despite the identification of a large number of general K+ 
channels, very little is known about the K+ channels which respond to hypo-
osmotic swelling and their mechanism of regulation. Swelling activates at least 
two different types of K+ channels. In some cells, mainly epithelial cells, volume-
sensitive K+ channels (VSKC) are calcium-dependent and large conductance 
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(100 – 200 pS) channels. In other cell types, K+ channels are small channels with 
conductance of 20-30 pS, the majority of which are calcium-independent (For 
review, see Pasantes-Morales and Morales Mulia, 2000). The calcium-dependent 
K+ channels that are activated only by osmolarity show a pharmacological profile 
characterized by insensitivity to typical K+ channel blockers such as 
tetraethylammonium (TEA), quinidine, 4-aminopyridine and barium but sensitivity 
to clofilium (Ordaz et al., 2004b). Therefore depending on the cell type examined, 
volume regulatory K+ channels include Kv 1.3, Kv 1.5 (voltage-sensitive K 
channels), the mini K channels and members of the 4M two-pore family of 
channels (Deutsch and Chen, 1993; Pasantes-Morales and Morales-Mulia, 2000; 
Niemeyer et al., 2001a, b; Barfield et al., 2005). These K+ transport mechanisms 
activated by cell swelling are now also known to play an important role in 
initiating apoptosis (Trimarchi et al., 2002). Electroneutral K+ Cl- (KCC) symport 
activity is also known to be involved in RVD (Wehner et al., 2003; Shen et al., 
2004). 
The activation of K+ channels is effective for volume regulatory ion release 
only if the anion channels are operating in parallel, since prolonged release of K+ 
could lead to hyperexcitability of the cells without a significant regulatory volume 
decrease (Lang et al., 1998). 
 
Chloride conductance  
Chloride concentration inside cultured cells can reach ~40 mM and 
therefore chloride anion channels are found in nearly every cell type known 
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(Kettenmann, 1987). Cl- channels play a crucial role in controlling the ionic 
composition of the cytoplasm and the volume of cells. In addition to their pivotal 
role in cell volume regulation, they participate in a variety of functions including 
transport across epithelia, acidification of intracellular organelles, stabilization of 
cell membrane potential and glioma cell migration  (Nilius and Droogmans, 2003; 
Mcferrin and Sontheimer, 2006). These functions are performed in a close 
interplay with various ion transporters, including pumps, cotransporters and other 
ion channels (Jentsch et al., 2002).  
 
Volume Sensitive Organic osmolyte and Anion Channel (VSOAC) 
A robust chloride conductance is observed by whole-cell electrophysiology 
when a wide variety of cells are exposed to hypo-osmolar solutions (decrease in 
osmolarity). The channel exhibits the following characteristics (a) outward 
rectification with an intermediate unitary conductance of 40-78 pS (b) time- 
dependent inactivation at positive membrane potential above 60 mV and 
recovery from inactivation at negative potentials (c) a permeability sequence of 
SCN- > I- > Br- > Cl- > HCO3- >> taurine > gluconate > aspartate, corresponding 
to the Eisenmann’s sequence I and (d) requirement for ATP, but not its 
hydrolysis for its activation, since non-hydrolyzable analogs of ATP, ADP or GTP 
can be substituted (Jackson et al., 1994; Strange et al., 1996) (e) sensitivity to 
chloride channel blockers such as disulfonic stilbenes DIDS, SITS, as well as 
NPPB, DDF and niflumic acid (Nilius et al., 1996; Voets et al., 1997; Nilius and 
Droogmans 2003; Suzuki et al., 2006). These chloride channel blockers are 
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however, rather non-specific and have low potency. DCPIB, a derivative of 
ethycrinic acid (Decher et al., 2001; Best et al., 2004) is so far considered to be 
the most specific agent yet identified for inhibiting swelling-activated chloride 
channels (Abdullaev et al., 2006).  
The current through this channel closely correlates with changes in cell 
volume and has been labeled as volume- or swelling-activated Cl- current, or ICl- 
swell. This ubiquitously expressed channel has also been referred to as volume-
regulated anion channel (VRAC), volume expansion sensing sensor (VSOR) or 
volume sensitive organic osmolyte and anion channel (VSOAC) (Jackson et al., 
1994; Okada, 1997). The permeability ratio (Px/PCl-) for the different osmolytes 
range from ~0.1 for glutamate, ~0.2 for taurine to ~0.6 for the small amino acid, 
glycine. The pore diameter of VSOAC lies between 5.4 and 8 Å (~1.1 nm) 
(Jackson and Strange, 1995; Nilius et al., 1997). This large diameter of the 
channel may explain the range of permeating compounds allowing Cl- anion (3.6 
Å; Franciolini and Nonner, 1987) as well as organic osmolytes such as glycine 
and inositol (4.4-5.9 Å)  to readily permeate (Strange and Jackson, 1995). There 
is also some evidence suggesting that VSOAC itself can be permeated by water 
and its closure would reduce the overall water permeability (Nilius, 2004). 
VSOAC has also been implicated in setting the membrane potential, in 
modulating salt and fluid secretion as well as cell cycle progression, cell 
proliferation, angiogenesis, mechanosensitivity of various cell types and also in 
apoptosis (Okada and Maeno, 2001; Nilius  and Droogmans, 2003).  
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Although the VSOAC has been pharmacologically and 
electrophysiologically characterized, its molecular identity is still not known and 
the gene or genes encoding the channel mediating the swelling activated Cl- 
current have not yet been identified. Reasons for this include the ubiquity of the 
VSOAC and the absence of a specific high-affinity ligand.  There have been 
certain candidates for the VSOAC and these include:  
• members of the ClC family (Duan et al., 1997; Wang et al., 2000; Jin et al., 
2003) 
• phospholemman (Moorman et al., 1998; Morales-Mulia et al., 2000; Moran     
et al., 2001) 
• P-glycoprotein (Multi-drug resistant protein (MDR) ; Hardy  et al., 1995; 
Valverde et al., 1996)  
• ICln (Krapivinsky et al., 1994; Musch et al., 1998) 
• maxi anion channel (see Nilius et al., 1997 for review)  
However some of the electrophysiological and pharmacological properties 
of these Cl- channels are at variance with VSOAC and organic osmolyte efflux 
and none of them fulfill all the requirements to function as a universal osmo-
sensitive Cl- channel (Vanoye et al., 1997; Pasantes-Morales et al., 1997; 
Moran et al., 1997; Li et al., 2000; Weylandt et al., 2001). 
 
Organic Osmolytes 
Organic osmolytes are found in high concentration (10 to 100 mM) in the 
cytosol of all organisms from bacteria to humans. Although inorganic ions are the 
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quantitatively major osmolytes, contributing 62-70% of total osmolyte content, 
they are insufficient to compensate for the entire loss of water (Lang et al., 
1998b). Therefore, organic osmolytes (23-29%) are important to be considered 
and can be grouped into three classes (1) polyols (glycerol, sorbitol, myo-inositol) 
(2) amino acid and derivatives (taurine, glutamate, alanine, proline) and (3) 
methylamines (betaine, glycerophosphorylcholine) (Pasantes-Morales et al., 
2002a; Figure 1.3). Unlike inorganic ions that can interfere with structure and 
function of proteins and nucleic acids, most organic osmolytes, even if 
accumulated at high concentrations, are neutral (either zwitterionic or lacking 
charge at physiological pH), non-perturbing “compatible” solutes without any 
deleterious effects. Changes in their concentration do not significantly affect 
membrane potential, enzyme activities or ionic strength of the cytoplasm, which 
is of particular importance especially for excitable cells such as neurons. Many of 
these organic osmolytes, are in turn “counteracting” and have cytoprotective 
properties such as anti-oxidation and stabilization of proteins (Hoffman and 
Lambert, 1983; Lang et al., 1998a).  
Different tissues and organs of the body have different distributions of 
organic osmolytes, the concentration of which varies through the developmental 
stages of growth and differentiation (Miller et al., 2000). Whether it’s the kidney 
enriched in sorbitol, myo-inositol, glycerophosphorylcholine and betaine or the 
heart, brain and eye lens with its myo-inositol and taurine concentration, more 
and more studies suggest the importance of these organic osmolytes in 







Figure 1.3. Relative contribution of various inorganic and organic 
osmolytes to RVD in the brain. Inorganic and organic osmolytes involved in the 
control of brain water content during chronic hyponatremia. GPC: 
glycerophosphorylcholine, PEA: phosphatidyl ethanolamine, NAA: N-acetyl 
aspartate, Cr/PCr: creatine/phosphocreatine; Myo-I: myo-inositol, AA: amino 









In the central nervous system (CNS), the three major organic osmolytes 
are taurine, glutamate and myo-inositol. These osmolytes differ in their sizes and 
do not have similar structures (Figure 1.4; Jackson and Strange, 1993; McManus 
et al., 1995; Nilius et al., 1997). Generation of these osmolytes is a relatively slow 
process requiring months to days and are accumulated by cells in three ways: 
increased synthesis, decreased degradation and by transport across the plasma 
membrane via Na+ dependent transporters. Although a high concentration of 
glutamate is involved in ischemic brain injury and spreading depression, the 
release of glutamate as an osmolyte through VSOAC is now suggested to play 
an important role in synaptic communication and astrocyte-neuron signaling 
(Mulligan and MacVicar, 2006). 
 
Taurine, the ideal osmolyte 
Taurine (2-aminoethanesulphonic acid) was isolated from ox bile in 1827 
where it is found in high concentrations (Jacobsen and Smith, 1968). Chemically, 
taurine is distinct from other amino acids in that it is not chiral, and like glycine 
does not polarize light. It occurs in the body as a free molecule and is never 
incorporated into muscle proteins. The high water solubility, very limited 
permeation across cell membranes and poor ability to chelate cations make the 
non-cytotoxic taurine well suited as osmolyte for adjustment of the intra-cellular 
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Figure 1.4. Structure of three quantitatively major organic osmolytes in the 











Although taurine has been reported to form the carboxylic terminal of 
some low molecular weight brain synaptic peptides (Marnela et al., 1985) and to 
be incorporated into membrane lipids (Kaya and Sano, 1991), most of taurine 
remains free as a zwitterion in the body fluids. Taurine is not considered an 
essential amino acid, because most carnivores and omnivores can synthesize it 
from a combination of two natural amino acids, cysteine and methionine, with the 
help of vitamin B6. However new born mammals including cats and certain 
monkeys have little or no capacity for de novo taurine biosynthesis and therefore 
rely on dietary supply of taurine (Gaull, 1989). Taurine has been claimed to be of 
benefit in the treatment of congestive heart failure and affords protection against 
arrythmogenesis, however the exact mechanism for this is still not known 
(Schaffer et al., 2000a; Gupta et al., 2005). Lack of sufficient taurine is also 
considered to be associated with cardiomyopathy, retinal degeneration and 
growth retardation (Lombardini, 1991; Aerts et al., 2002). Nevertheless the main 
purported functions for taurine are 1) bile acid conjugation 2) detoxification 
(Birdsall, 1998) 3) osmoregulation (Hussy et al., 2000) 4) modulation of 
intracellular calcium (Xu et al., 2006b). 
 Although taurine has been thought of as an inhibitory neurotransmitter 
since it exhibits effects as a weak agonist at GABAA and glycine receptors, it is 
not a bona fide neurotransmitter (Hussy et al., 1997). Although taurine does not 
scavenge reactive oxygen species (ROS), it can directly bind to HOCl to form 
stable N-chlorotaurine (Aruoma et al., 1988; Schaffer et al., 2003). Hypotaurine, 
a taurine derivative on the other hand is a strong antioxidant and is known to 
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occur at significant levels in mammalian reproductive fluids and in marine 
animals living in sulfide-laden waters (Setchell et al., 1993).  Taurine influx 
against a steep concentration gradient is accomplished by a taurine transporter 
(TauT) that is dependent on Na+, Cl- and pH and is driven by the transmembrane 
electrochemical gradient (Lambert and Hoffman, 1993; Han et al., 2006).  
Taurine is the most intensively studied compatible solute in counteracting 
RVD and often used as a representative of the organic osmolyte pathway. Large 
quantities of taurine can be lost from cells without altering the resting membrane 
potential or modifying cell function. The sulfonic amino acid taurine has been 
conserved strongly from amoebae to mammals and is present at high 
concentration (5-50 mM) in neuronal cells (Lehman and Hansson, 1987; 
Huxtable, 1989; Olson et al., 2003) and mammalian heart (Miller et al., 2000). In 
fact, it has been demonstrated that the volume regulatory capability of cultured 
astrocytes and hippocampal slice cultures varies with intracellular taurine 
concentration, with diminished effects in taurine-deficient media (Moran et al., 
1994, 1996a; Kreisman and Olson, 2003). Taurine concentrations have been 
demonstrated to be reduced from 53 to 7 mM within 40 min after transfer to  
hypotonic medium (50% reduction in osmolarity) in Ehrlich tumor cells (Hoffmann 
and Lambert, 1983) and an equivalent loss of taurine in response to cell swelling 
in vivo has also been demonstrated by intracranial microdialysis (Wade et al., 
1988). Taurine is the osmolyte which is most sensitive to osmotic perturbation, 
with the lowest release threshold and largest amount released in most 
mammalian cells (Pasantes-Morales et al., 2000b). Taurine is not concentrated in 
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secretory granules but is equally distributed in the cytoplasm and in the nucleus 
(Bustamante et al., 2001). At normal physiological pH taurine is present 
predominantly as an electroneutral zwitterion and it is in this form that taurine is 
released from swollen cells (Guizouarn et al., 2000).  
 
Pathways for Organic and Inorganic Osmolytes 
Arguments in support of the involvement of a Cl- channel (VSOAC) as a 
major route for the volume-regulatory efflux of organic osmolytes comes mainly 
from electrophysiological studies showing that the swelling-activated Cl- current, 
swelling-induced transport of organic osmolytes and RVD are all inhibited by a 
range of anion channel blockers (Strange et al., 1996). The pharmacological 
profile of organic osmolyte inhibition is similar to that of VSOAC, suggestive of a 
common pathway with Cl- or of a close connection between the two pathways. 
The swelling-activated taurine efflux is not an exchange of cellular taurine for 
extracellular Cl- via an anion exchange system (Jackson and Strange, 1993; 
Lambert and Hoffman, 1994;). It is Na+ independent, temperature-insensitive and 
not antagonized by guanidinoethane sulfonate (GES), an inhibitor of the taurine 
transporter. Taurine translocation and prompt release in response to swelling is 
passive, directed only by its concentration gradient (no energy dependent carrier) 
(Sanchez-Olea et al., 1991; Schousboe and Pasantes-Morales, 1992). 
Furthermore, the pathway mediating swelling-dependent efflux of taurine is 
shared by a variety of structurally unrelated organic molecules, does not appear 
to saturate with increasing concentrations of transported solute and is not 
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stereoselective. These characteristics of transport pathways are unlike those of 
typical membrane transporters. Instead they are those suggestive of a pore or 
channel (Kirk and Strange, 1998; Junankar and Kirk, 2000). 
Although the evidence for a common osmosensitive permeability pathway 
for Cl- and organic osmolytes is strong, there is a growing body of research data 
suggesting that the efflux profiles of different osmolytes under hypo-osmotic 
conditions may vary. There have been reports of differential activation and 
blockade of swelling activated taurine and Cl- efflux in Ehrlich mouse ascites 
tumor cells and rat mammary tissue (Lambert and Hoffman, 1994; Shennan et 
al., 1994; Stutzin et al., 1999). Discrepancies between time-courses for 
inactivation and activation of 125I- (used as a tracer for Cl-) and amino acid efflux 
have also been demonstrated in Chinese Hamster Ovary, NIH/3T3 and HeLa 
cells (Moran et al., 1997; Stutzin et al., 1999). The possibility of two or more 
isoforms of volume-sensitive taurine efflux pathways that are differentially 
regulated cannot be excluded (Mongin et al., 1999b). This has led to speculation 
regarding the possible existence of more than one isoform of VSOAC or separate 
permeation pathways for the osmolytes depending on the cell or tissue 
examined. Chapter 3 of my thesis investigates the similarities and differences of 
the release of taurine and 125I- (tracer for Cl-) in neuroblastoma cells. 
 
Physiological Significance of Cell Volume Regulation in the CNS 
Disturbances of body fluid osmolarity are common as clinical entities and 
can give rise to a diverse group of disease states and complications. Normal 
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plasma osmolarity is around 287 mOsM varying only about 1% from day to day. 
As little as a 2 mOsM increase in plasma osmolarity can activate thirst and 
arginine vasopressin (AVP) release from the posterior pituitary to offset the 
increased osmolarity (Mckinley and Johnson, 2004). This finely tuned 
homeostatic mechanism can be compromised in the face of acute osmotic stress 
from clinical intervention, accident or disease. The primary clinical manifestations 
of both hyper- and hypo-osmolar states are central nervous system dysfunction 
due to the restrictions of the skull. In the brain, even modest reductions in plasma 
osmolarity can raise the intracranial pressure and cause tissue damage. With 
hyperosmolar perturbations in plasma osmolarity, the brain passively shrinks as 
a result of secondary substantial cellular water loss. In hours to days, depending 
on the extracellular solutes, restoration of brain volume may be achieved if the 
solute is endogenous. This occurs largely by the generation of new, non-
electrolyte intracellular solutes in the brain. On the other hand, in hypo-osmolar 
states, the brain expands its volume on the basis of passive water movement. In 
time, restoration of cell volume is achieved largely through loss of intracellular 
electrolytes as well as amino acids and myo-inositol (Lien et al., 1991; Pasantes-
Morales et al., 2002b; Table 1.1). With time, these mechanisms appear to protect 
brain volume at the expense of the intracellular milieu. The resultant alteration of 
intracellular osmolyte composition may be largely responsible for the neurological 
symptoms observable in patients and experimental animals with such afflictions 
(Pollock and Arieff, 1980; Gullans and Verbalis, 1993).  
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The most common manifestation of a decrease in osmolarity leading to 
hypo-osmotic swelling is hyponatremia. Hyponatremia is a disorder of fluid-
electrolyte balance (serum sodium concentration < 135 mM; normal being 145 
mM) (Palm et al., 2006). The clinical prevalence of hyponatremia has been 
reported to be as high as 2.5% among hospitalized adult patients (Anderson et 
al., 1985; Bussman et al., 2001; Hoorn et al., 2006). A sustained decrease in 
plasma sodium concentration disrupts the osmotic balance across the blood-
brain barrier, resulting in a rapid influx of water into the brain. This causes brain 
swelling and a cascade of severe neurological responses (Murray et al., 2004). 
Hyponatremia is associated with clinical conditions such as congestive heart 
failure, hepatic cirrhosis and renal failure, inappropriate secretion of the 
antidiuretic hormone (SIADH), glucocorticoid deficiency and use of thiazide 
diuretics (Haussinger et al., 1994b; Rovira et al., 2002; Pasantes-Morales et al., 
2002b). Water overload that occurs in psychiatric disorders such as 
schizophrenia and psychogenic polydipsia can drop plasma osmolarity by 40 
mOsM or more (Hayashi et al., 2005). In addition, neural swelling is also a major 
complication observed with stroke, traumatic brain injury, diabetes, excessive 
diarrhea or hepatic encephalopathy (Patel and Balk, 2007). This swelling, if 
uncorrected can be lethal as it can lead to compression of blood vessels, 
cerebral ischemia, infarct, excitotoxicity and eventually causing the displacement 
of the brain parenchyma through the foramen magnum (brain herniation) and 
respiratory arrest (Pasantes Morales et al., 2000). Paradoxically, if hyponatremia 







Table 1.1. Electrolytes and organic osmolytes in rat brain after chronic 
hyponatremia. Immediate response to hyponatremia in brain involves K+ and Cl− 
efflux, whereas sustained adaptation is carried out by organic osmolytes, 
particularly taurine. This has been confirmed in studies in vitro in astrocytes 
demonstrating how swelling-activated efflux of myo-inositol- and taurine persists 
for several hours after the hyposmotic stimulus, in contrast to glutamate and K+, 
which remained unchanged. Note that the percent decrease in organic osmolyte 







absence of adequate concentrations of organic osmolytes may lead to central 
pontine myelinolysis and seizures (Kleinschmidt-DeMasters and Norenberg, 
1981; Lien et al., 1991; Videen et al., 1995; Gross et al., 2001). 
 It is now well recognized that excess hydration can also lead to 
hyponatremia, for instance during military operations and marathon runs (O’ 
Toole et al., 1995; Kratz et al., 2005). In 2002, 13% of Boston marathon runners 
were reported to have hyponatremia (Almond et al., 2005). Signs and symptoms 
for this include nausea, emesis and headaches which could be followed by 
seizures, respiratory arrest and coma (Farrell et al., 2003). Risk factors for hypo-
osmotic neural swelling may also include pregnancy, elderly age and drugs such 
as selective serotonin reuptake inhibitors (e.g. paroxetine), antiepileptics and 
even the recreational drug, Ecstacy (Holmes et al., 1999; Jacob and Spinler, 
2006). The blood-brain barrier imposes unique features of solvent and water 
movement into and out of the CNS. In cases where the blood-brain barrier is 
compromised and in 60% of meningiomas, treatment is complicated by brain 
edema (Bitzer et al., 2000).  
The treatment of hyponatremia has changed little in the past decade. 
Intravenous injection of hypertonic solutions (3% saline or mannitol) is most 
frequently used to reduce increased intracranial pressure and cellular swelling 
(Wise and Chater, 1962; Munger, 2007). Conventional management techniques 
also include water restriction, demeclocycline, lithium and urea which have 
demonstrated variable efficacy and toxicity (Verbalis, 1993; Verhoeven et al., 
2005; Kazama et al., 2007). Drugs such as furosemide (loop diuretics) are also 
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used in combination with hypertonic solutions, however, these treatments are not 
well-tolerated in all patients (Goldsmith, 2005). Therefore osmotic stress 
response must be considered within the context of intracellular water 
homeostasis which is influenced not only by extracellular environment but also by 
cellular metabolic activity. Arginine vasopressin (AVP) receptor antagonists 
(conivaptan, lixivaptan, and tolvaptan) are promising new therapeutic options 
whose safety and efficacy have been clinically established recently for some 
forms of hyponatremia (plasma Na+ decrease by 20 mM within 12 hrs-acute 
hyponatremia) (Cawley, 2007; Miyazaki et al., 2007).  
On a molecular level, an understanding of the basic physiological 
processes and mechanisms of cell volume regulation is of crucial importance in 
neural cells. Osmolarity changes can have profound effects on cell-cell signaling 
because of the spatial relationship between neurons and astrocytes and as 
extracellular space becomes compromised due to swelling. Swelling can have 
dramatic consequences on diffusion of neurotransmitters such as glutamate, 
synaptic excitability, pH and amino acid homeostasis (Parkerson and 
Sontheimer, 2003). In such cases, non-perturbing organic osmolytes such as 
taurine serve as osmo-mediators between neural cells to critically regulate the 
composition of the extracellular space (Kimelberg et al., 2000). In vivo 
experiments in hyponatremic rats and humans show a substantial decrease in 
organic osmolyte content in neural tissue, including a profound depletion of 
taurine with comparatively modest decreases in inorganic osmolytes (Lien et al., 
1991; Massieu et al., 2004). Although astrocytes are considered to swell more 
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than neurons (Ordaz et al., 2004a), the release of osmolytes through VSOAC 
provides a means of neural communication between astrocytes and neurons 
even under physiological reductions in osmolarity (Mulligan and MacVicar, 2006). 
 
Cellular and Molecular Mechanisms of Cell Swelling 
Volume  sensing 
RVD is a complex chain of events requiring a sensor to detect transient 
changes in cell volume, a signaling cascade to transduce information regarding 
volume changes into activation of pathways for osmolytes extrusion, and a 
“memory” of original cell volume to set the timing for inactivation (Pasantes-
Morales et al., 2002a; Ordaz et al., 2004a). The nature of the initial critical step of 
volume sensing remains elusive. Among the possible mechanisms considered in 
the activation of the ion channel(s) are as follows: (1) direct activation by 
membrane stretch (Okada, 1997), (2) integrins and second messenger signals 
such as tyrosine kinases (Lambert and Hoffmann, 1994; Mongin and Orlov, 
2001; Jakab et al., 2002), (3) changes in macromolecular crowding or cellular 
ionic strength (Voets et al., 1999; Burg, 2000) and (4) regulation through 
interaction of cytoskeleton (Papakonstanti et al.,2000).  
However no one signaling mechanism can account for the volume 
sensitivity in all cells types. Mammalian cells have large membrane areas with 
numerous invaginations or ruffles that can accomodate for the increase in 
volume with no concomitant stretching of the membrane. Work on osmosensing 
in bacteria, their signal paths and membrane-based sensors have led to the 
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discovery of a group of proteins involved in osmoregulation termed the Osm 
proteins. These proteins share significant homology with Drosophila transient 
receptor potential (TRP) channels which are cation channels that mediate Ca2+ 
influx into cells and appear to play important roles in osmosensation and 
mechanosensation. Two mammalian TRP channels have recently been cloned 
and shown to be osmotically-regulated (Lietdke, 2005). Integrins are adhesion 
receptors that link the extracellular matrix to the actin cytoskeleton. It has been 
speculated that a change in cell volume may take place via modulation of integrin 
clustering that triggers intracellular signals (Pedersen et al., 2001). According to 
the macromolecular theory, the kinetics and equilibria of enzymes can be greatly 
influenced by small changes in the concentration of intracellular macromolecules 
and solutes. A 10% change in the concentration of intracellular proteins can lead 
to changes of up to a factor of ten in the thermodynamic activity of molecular 
regulatory mechanisms (Burg, 2000). However the evidence for these 
mechanisms along with the role of cytoskeleton in swelling is not entirely clear 
and may depend on the specific cell type (Moran et al., 1996b; Papakonstanti et 
al., 2000).  
Thus, even though the initial volume-sensitive step awaits identification, it 
appears that unfolding of the plasma membrane, microdomains and 
reorganization of the cytoskeleton are potential elements of downstream 





Signal transduction for swelling-induced VSOAC activity 
Depending on the specific cell type, swelling of the cell triggers many 
signal transduction mechanisms linked to the opening of the VSOAC (Okada, 
1997; Calpham, 1998). These mechanisms are discussed below. 
 
Tyrosine Kinases 
Hypo-osmotic swelling elicits rapid and transient phosphorylation of a 
number of tyrosine kinases in a variety of cells such as cardiomyocytes, 
hepatoma, endothelial, epithelial cells and lymphocytes (Schliess et al., 1995; 
Sadoshima et al., 1996; Pasantes-Morales and Franco, 2002). The kinases Src, 
p125FAK, p38, JNK, p56LCKand mitogen activated protein kinases (MAPK) are 
among the phosphorylated proteins considered to be involved, depending on the 
cell type (Tilly et al., 1993; Crepel et al., 1998; Lepple-Wienhues et al., 1998). 
This has been addressed by testing the effects of various inhibitors of 
phosphotyrosine kinases (PTK). Tyrphostins, genistein and herbimycin strongly 
attenuate swelling activated Cl- and taurine efflux, although they exhibit different 
potencies according to the cell type (Nilius et al., 1997). Conversely, 
orthovanadate, a tyrosine phosphatase inhibitor, potentiates this pathway (Lang 
et al., 1998; Pasantes-Morales et al., 2000a). However a role for protein tyrosine 
phosphorylation in eliciting RVD is not universal and there is contradictory 
evidence in neural cells (Estevez et al., 1999, 2001; Franco et al., 2001; Heacock 
et al., 2004). Tyrosine kinases may also be involved in steps activated by 
processes occurring in association with swelling and volume regulation such as 
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cell adhesion, retraction and organization of the cytoskeleton, which makes it 
difficult to identify the precise step.  
Nevertheless, a vast majority of studies suggest the role of tyrosine 
kinases in modulating the basal (swelling-activated) osmolyte release (Mongin et 
al., 1999; Delueze et al., 2000). Although the current literature provides evidence 
of one or more tyrosine phosphorylation steps for osmolyte efflux, the identity of 
specific kinase(s) and the precise step of the reaction are still unknown. 
 
Calcium, calmodulin and protein kinase C 
Exposure to hypotonic solutions can cause a rise in intracellular calcium in 
a variety of cells, whereas it remains constant in others (Lang et al., 1998). 
Swelling may increase calcium by both activation of calcium-permeable channels 
and calcium release from intracellular stores. Calcium (Ca2+) release from stores 
is presumably triggered by inositol phosphates or Ca2+-induced Ca2+ release. 
Although a minimal amount of cell Ca2+ > 50 nM, referred to as permissive Ca2+, 
appears necessary for the activation of osmosensitive Cl-/taurine fluxes, RVD 
and osmolytes effluxes are either Ca2+-dependent or Ca2+-independent 
depending on the cell type examined (Grinstein et al., 1982; O’Connor and 
Kimelberg, 1993; Szucs et al., 1996). Although Ca2+ is required for volume 
regulation in astrocytes (Mongin et al., 1999a), in neuroblastoma cells this 
requirement is only minimal for swelling-induced basal Cl- and osmolyte release 
(Basavappa et al., 1995; Heacock et al., 2006).  
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Calmodulin inhibitors such as trifluoperazine and pimozide have been 
shown to block RVD and basal taurine release from astrocytes, Ehrlich and Hela 
cells (Li et al., 2002; Falktoft and Lambert, 2004) but they even inhibit efflux in 
cells where the calcium is below the threshold level for calmodulin activation 
(Szucs et al., 1996; Jorgensen et al., 1997). This suggests caution is warranted 
on conclusions reached based on these blockers as some of these inhibitors 
could directly affect the VSOAC. The increase in intracellular calcium may also 
activate Ca2+-dependent kinases such as Ca2+/calmodulin-dependent protein 
kinases and protein kinase C (PKC). PKC involvement in activating taurine efflux 
and RVD under swelling-activated basal conditions is also controversial and 
appears to be dependent on the cell type. It has been reported that chelerythrine 
inhibits the hypoosmotic amino acid release from cardiac cells, renal tubular cells 
and intestinal epithelial cells but not from rat cerebral cortex and glial cells. 
Conventional PKC isoforms are good candidates, however inhibitors presumably 
selective for cPKC isoforms show inhibition to a lesser extent than chelerythrine 
(Song et al., 1998; Estevez et al., 1999) 
 
Other signaling mechanisms 
In addition to the above signaling mechanisms, several other messengers 
have been implicated in activation of RVD. These include, phosphatidylinositol-
3’-kinase, cytoskeleton remodeling and Rho effectors, formation of arachidonic 
acid and/or its metabolites (Tilly et al., 1996; Nilius et al., 1999, 2000; Lambert, 
2004; Barfod et al., 2005)  
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These studies show interconnectivity of the vast signal transduction 
network involved in RVD. Phosphatidylinositol-3’-kinase has links to tyrosine-
kinase membrane receptor, integrin-Focal Adhesion Kinase (FAK) pathway and 
also to small molecular weight (M.W) GTPases of the Rho family associated with 
remodeling of the cytoskeleton (Nilius et al., 1997). Cytochalasins that interfere 
with actin assembly show different results depending on the cell type (Shen et 
al., 1999); however it has been speculated that the cytoskeleton may play a role 
in insertion of cell volume regulatory channels into the plasma membrane (Lang 
et al., 1998). Rho kinase and myosin light chain kinases (MLCK) have also been 
reported to be involved in the activation of Cl- in endothelial cells, (Nilius et al., 
1999) however Rho kinase inhibition does not affect taurine efflux in NIH3T3 
cells (Pedersen et al., 2002).  
Together these data suggest that the molecular mechanisms required to 
regulate cell volume may be extensive, complex and specific for every cell type. 
It may possibly involve the cytoskeleton and signal transduction cascade 
molecules including kinases, calcium and phospholipases. The experimental 
evidence provided in this thesis confirms the modulatory but not essential role of 
calcium and PKC in cell volume regulatory processes. 
 
Regulation of Osmolyte Release: Role for Receptor Activation 
The mechanisms through which cell volume and osmolyte efflux can be 
modulated have recently received much attention. It has been observed that 
large, non-physiological decreases in extracellular osmolarity (>30%) are often 
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necessary to initiate intrinsically-induced osmolyte efflux in vitro. In contrast, in 
vivo volume changes can be observed during normal physiological changes in 
osmolarity and normal patterns of neuronal activity (Mulligan and MacVicar, 
2007).  
Previous reports suggest that osmolyte release can be enhanced by Ca2+ 
ionophores, phorbol esters (activators of PKC), or agents known to elevate cyclic 
AMP concentrations (Strange et al., 1996; Lambert, 2004). Intracellular 
application of non-hydrolyzable GTP analog, GTPγS has also been shown to 
activate swelling-induced Cl- current which can be impaired by the addition of 
intracellular GDPßS (Doroshenko, 1991; Voets et al., 1998). Although these 
results do not give any clue as to the type of G protein(s) that is involved, they 
raise the possibility that, in vivo, the activity of VSOAC may be under 
neurohumoral control.  
Recently there have been a number of studies suggesting the role of G 
protein-coupled receptors (GPCRs) in the regulation of VSOAC. In non-neural 
cells, a few distinct receptors have previously been recognized to regulate 
swelling-activated chloride currents and organic osmolyte efflux. These include 
receptors for endothelin-2 in atrial cells (Du and Sorota, 2000), Epidermal Growth 
Factor in murine mammary cells (Abdullaev et al., 2003), thrombin and 
bradykinin in Ehrlich ascites tumor cells (Jorgensen et al., 1999), vasopressin in 
renal cells (Nakanishi et al., 1994), aldosterone in endothelial cells (Schneider et 
al., 1997), H1 histamine and Lyso-phophatidic acid (LPA) receptors in HeLa cells 
(Lambert and Falktoft, 2000, 2004). 
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In contrast, in neural cells, vasopressin, an agonist at the V1 receptor, has 
been shown to play an important role in regulating RVD in pituicytes and 
astrocytes (Sarfaraz and Fraser, 1999; Hertz et al., 2000; Rosso et al., 2004). In 
addition, two pharmacologically distinct receptors that had been extensively 
characterized in the regulation of volume-sensitive efflux of osmolytes at the 
initiation of this thesis include: M3 muscarinic cholinergic (mAChR) in human SH-
SY5Y neuroblastoma cells (Loveday et al., 2003; Heacock et al., 2004) and P2Y 
purinergic receptor in rat primary astrocytes (Mongin and Kimelberg, 2002). In 
each case, receptor activation reduced the “set-point” for osmolyte efflux to more 
physiologically relevant reductions in osmolarity (0-15%). Since these receptors 
can potentially couple to phospholipase C (PLC) activation and Ca2+ mobilization, 
the possibility existed that there is a mechanistic link between these and other 
GPCRs and regulation of osmolytes efflux. Of particular importance is whether 
GPCR activation can modulate the release of organic osmolytes from neural cells 
and thereby contribute to RVD in response to hypo-osmotic stress.  
 
G protein-coupled receptors 
The majority of hormones and neurotransmitters exert their biological 
effects through GPCRs. All GPCRs share one common structural element: a 
single polypeptide chain that forms seven transmembrane helices, connected by 
three intracellular and three extracellular loops. The transmembrane helical 
bundle forms a pocket where ligands can bind and interact with the receptor. 
Depending on the structure of the ligand, its binding can trigger (agonist) a 
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conformational change in the receptor molecule which affects its interaction with 
an associated, membrane-anchored G protein. G proteins act as molecular 
switches that transduce signals from more than 1,000 different receptors to 
intracellular effectors. A variety of effectors of G alpha subunits define different 
classes of G proteins, including adenylyl cyclase stimulating G proteins (Gs), 
adenylyl cyclase inhibiting G proteins (Gi), and phosphoinositide hydrolysis 
stimulating G proteins (Gq) (Birnbaumer et al., 1990). Gßγ also have a multitude 
of effectors. 
Considering the physiological significance of regulating cell swelling in the 
brain and the fact that the CNS possesses a large number of GPCRs, the 
receptors yet identified to play an important role in osmoregulation in the CNS 
are as follows. 
 
Purinergic receptors  
There are eight human P2Y receptors currently recognized. These can 
couple to G proteins that are linked to IP3 production and Ca2+ mobilization, 
phosphatidylinositol 3-kinase (PI3K) via Gi, RhoA and Rho kinases, cAMP 
production and also are commonly associated with MAPK phosphorylation 
(Abbracchio et al., 2006). Multiple P2Y receptor subtypes are expressed in 
astrocytes, oligodendrocytes, and microglia and have been claimed to activate 
neuroprotective and pathophysiological mechanisms (Chorna et al., 2004; 
Abbracchio and Verderio, 2006). For cell volume regulation in neural cells, the 
purinergic receptor agonist, ATP, can enhance aspartate (used as a marker for 
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glutamate) efflux in primary cultures of astrocytes (Mongin and Kimelberg, 2002, 
2005). ATP, preferentially via the P2Y1 and P2Y2 receptors that activate 
phospholipase C (PLC) -mediated Ca2+ mobilization, acts synergistically with cell 
swelling in enhancing aspartate release. ATP-induced organic osmolyte release 
was inhibited by cell shrinkage and anion channel blockers and was completely 
insensitive to 24-h pretreatment with tetanus toxin, in contrast to the astrocytic 
vesicular-like glutamate release (Mongin and Kimelberg, 2002). On the other 
hand, ATP itself is known to be released from cells during conditions that cause 
swelling (Junankar et al., 2002; Darby et al., 2003), which can in turn further 
modulate the release of other osmolytes such as taurine from neuronal 
populations (Li and Olson, 2004). This loss of organic osmolytes may lead to 
volume regulation in the CNS and is suggested to be the primary cellular 
mechanism for net transfer of taurine from neurons to astroglia observed in the 
osmotically swollen rat cerebellum in situ (Nagelhus et al., 1993). Besides the 
importance of this in neural cell communication, it must be kept in mind that high 
concentrations of the osmolyte, glutamate, can also cause excitotoxicity and 
pathological states. 
 
Muscarinic cholinergic receptors 
Molecular cloning studies have revealed the existence of five muscarinic 
subtypes. The even numbered receptors (M2 and M4) couple to inhibition of 
adenyl cyclase through Gi/o and are pertussis toxin-sensitive. The odd numbered 
subtypes (M1, M3 and M5) couple through pertussis toxin-insensitive Gq/11 and 
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mediate increases in inositol lipid turnover (Felder, 1995). The central nervous 
system contains a high density of muscarinic cholinergic receptors (mAChRs) 
that have been linked to a number of neuropsychiatric disorders such 
Alzhiemer’s dementia, aging and Parkinson’s disease (Dubois et al., 1983; Flynn 
et al., 1995). The presence of muscarinic cholinergic (M3) receptors has been 
documented in human 1321N1 astrocytomas and SH-SY5Y neuroblastoma cells 
and stimulation of these receptors is known to lead to activation of PLC and 
subsequent hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to form 
diacylglycerol (DAG) and inositol triphosphate (IP3) (Fisher and Heacock, 1988; 
Tang et al., 2002). Thus, agonist occupancy of this receptor subtype elicits the 
formation of two intracellular second messengers which are linked to activation of 
PKC and regulation of Ca2+ homeostasis. Given the role that changes in protein 
phosphorylation and Ca2+ play in cell volume regulation, the ability of these 
receptors to activate such signaling pathways assumes major importance. 
In our laboratory, the ability of muscarinic cholinergic receptors (mAChRs) 
to regulate the volume-sensitive efflux of two organic osmolytes, namely taurine 
and D-aspartate, from human SH-SY5Y neuroblastoma cells has been examined 
(Loveday et al., 2002; Heacock et al., 2004). Inclusion of oxotremorine-M (Oxo-
M), a muscarinic cholinergic agonist, not only results in a marked enhancement in 
the release of both osmolytes over a wide range of osmolarities but also lowers 
the threshold osmolarity at which the efflux of taurine and D-aspartate can occur. 
The results indicate that the activation of M3 mAChRs on SH-SY5Y 
neuroblastoma facilitate the cell's ability to respond to hypotonic stress by 
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potentiating organic osmolyte efflux through the VSOAC, and this enhancement 
seems to be dependent on Ca2+, tyrosine kinases, and PKC activity (Loveday et 
al., 2002; Heacock et al., 2004). 
My thesis further investigates the involvement of mAChRs in regulating 
the inorganic osmolyte, Cl- as well as the ability of cholesterol to further modulate 
the taurine efflux response (Chapter 3, 4). 
 
Thrombin and its Protease-Activated Receptors 
One of the receptors upon which my thesis focuses is the protease-
activated receptor (PAR) activated by thrombin. Thrombin is a serine protease 
cleaved from the proenzyme, prothrombin, by Factor Xa. The biological activities 
of thrombin include an essential component of the coagulation cascade, 
cleavage of fibrinogen to fibrin, platelet activation and stimulation of cellular 
responses involved in inflammation (Coughlin, 2000). Although it is difficult to 
detect thrombin levels in the brain, pro-thrombin RNA is found in various regions 
of the brain and the plasma levels of pro-thrombin are reportedly 1-5 µM (Arai et 
al., 2006). During embryonic development when the blood-brain barrier is not yet 
intact, thrombin can directly affect neuronal cell growth and differentiation (Griffin 
et al., 2001). However, thrombin can be produced in the brain either immediately 
after cerebral hemorrhage or after breakdown of the blood-brain-barrier following 
brain injury such as trauma or ischemia (Lee et al., 1996). As a result thrombin 
can enhance the synthesis and secretion of nerve growth factor in glial cells, 
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change the morphology of neurons and astrocytes and induce glial proliferation 
in the brain (Cavanaugh et al., 1990; Wang and Reiser, 2003).  
Thrombin regulates cellular functions in a large variety of cells through a 
family of receptors known as Protease Activated Receptors (PARs). PARs 
belong to the GPCR superfamily and currently four members of the group (PAR1, 
PAR2, PAR3, and PAR4) have been identified. Thrombin activates PAR1, PAR3, 
and PAR4, whereas PAR2 is activated by trypsin. PARs are activated by an 
irreversible proteolytic cleavage of the receptor’s extracellular N-terminus. This 
unmasks a new N-terminus that functions as a “tethered peptide ligand,” which 
then binds intra-molecularly to the receptor and initiates intracellular signal 
transduction (Macfarlane et al., 2001; Hollenberg, 2003). Synthetic peptides that 
mimic this tethered ligand comprise at least six amino acids and can activate the 
respective receptor, thereby by-passing the requirement for receptor proteolysis 
(Coughlin, 2000; Wang et al., 2002). Due to the unavailability of specific PAR 
antagonists, these peptides serve as important tools to probe the effects of 
different PAR receptor subtypes. 
PARs are pleiotropic GPCRs capable of activating members of the Gi/o, Gq, 
and G12/13 families of G proteins and hence a host of intracellular effectors 
depending on the cell type (Figure 1.5). PAR-1 can couple to inhibition of cAMP 
accumulation through Gi in a pertussis toxin-sensitive manner. Alternatively, it 
can couple to phospholipase C (PLC)-catalyzed hydrolysis of phosphoinositides 
through the Gq pathway. This leads to the production of inositol trisphosphate 
(IP3) which mobilizes intracellular Ca2+ and DAG, and in turn activates PKC 
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(Macfarlane et al., 2001; Hollenberg, 2003; Trejo, 2003). More recent studies 
have illustrated coupling of PAR1 to G12/13, modulating effectors such as Rho 
GEFs and small molecular weight (M.W) G-proteins such as Ras and Rho 
(Offermanns, S., et al, 1994; Majumdar et al., 1998). It can also activate other 
pathways such as the activation of Src tyrosine kinase, PI3K, MAPK, FAK and 
phospholipase A2 (Choudhury et al., 1996; Wang, et al., al., 2002). Thrombin can 
promote a number of physiological responses due to its production of such 
various second messengers. 
A role for thrombin in brain injury has only recently become apparent 
(Gingrich and Traynelis, 2000). Low concentrations of thrombin (50 pM to 100 
nM) mediate neuroprotection against ischemia and environmental insults such as 
hypoglycemia, growth supplement deprivation, oxidative stress and β-amyloid 
toxicity (Vaughan, et al., 1995; Jiang et al., 2002; Guo et al., 2004) whereas 
prolonged administration of high concentrations of thrombin can cause neural 
degeneration and cell death (Striggow, et al., 2000; Hua et al., 2007). In vivo, 
pretreatment of the brain with a low dose of thrombin attenuates brain injury 
induced by cerebral hemorrhage or trauma (Xi et al., 1999, 2003; Masada et al., 
2000). It has also been demonstrated that pro-thrombin mRNA and PAR1 and 
PAR3 receptors are up-regulated in various regions of the brain after 
environmental insults (Citron et al., 2000; Striggow, et al., 2001). Although these 
data indicate the regulatory importance of thrombin in the brain, the mechanism 
for this neuroprotection remains to be established. Therefore, thrombin is a 









Figure 1.5. Thrombin receptor signaling  
PAR-1 can couple to members of the Gi, Gq and G12/13 families to impact a 
substantial network of signaling pathways as shown in the figure. The pleitropic 
effects of PAR-1 activation are consistent with many of thrombin’s diverse 









in modulating osmolyte efflux is the major focus of this thesis. Although the role 
of thrombin in enhancing taurine and Cl- efflux was observed previously in 
myoblasts and endothelial cells (Sullivan et al., 1996; Manolopoulos et al., 
1997a, b), the present thesis was the first to determine its role and mechanism in 
modulating osmolyte release in neuronal cells. These findings are of interest in 




During this thesis it was recognized by other members in our lab that 
lysophospholipids such as sphingosine 1-phosphate (S1P) and lysophosphatidic 
acid (LPA) can also facilitate the ability of SH-SY5Y neuroblastoma cells to 
respond to small reductions in osmolarity (Heacock et al., 2006). The principal 
effects of both LPA and S1P are mediated via a family of edg (endothelial 
differentiation gene) cell-surface receptors of which eight have been identified, 
three encoding receptors for LPA and five for S1P (Contos et al., 2000). SH-
SY5Y cells express mRNA for edg 3, 4, 5, 7, and 8, which indicates the presence 
of LPA2 and LPA3 receptors (edg 4 and 7), and S1P, S1P2, and S1P3 receptors 
(edg 8, 5, and 3, respectively) (Villullas et al., 2003). In the central nervous 
system, these lysophospholipids have also been implicated in neuronal growth, 




  The addition of micromolar concentrations of LPA (10 µM) or S1P (5 µM) 
to SH-SY5Y cells elicits a robust increase in taurine efflux under isotonic as well 
as mild hypoosmotic conditions. The ability of LPA and S1P to increase osmolyte 
release was mimicked by certain analogs and other glycerophospholipids 
(Heacock et al., 2006) suggesting that  several non-edg receptors that are 
phylogenetically closely related may also be involved (Kostenis, 2004). These 
results indicate that SH-SY5Y cells express multiple receptors that are activated 
by glycerophospholipids and sphingophospholipids that couple to the release of 
osmolytes. The involvement of a VSOAC in osmolyte release triggered by S1P or 
LPA is indicated by the ability of nonselective anion channel inhibitors, such as 
DDF and NPPB, as well as DCPIB, a highly selective inhibitor of VSOAC (Decher 
et al., 2001). Athough a rise in [Ca2+]i is elicited by S1P or LPA, omission of 
extracellular Ca2+ does not significantly reduce the magnitude of taurine efflux in 
response to the addition of either lysophospholipid. However, a requirement for 
an intracellular pool of Ca2+ and PKC is essential for S1P- and LPA-stimulated 
osmolyte efflux. Pretreatment of SH-SY5Y cells with either pertussis toxin, 
cytochalasin D or toxin B, conditions previously established to disrupt the 
cytoskeleton in these cells (Linseman et al., 1998), does not alter basal or 
lysophospholipid-stimulated taurine efflux. 
 
Role of Cholesterol in the Regulation of VSOAC 
Cholesterol is one of the major lipid components of the plasma membrane 
in mammalian cells making up to ~90% of the total cholesterol content in certain 
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cells (Lange et al., 1989). Changes in levels of cholesterol have a major impact 
on the physical properties of the membrane lipid bilayer such as ordering of 
phospholipids, changes in membrane fluidity, thickness, curvature and 
permeability (Xu and London, 2000). An increase in cholesterol, in turn, restricts 
the motion of phospholipids resulting in lipid ordering and a decrease in 
membrane fluidity (Cooper, 1978; Xu and London 2000). However, cholesterol 
distribution is heterogenous and the sterol is now known to be concentrated in 
cholesterol- and sphingomyelin-rich membrane domains (membrane rafts). The 
recent Keystone Symposium on lipid rafts and cell function (March 23-28, 2006 in 
Steamboat Springs, CO) defined membrane rafts or caveolae as “small (10 - 200 
nm) heterogenous, highly dynamic, sterol- and sphingolipid-enriched domains 
that compartmentalize cellular processes” (Pike, 2006).  
These lipid domains have recently received attention as they often serve 
as a molecular scaffold or regulatory platforms for signaling proteins such as 
PKC, G-proteins, Src tyrosine kinases or small GTPases Ras and Rho (Allen et 
al., 2007). Changes in membrane cholesterol content and association of the 
protein, caveolin, with lipid microdomains have also been demonstrated to 
modulate the function of a number of membrane transporters such as serotonin 
and ABC transporters (Scanlon et al., 2001; Dos-Santos et al., 2007), a number 
of distinct ion channels such as antibiotic ion channel gramicidin, large 
conductance Ca2+-dependent K channel, L-type Ca2+ channel, Kv1.5 and TRP1 
channels (Lundbaek et al., 1996; Lockwich et al., 2000; Martens et al., 2001) as 
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well as receptors such as oxytocin, 5-hydroxytryptamine 1A, neurokinin-1 and 
epidermal growth factor receptors (Burger et al., 2000). 
The significance of cholesterol and lipid rafts in the regulation of VSOAC 
and taurine transport is controversial. It has been shown that swelling-induced Cl- 
conductance is limited in caveolin-1-deficient cells but that caveolin-1 protein 
expression facilitates the hypotonicity-induced Cl- current and taurine release in 
polarized colon cancer cells (Caco-2) and breast cancer cells  (MCF-7 and T47D) 
(Trouet et al., 1999; Ullrich et al., 2006). In addition, transfection of mutant 
caveolin-1 in endothelial cells was found to reduce the hypotonicity-induced 
current (Trouet et al., 2001). In contrast, recent studies have demonstrated an 
inverse relation of VSOAC activity with a decrease in plasma membrane 
cholesterol content using methyl-ß-cyclodextrin (CD) (Levitan et al., 2000; 
Romanenko et al., 2004; Byfield et al., 2006).  
CDs are cyclic oligosaccharides consisting of α-(1-4)-linked D-
glycopyranose units and exist as heptamers. These compounds, although water-
soluble, have been long recognized as potent carriers for hydrophobic drugs, 
since they contain a hydrophobic cavity that can encapsulate various 
hydrophobic molecules. CDs are most widely used in cell biology to deplete 
sterols or serve as shuttles for sterol. They also function as agents known to 
perturb raft organization as well as decrease membrane fluidity by the extraction 
of cholesterol (Zidovetski and Levitan, 2007). 
 In bovine endothelial and intestinal epithelial cells CD-induced cholesterol 
depletion potentiated VSOAC current whereas an increase in cholesterol content 
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resulted in inhibition of swelling-activated Cl- current (Levitan et al., 2000; 
Romanenko et al., 2004; Byfield et al., 2006; Lim et al., 2006). These data 
together suggest that cholesterol availability may provide another mechanism of 
cell volume regulation based on (a) the proximity of VSOAC to second 
messengers in lipid rafts (b) change in the biophysical properties of the 
membrane that could alter the pore properties, sorting or trafficking of the 
channels (Lim et al., 2006) or (c) change in the cellular distribution and content of 
F-actin (Klausen et al., 2006; Byfield et al., 2004).  
A normal physiological level of cholesterol is essential for cell function and 
growth and is an important component of the white matter in the brain. 
Alterations in cholesterol content take place not only in conditions associated 
with disorders of cholesterol metabolism or transport such as Smith-Lemli-Opitz 
syndrome, Niemann-Pick type C, or Tangier disease (Maxfield and Tabas, 2005) 
but also by the intake of altered compositions of dietary lipids (Foot et al., 1982). 
Since the brain is the organ that is richest in cholesterol, the outcome of 
manipulating cholesterol and thereby intracellular signaling has been studied in 
various pathologies such as neuroinflammation, Huntington’s disease, 
Alzhiemer’s disease and stroke (Zipp et al., 2007).  
The activation of a plethora of events that may regulate VSOAC activity 
and organic osmolyte release after hypo-osmotic stress have to be analyzed 
systematically in an effort to dissect the interconnections and interdependence of 





For this thesis, human 1321N1 astrocytomas and SH-SY5Y 
neuroblastoma were used as model neural cell lines. 1321N1 and SH-SY5Y cell 
lines originated from highly malignant form of tumor in brain astrocytes and 
sympathetic neuroblasts of the peripheral nervous system, respectively. There 
are several advantages in using these cell lines, including their widespread use 
in previous research projects, ease of culture, but most importantly their 
homegeneity and presence of pharmacologically distinct receptors. 
Recent studies from our laboratory showed that muscarinic receptors (M3) 
on SH-SY5Y cells regulate the efflux of organic osmolytes through the VSOAC.  
However, little was known about the regulation of VSOAC by other GPCRs in 
these neural cells and the mechanisms involved. My thesis was therefore 
focused on understanding the GPCR mechanisms of regulating osmolyte 
efflux through the VSOAC in neural cells. This dissertation work is comprised 
of three data chapters (Chapters 2, 3, 4). 
After an extensive investigation of receptor ligands that enhance organic 
osmolyte efflux in response to hypoosmotic stress, I discovered that thrombin 
produced the most robust potentiation in organic osmolyte efflux. Hence, the 
focus of chapter 2 is the observation that sub-nanomolar concentrations of 
thrombin, mainly via the PAR-1 receptor, can robustly enhance the release of the 
organic osmolyte, taurine, through the VSOAC from 1321N1 astrocytoma cells. 
To the best of my knowledge, this was the first demonstration that thrombin in 
neural cells can enhance taurine efflux at physiologically relevant reductions in 
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osmolarity. I performed a detailed biochemical and pharmacological 
characterization of thrombin-stimulated taurine release and demonstrated that 
both intracellular calcium and protein kinase C (PKC) are required for thrombin-
induced taurine release. This work has been published in the Journal of 
Pharmacology and Experimental Therapeutics 2005; 315 (2):755-63. 
The goals of chapter 3 were two-fold: first, to determine whether the 
release of the inorganic osmolyte, chloride, from hypotonically stressed SH-SY5Y 
neuroblastoma cells was, like that of taurine, subject to receptor regulation, and 
second, to evaluate whether these two osmolytes are released from the cells via 
distinct or similar mechanisms. This was important in view of the recent 
controversy that organic osmolytes and Cl- may exit through separate channels 
instead of a common VSOAC. Radioactive 125I- (used as a tracer for Cl-) and 
[3H]taurine was monitored for these studies. I found that although thrombin and 
Oxotremorine-M enhanced both taurine and 125I- efflux, the kinetics and 
magnitude of 125I- release were greater. Inclusion of anion channel blockers also 
attenuated the release of both 125I- and taurine under basal- and receptor-
stimulated conditions. Although PAR-1 and mAChR-stimulated taurine efflux was 
attenuated by either a depletion of intracellular Ca2+ or inhibition of PKC, the 
enhanced release of 125I- was less dependent on these parameters. Together, 
these results indicate that although the release of these two osmolytes from SH-
SY5Y cells may occur via pharmacologically similar membrane channels, the 
receptor-mediated release of taurine and 125I- is differentially regulated by PKC 
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and Ca2+ availability. This work has been published in the Journal of 
Pharmacology and Experimental Therapeutics 2007; 320(3):1068-77. 
In chapter 4, I attempt to further elucidate the regulation of receptor-
mediated taurine release through the VSOAC by testing the role of cholesterol in 
SH-SY5Y neuroblastoma cells. Cholesterol depletion, elicited by methyl-ß-
cyclodextrin (CD), enhanced both the basal (swelling-induced) and receptor-
stimulated release of taurine. The stimulatory effect of cholesterol-depletion was 
more pronounced for all the receptors tested (PAR-1, mAChR and S1P) than for 
the basal release. Therefore, the ability of cholesterol depletion to regulate 
agonist potency and efficacy was tested by means of studies with PAR-1 and 
mAChR receptor subtypes. To ensure that the CD-induced stimulatory effects 
were specific, experiments were performed after repleting the cells with 
cholesterol or substituting it with its chiral analog, epi-cholesterol. To further 
determine if the cholesterol depletion effects on the basal- and receptor- 
stimulated taurine release were due to disruption of lipid rafts, other agents such 
as cholesterol oxidase, sphingomyelinase and filipin, which also perturb raft 
organization, were tested. The results provide evidence that cholesterol serves to 
further regulate receptor-mediated taurine release most likely due to the selective 
effects of the sterol on membrane properties such as fluidity rather than through 
lipid rafts. 
The data discussed in Chapters 2, 3, and 4 demonstrate the importance of 
receptor and cholesterol regulation of osmolyte release through the Volume 
Sensitive Organic osmolyte and Anion Channel. Also, the novel role of thrombin 
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in osmoregulation, adds to the growing list of functions attributed to this protease 
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SUBNANOMOLAR CONCENTRATIONS OF THROMBIN ENHANCE THE 






The ability of subnanomolar concentrations of thrombin to protect both 
neurons and glia from ischemia and other metabolic insults has recently been 
reported.  In this study, we demonstrate an additional neuroprotective property of 
thrombin; its ability to promote the release of the organic osmolyte, taurine, in 
response to hypoosmotic stress.  Incubation of human 1321N1 astrocytoma cells 
with hypoosmolar buffers (320-227 mOsM) resulted in a time-dependent release 
of taurine.  Inclusion of thrombin (EC50=60 pM), resulted in a marked increase in 
taurine efflux which, although evident under isotonic conditions (340 mOsM), was 
maximal at an osmolarity of 270 mOsM (3-4 fold stimulation).  Thrombin-
stimulated taurine efflux was dependent upon its protease activity and could be 
mimicked by addition of the peptide SFLLRN, a Proteinase Activated Receptor-1 
(PAR-1) subtype specific ligand. Inclusion of anion channel blockers known to 
inhibit the volume-sensitive organic osmolyte anion channel attenuated thrombin-
stimulated taurine release.  Depletion of intracellular Ca2+ with either 1,2-bis(o-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA) or thapsigargin, or 
alternatively, inhibition of protein kinase C (PKC) with bisindolylmaleimide or 
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chelerythrine, resulted in a 30-50% inhibition of thrombin-stimulated taurine 
efflux.  Under conditions in which intracellular Ca2+ was depleted and PKC 
activity inhibited, thrombin-stimulated taurine efflux was reduced by >85%.  The 
results indicate that activation of PAR-1 receptors by thrombin facilitates the 
ability of 1321N1 astrocytoma cells to release osmolytes in response to a 
reduction in osmolarity via a mechanism that is dependent on intracellular Ca2+ 
and PKC activity. 
 
Introduction 
Recent evidence indicates that in addition to its role in platelet aggregation 
and tissue repair, thrombin, a serine protease generated from prothrombin, 
regulates numerous physiological and pathological responses including 
development, inflammation, atherogenesis, stroke and Alzheimer’s disease 
(Gingrich and Traynelis, 2000; Xi et al., 2003; Ossovaskaya and Bunnett, 2004; 
Suo et al., 2004).  Thrombin may also be produced in the brain following cerebral 
hemorrhage or disruption of the blood brain barrier.  It mediates its cellular 
functions through a family of receptors known as Proteinase Activated Receptors 
(PARs).  PARs belong to the superfamily of G-protein coupled receptors 
(GPCRs) which operate via Gq, Gi or G12/13 families of G-proteins and currently 
four members of the group (PAR1, PAR2, PAR3 and PAR4) have been 
identified. PARs have a unique activation mechanism.  They are activated by an 
irreversible proteolytic cleavage of the receptor’s extracellular N-terminus, thus 
unmasking a new N-terminus that functions as a “tethered peptide ligand,” which 
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then binds intra-molecularly to the receptors and initiates intracellular signal 
transduction (Macfarlane at al., 2001; Hollenberg and Compton, 2002; Trejo, 
2003; Wang and Reiser, 2003).  
All four PARs are expressed abundantly in the central nervous system 
(Striggow et al., 2001); however, their function is still unclear.  Previous studies 
indicate biphasic and dose-dependent actions of thrombin on astrocytes.  Low 
concentrations of thrombin (50 pM to 100 nM) mediate neuroprotection against 
ischemia and environmental insults such as oxidative stress, hypoglycemia, 
hypoxia and growth supplement deprivation.  High concentrations of thrombin 
however, can cause degeneration and cell death (Vaughan et al., 1995; Striggow 
et al., 2000; Jiang et al., 2002).  In vivo, pretreatment of the brain with a low dose 
of thrombin attenuates brain injury induced by cerebral hemorrhage or trauma 
although high dose thrombin infusion can cause astrogliosis (Xi et al., 1999; 
Masada et al., 2000).  It has also been demonstrated that PAR1 and PAR3 
receptors are up-regulated in various regions of the brain after environmental 
insults (Xi et al., 2003).  Recently, PAR1 and PAR3 were shown to mediate anti-
apoptotic signaling by activated protein C in neurons (Guo et al., 2004).  
Although these studies indicate the potential importance of low concentration of 
thrombin for the development of new therapeutic strategies to treat 
neurodegenerative disorders, the molecular mechanism(s) underlying 
neuroprotection remain to be established.  
A neuroprotective mechanism utilized by both neurons and glia is that of 
volume regulation following exposure of the cells to osmotic insult.  In response 
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to hypotonic stress, cells swell with a magnitude proportional to the reduction in 
osmolarity.  This rapid increase in volume is transient and followed by a recovery 
process of regulatory volume decrease (RVD), during which intracellular 
osmolytes (K+, Cl- and organic osmolytes) are extruded and cell volume 
normalized following the exit of intracellular water (McManus et al.,1995).  Of the 
 
organic osmolytes utilized by cells, taurine is ideally suited because of its 
abundance, water solubility and metabolic inertness (Lambert, 2004).  Swelling of 
neural cells due to fluctuations in osmolarity is very common in elderly, infants 
and during pregnancy.  It can be derived from excessive water intake, such as 
occurs in athletes and psychotic polydipsia, or alternatively in conditions such as 
glucocorticoid deficiency, hypothyroidism, use of thiazide diuretics, and renal or 
hepatic failure (Kimelberg, 2000; Pasantes-Morales et al., 2000, 2002).  The 
principal cell type involved in volume regulation within the central nervous system 
is the astrocyte, since these cells comprise up to 90% of cell number within the 
brain.  The importance of taurine release in RVD is indicated from studies in 
which taurine-deficient astrocytes were shown to exhibit a less efficient volume 
recovery in comparison to control cells (Moran et al., 1994).  The extrusion of 
taurine occurs predominantly via a channel known as Volume Sensitive Organic 
Osmolyte Anion Channel (VSOAC).  VSOAC is a chloride channel, impermeable 
to cations (for reviews, see Nilius et al.,1997; Lang et al.,1998; Nilius and 
Droogmans, 2003).  Taurine efflux, as well as RVD, can be blocked by classical 
non-selective Cl  channel inhibitors, such as - 1,9-dideoxyforskolin (DDF), 5-nitro-
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2-(3-phenypropylamine)benzoic acid (NPPB), 4,4’ diisothiocyano-2-2’ disulfonic 
stilbene (DIDS) and 4-acetamido-4 isothiocyano-2-2’ disulfonic stilbene (SITS).  
In the present study, we demonstrate that subnanomolar concentrations of 
thrombin, operating primarily via a PAR-1 receptor, facilitate the volume-sensitive 
efflux of taurine from human astrocytoma cells.  Thrombin-stimulated taurine 
efflux is mediated via a VSOAC channel and intracellular Ca and protein kinase 
C (PKC) are implicated in the mechanism of osmolyte release.  A preliminary 




Materials. [1,2-3H]Taurine (1.15 TBq/ml) was obtained from Amersham 
Biosciences (Piscataway, NJ).  Thrombin, DIDS, NPPB, SITS and 4α-phorbol 
12,13-didecanoate were purchased from Sigma-Aldrich (St. Louis, MO). 1,9-
Dideoxyforskolin, PMA, ionomycin, KN-93, PD 98059 and wortmannin were 
obtained from Calbiochem (San Diego, CA).  Pertussis toxin was obtained from 
List Biological Laboratories (Campbell, CA).  Thrombin receptor activating 
peptides, SFFLRN, TFLLRN, TFRGAP, GYPGKF were obtained from BaChem 
(Torrance, CA).  Guanidinethyl sulfonate was obtained from Toronto Chemicals 
(Toronto, ON).  Dulbecco’s modified Eagle medium (DMEM) and 50x 
penicillin/streptomycin were obtained from Invitrogen (Carlsbad, CA).  Fetal calf 
serum was obtained from Cambrex Bio Science Walkersville, Inc. (Walkersville, 
MD).  Tissue culture supplies were obtained from Corning Glassworks (Corning, 
NY), Starstedt (Newton, NC) and BD BioSciences (Franklin Lakes, NJ).  
 77
  
Universol was obtained from ICN biomedical (Urora, OH).  Dowex-1 resin 100-
200 mesh; x 8 formate) was obtained from Bio-Rad (Hercules, CA). 
 
Cell culture conditions. 
1321N1 astrocytoma cells (passages 5-21) were grown in tissue culture flasks 
(75 cm2/250 ml) in 20 ml of DMEM supplemented with 10% (v/v) of fetal calf 
serum with 1% penicillin/streptomycin.  The osmolarity of the medium was 330 - 
340mOsM.  Cells were grown at 37°C in a humidified atmosphere containing 
10% CO2.  The medium was aspirated and the cells detached from the flask with 
a tryspin-versene mixture (Biowhittaker, MD).  Cells were then resuspended in 
DMEM/10% fetal calf serum with penicillin/streptomycin and subcultured into 35 
mm, six-well culture plates for 3-5 days.  Experiments were routinely conducted 
on cells that had reached 50–90% confluency.  
 
Preparation of primary astrocyte cultures 
 
Neonatal cultures of rat astrocytes were prepared from 2-day-old rats (Sprague 
Dawley) essentially according to the method previously described (Jiang et al., 
2002). 
 
Measurement of taurine efflux. 
 Osmolyte efflux from 1321N1 astrocytoma cells was monitored essentially as 
previously described (Loveday et al. 2003, Heacock et al., 2004).  In brief, cells 
were prelabeled overnight with 18.5 KBq/ml of [3H]taurine at 37oC.  Under these 
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conditions, approximately 10-20% of the added radiolabel was taken up into the 
cells.  Uptake of radiolabel into 1321N1 cells was time-dependent (t1/2 ~7h), 
temperature sensitive (inhibited >98% by lowering the temperature to 4oC) and 
was inhibited by 75-80% by inclusion of a 500 µM guanidinethyl sulfonate, an 
inhibitor of the taurine uptake transporter (Lambert, 2004).  After prelabeling, the 
cells were washed with 2 x 2 ml of isotonic Buffer A (142 mM NaCl, 5.6 mM KCl, 
2.2 mM CaCl2, 3.6 mM NaHCO3, 1 mM MgCl2 and 30 mM HEPES, pH 7.4, 1 
mg/ml D-glucose; approx. 340 mOsM).  Cells were then allowed to incubate in 
2ml of hypotonic buffer A (320-200 mOsM; rendered hypotonic by a reduction in 
NaCl concentration) in the absence or presence of thrombin.  In some 
experiments, buffer A was made hypertonic (370 mOsM) by the addition of NaCl.  
Osmolarities of buffer A were monitored by means of an Osmette precision 
osmometer (PS Precision Systems, Sudbury, MA).  At times indicated, aliquots 
(200 µl) of the extracellular medium were removed and radioactivity determined 
after the addition of 5ml Universol scintillation fluid.  The reactions were 
terminated by rapid aspiration of the buffer and cells lysed by the addition of 2 × 
1 ml of ice-cold 6% (wt/vol) trichloroacetic acid.  Taurine efflux was calculated as 
a fractional release, i.e., the radioactivity released in the extracellular media as a 
percentage of the total radioactivity present initially in the cells.  The latter was 
calculated as the sum of radioactivity recovered in the extracellular medium and 
that remaining in the lysate at the end of the assay (Novak et al., 1999). “Basal” 
release of taurine is defined as that which occurs at a specified osmolarity in the 
absence of thrombin. 
 79
  
Measurement of Phosphoinositide Turnover.  
To monitor phosphoinositide turnover, 1321N1 cells that had been prelabeled 
with 148 KBq/ml of [3H]inositol for 96 h were incubated in hypotonic buffer A (270 
mOsM) that contained 5 mM LiCl.  The accumulation of radiolabeled inositol 
phosphates present in the trichloroacetic acid cell lysates was determined as 
previously described (Thompson and Fisher, 1990). 
 
Measurement of Cytoplasmic Calcium Concentration. 
Cytoplasmic free calcium concentrations, [Ca2+]i, were determined in 
suspensions of 1321N1 astrocytoma cells after preloading cells with the Ca2+ 
indicator, fura-2 AM (Molecular Probes, OR), as previously described (Fisher et 
al., 1989).  The fluorometer used was a Shimadzu RF-5301PC 
spectrofluorometer (Shimadzu Scientific Instruments, Columbia, MD).  
 
Data analysis. 
Experiments were performed in triplicate and repeated at least three times.  
Values quoted are given as means ± SEM for the number (n) of independent 
experiments indicated.  A two-tailed Student’s t-test (paired) was used to 
evaluate differences between two experimental groups (level of significance, 
p<0.05).  One-way or repeated measures Analysis of Variance (ANOVA) 
followed by Dunnett’s multiple comparisons test was used for statistical 
significance of differences between multiple groups.  EC50 values were obtained 




Osmosensitive efflux of taurine from 1321N1 astrocytoma cells is enhanced 
by the addition of thrombin.  When 1321N1 astrocytoma cells that had been 
prelabeled with [3H]taurine were exposed to hypotonic buffer (270 mOsM), there 
was a time-dependent release of the radiolabeled amino acid from the cells (Fig. 
2.1A).  The initial rate of release monitored over the first 5 min was greater than 
that observed following prolonged incubations.  Inclusion of thrombin (0.25U/ml 
equivalent to 1.25 nM) significantly enhanced the rate of release of taurine at all 
time points examined and increased the magnitude of response by approximately 
3-fold over basal (basal release being that monitored in the absence of thrombin; 
Fig. 2.1A).  If 1321N1 cells were first exposed to hypotonic buffer for 10 min and 
then thrombin added (i.e. after the initial rapid phase of taurine efflux), a 
significant stimulation of taurine release was still observed (Fig. 2.1B).  As a 
result of these observations, taurine efflux was routinely monitored after a 20 min 
incubation in subsequent experiments.  The addition of thrombin resulted in a 
concentration-dependent stimulation of taurine efflux with a maximum effect 
observed at 1.25 nM (Fig. 2.2).  The EC50 value for thrombin-stimulated taurine 
release from 1321N1 astrocytoma was 0.06 nM. 
 
Thrombin enhances osmosensitive taurine release via the PAR-1 receptor.  
To determine whether the ability of thrombin to enhance taurine release was 
mediated via its protease action at a receptor, two series of experiments were 
performed.  In the first, thrombin was pretreated with 4 µM D-Phe-Pro-Arg 
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Chloromethyl Ketone (PPACK), a protease inhibitor.  Although PPACK had no 
effect on basal taurine release, it essentially abolished the ability of thrombin to 
enhance taurine release (Fig. 2.3A).  In a second series of experiments, the 
ability of three synthetic Proteinase-Activated Receptor (PAR) peptides to 
enhance taurine release was evaluated.  Addition of 100 µM SFFLRN, a 
synthetic peptide specific for PAR-1 subtype, significantly increased taurine 
release over basal (275% of basal; Fig. 2.3B).  This enhancement, which was 
also observed with 100 µM TFFLRN-an additional PAR-1-specific peptide, was 
similar in magnitude to that observed for thrombin. Although inclusion of 500 µM 
PAR-3 specific peptide (TFRGAP) also increased taurine release, the effect was 
not significant and was markedly less than that of the PAR-1 agonist.  In contrast, 
the addition of the PAR-4 peptide, GYPGKF, did not significantly increase taurine 
release over basal.  Taken collectively, these data indicate that the ability of 
thrombin to enhance taurine release in 1321N1 astrocytoma is mediated 
primarily by the PAR-1 receptor subtype.  The ability of thrombin to stimulate 
taurine release under hypotonic conditions was also observed for primary 
cultures of rat astrocytes, although the effect was less marked (148% of basal; 
Fig. 2.3C) than that observed for 1321N1 astrocytoma cells.  
 
Thrombin enhances the volume-sensitive efflux of taurine from 1321N1 
astrocytoma cells as osmolarity decreases.  The ability of thrombin to 
potentiate the release of taurine at different osmolarities was examined.  Both 
basal and thrombin-stimulated release of taurine was monitored under conditions 
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of isotonicity (340 mOsM: defined by the osmolarity of the DMEM/fetal calf serum 
medium in which the cells are grown), mild- severe hypotonicity (320-227 mOsM) 
or mild hypertonicity (370 mOsM).  In the series of experiments conducted, the 
basal release of taurine was not significantly enhanced until the osmolarity of the 
buffer had been reduced to 227 mOsM.  In contrast, the addition of thrombin 
resulted in a significant increase in taurine efflux (279% of basal) even under 
isotonic conditions (Fig. 2.4).  Moreover, as the osmolarity of the buffer was 
reduced, the ability of thrombin to enhance taurine efflux over the basal 
component was further increased.  The maximum enhancement of taurine efflux 
was observed at an osmolarity of 270 mOsM (442 % of basal).  In contrast, when 
cells were exposed to mildly hypertonic buffer A (370 mOsM), the addition of 
thrombin did not significantly enhance taurine release.  As a result of these 
findings, an osmolarity of 270 mOsM was chosen for all subsequent experiments. 
 
Taurine efflux from 1321N1 astrocytoma is mediated via a VSOAC.  To 
determine whether thrombin-stimulated taurine release occurred via a VSOAC, 
the ability of four anion channel inhibitors, all of which are putative blockers of the 
VSOAC channel, to inhibit the basal and thrombin-stimulated efflux of taurine 
was examined.  All four anion channel inhibitors resulted in a significant inhibition 
of both basal- and thrombin-stimulated taurine release (Fig. 2.5).  At a 
concentration of 100 µM, dideoxyforskolin and NPPB were more effective at 
inhibiting taurine release than either of the stilbene derivatives, DIDS and SITS 
(67-94% inhibition vs. 40-64% inhibition) at concentrations of 100 µM and 500 
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µM, respectively.  Higher concentrations of the latter agents could not be tested 
as they resulted in detachment of cells from the dishes. 
 
Thrombin-stimulated taurine release is unaffected by pertussis toxin or 
inclusion of inhibitors of phophatidylinositol 3-kinase, mitogen-activated 
protein kinase or Ca2+ calmodulin dependent protein kinase II signaling 
pathways.  Since the PAR-1 subtype is known to couple to the pertussis toxin-
sensitive Gi subfamily of hetrotrimeric G proteins (Coughlin, 2000), we tested the 
ability of pertussis toxin to inhibit thrombin-stimulated taurine release.  Overnight 
pretreatment of the cells with pertussis toxin (60 ng/ml) resulted in a small 
reduction in basal release of taurine (68 ± 9% of control, n=6), whereas thrombin-
stimulated taurine efflux was unaffected (387 ± 54% vs. 509 ± 29% of basal for 
untreated- and pertussis toxin-treated cells, respectively, n=6). 
To examine the possibility that other known mediators of PAR-1 activation 
were involved in the thrombin-induced taurine release, cells were incubated with 
wortmannin (100 nM), a phosphatidylinositol 3-kinase inhibitor or PD 98059 (50 
µM), mitogen activated protein (MAP) kinase inhibitor (Wang et al., 2002), and 
KN-93 (10 µM), a Ca2+ CaMK II inhibitor.  No significant effect on either basal or 
thrombin-stimulated taurine release was observed for any of these inhibitors 
(data not shown).  
 
Taurine release from 1321N1 astrocytoma cells is enhanced following a rise 
in the concentration of intracellular calcium or activation of protein kinase 
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C.  Activation of thrombin receptors on 1321N1 astrocytoma cell has also been 
reported to elicit an increase in the activity of phospholipase C (PLC) mediated 
via Gq, with a concomitant rise in the concentration of cytoplasmic calcium, 
[Ca2+]i, and activation of PKC (Jones et al., 1989).  In agreement with these 
previous observations, the addition of thrombin to 1321N1 cells (incubated in 
hypotonic buffer A) resulted in a small, but significant, increase in the release of 
inositol phosphates (146 and 174% of basal after 5 or 10 min respectively; Fig. 
2.6A).  Thrombin addition also elicited a rise in [Ca2+]i (592 ± 78 nM vs 196 ± 23 
nM for basal, n=13), which was markedly attenuated when extracellular Ca2+ was 
omitted (69 ± 4% inhibition, n=14; Fig. 2.6B).  In the absence of extracellular 
Ca2+, the depletion of intracellular Ca2+ stores with 5 µM thapsigargin further 
reduced the ability of thrombin to increase [Ca2+]i (89 ± 2% inhibition, n = 8).  
A rise in [Ca2+]i, mediated by the addition of 1 µM ionomycin (which 
facilitates both the influx of extracellular Ca2+ and the release of Ca2+ from 
intracellular stores), partially mimicked the ability of thrombin to enhance taurine 
efflux from the astrocytoma cells (165% of basal; Fig. 2.7A).  A similar significant 
increase in taurine release was observed following the addition of PMA, a PKC 
agonist (170% of basal; Fig. 2.7A) whereas its inactive analog, 4-α-phorbol 
12,13-didecanoate, was without effect (data not shown).  When both PMA and 
ionomycin were added to the hypotonically treated cells, their effect on taurine 
release was additive (219% of basal).  However, thrombin-stimulated taurine 




To determine the role, if any, played by Ca2+ in basal- and thrombin-
stimulated taurine efflux, taurine release was monitored under conditions in 
which extracellular- and/or intracellular Ca2+ had been depleted.  Removal of 
extracellular Ca2+ had little or no effect on either basal- or thrombin-stimulated 
taurine efflux (Fig. 2.8A).  In contrast, chelation of intracellular Ca2+ with BAPTA-
AM significantly reduced the extent of the thrombin-stimulated taurine efflux (56% 
inhibition) whereas basal efflux was unaffected.  To further examine the role of 
intracellular Ca2+ in osmolyte release, the cells were preincubated with 5 µM 
thapsigargin (in the absence of extracellular Ca2+) to discharge the intracellular 
Ca2+ pools.  Under these conditions, the ability of thrombin to stimulate taurine 
efflux was reduced by 52% (Fig. 2.8B). 
To test the involvement of PKC in thrombin-stimulated taurine efflux, cells 
were preincubated with either 1 µM BIM or 10 µM chelerythrine.  Although BIM 
slightly decreased the basal taurine efflux, both BIM and chelerytherine 
significantly attenuated thrombin-stimulated taurine release (30% inhibition; Fig. 
2.9A).  Down-regulation of PKC following overnight incubation of the cells with 
100 nM PMA also resulted in reduction in an inhibition of thrombin-stimulated 
taurine efflux (54 ± 6% vs control cells, n=3).  The combination of inhibition of 
PKC with 10 µM chelerythrine, along with depletion of intracellular Ca2+ with 5 µM 







Subnanomolar concentrations of thrombin have been demonstrated to 
protect both neurons and astrocytes against metabolic insults such as 
hypoglycemia, ischemia or oxidative stress (Vaughan et al., 1995; Striggow et al., 
2000).  In the present study, we demonstrate that similarly low concentrations of 
thrombin also markedly increase the release of taurine, an organic osmolyte, 
from human 1321N1 astrocytoma cells following a mild hypoosmotic insult.  The 
ability of thrombin to enhance taurine release, which is dependent on its protease 
activity, occurs rapidly (within 1-2 min of addition) and can be observed 
regardless of whether thrombin is added prior to or after the initiation of taurine 
release (Figs. 2.1A and B).  The concentrations of thrombin required to enhance 
taurine release (EC50= 60 pM) is similar to those previously demonstrated to 
provide neuroprotection (Fig. 2.2).  Based upon the ability of the receptor-specific 
peptides SFLLRN and TFLLRN to fully mimic the ability of thrombin to enhance 
taurine release (and the relative ineffectiveness of PAR-3- and PAR-4-specific 
peptides), it appears that the PAR-1 receptor subtype is primarily responsible for 
thrombin-stimulated osmolyte release (Fig. 2.3B).  Although an astrocytoma cell 
line was primarily utilized for the present study, we observed that the addition of 
thrombin to primary cultures of rat brain astrocytes incubated under hypoosmotic 
conditions also resulted in a stimulation of taurine release above basal (Fig. 
2.3C).  Although the ability of thrombin to stimulate osmolyte release has 
previously been reported for myoblasts (Manolopoulos et al. 1997), to the best of 
our knowledge, the present results are the first to indicate a similar role for 
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thrombin in neural tissues and to identify the receptor subtype involved.  Thus 
one of the in vivo functions of thrombin in the brain, whether synthesized within 
the CNS or resulting from cerebral hemorrhage or a compromised blood-brain 
barrier, may be that of osmoregulation. 
The pharmacological profile of inhibition of both basal- and thrombin-
stimulated taurine efflux from 1321N1 astrocytoma cells by anion channel 
inhibitors is consistent with the involvement of a VSOAC in osmolyte release.  
Thus, taurine efflux was significantly inhibited by DIDS, SITS, NPPB and DDF, all 
of which are purported to be inhibitors of volume-sensitive anion channels (Nilius 
et al., 1997).  However, as previously observed for the volume-dependent efflux 
of taurine from SH-SY5Y neuroblastoma cells (Heacock et al., 2004), DDF and 
NPPB are markedly more potent inhibitors of osmolyte release from the 
astrocytoma cells than either of the two stilbene derivatives, DIDS and SITS.   
One notable feature of thrombin-stimulated taurine efflux is that the 
protease is able to substantially enhance osmolyte release (279% of basal) even 
under isotonic conditions (340 mOsM; Fig. 2.4).  This result suggests that even 
though the VSOAC primarily responds to a reduction of osmolarity, the channel is 
partially open under conditions of isotonicity, but not under hypertonic conditions 
(370 mOsM).  The ability of receptor activation to enhance osmolyte release 
under isotonic conditions has been observed previously.  For example, ATP-
induced D-aspartate release from astrocytes and muscarinic cholinergic receptor 
(mAChR)-mediated taurine efflux from neuroblastoma cells can be observed 
under isotonic conditions (Mongin and Kimelberg, 2002; Heacock et al., 2004).  
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In contrast, the mAChR-stimulated release of myo-inositol, another quantitatively 
major organic osmolyte, was not observed under isotonic conditions (Loveday et 
al., 2003).  In this context, it should be noted that the ability of organic osmolytes 
to permeate VSOAC is dependent upon their molecular dimensions.  Since the 
minimum diameter of the pore channel of the VSOAC is reported to be between 
5.4 and 8.0 Å (McManus et al., 1995; Nilius et al., 1997), osmolytes such as 
glutamate, D-aspartate or taurine will readily exit the cells, whereas myo-inositol, 
whose molecular dimensions are close to the pore diameter, is released less 
readily.  Although activation of PAR-1 receptors on astrocytoma cells can 
enhance taurine release under isotonic conditions, its effects become even more 
pronounced when the osmolarity is reduced by 5-20% – conditions under which 
the basal release of taurine is only minimally increased (Fig. 2.4).  These results 
are consistent with the concept that PAR-1 activation facilitates the ability of the 
cells to release osmolytes (and, by inference, to regulate their volume) under 
conditions of very limited reductions in osmolarity, i.e. those that might be 
expected to pertain to physiological or pathological conditions in vivo. 
 Although PAR-1 receptors are pleiotropic and can couple to multiple GTP-
binding proteins thereby activating a diverse array of signaling pathways 
(Coughlin, 2000; Trejo, 2003), our data suggest that Ca2+ and PKC play the 
major roles in facilitation of taurine release.  The evidence for this is as follows.  
First, the ability of thrombin to enhance taurine release could be mimicked, in 
part at least, by the addition of the Ca2+ ionophore, ionomycin.  Second, the 
mobilization of an intracellular pool of Ca2+ appears to be required since either 
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chelation of intracellular Ca2+ with BAPTA, or discharge of the pool with 
thapsigargin, resulted in a 52-56% inhibition of thrombin-stimulated taurine efflux.  
In contrast, removal of extracellular Ca2+ had no effect on the magnitude of 
efflux.  The reliance of thrombin-stimulated taurine release on intracellular (rather 
than extracellular) stores of Ca2+ contrasts with the Ca2+ signals generated in 
fura-2 loaded cells upon thrombin addition, which depend on both sources of 
Ca2+ (Fig. 2.6B).  This result suggests that (1) thrombin-stimulated taurine 
release may require a rise in [Ca2+]i, (2) the magnitude of osmolyte release is not 
directly proportional to that of the Ca2+ signal.  Moreover, it appears that a 
significant fraction of thrombin-stimulated osmolyte release can still occur in the 
absence of Ca2+ (see Fig. 2.8B).  Although thrombin addition results in an 
activation of PLC (Fig. 2.6A) and a rise in [Ca2+]i in these cells, an obligatory link 
between this pathway and osmolyte release is yet to be established because of 
the absence of a specific inhibitor of PLC (see Loveday et al., 2003). 
A role for PKC is indicated from the ability of PMA, when added alone, to 
stimulate taurine efflux and from the observation that either BIM or chelerythrine, 
two inhibitors of PKC, can inhibit thrombin-stimulated taurine release.  Further 
indication of the involvement of PKC was obtained from experiments in which 
down-regulation of the enzyme, following an overnight incubation of the cells with 
PMA, resulted in an attenuation of thrombin-stimulated taurine efflux.  Under 
conditions in which both intracellular Ca2+ is depleted and PKC inhibited, 
thrombin’s ability to stimulate osmolyte release was inhibited by 87%. In contrast 
to the Ca2+- and PKC-dependence of thrombin-stimulated taurine efflux, the 
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basal release of taurine is not dependent on either parameter.  This suggests 
that the ability of thrombin to activate VSOAC involves signaling pathways that 
are distinct from those elicited by hypotonicity alone.  A requirement for Ca2+ and 
PKC in receptor-regulated osmolyte release is emerging as a general 
characteristic (Loveday et al., 2003; Mongin and Kimelberg, 2005).  However, the 
source of Ca2+ may differ depending upon the receptor and/or cell type (Loveday 
et al., 2003).  Both PKC and Ca2+ CaMKII are potential downstream targets for 
Ca2+ activation.  However, the inability of KN-93 to inhibit thrombin-stimulated 
taurine efflux suggests that Ca2+ CaMKII  is not involved in VSOAC regulation. 
Although the general characteristics of swelling-induced osmolyte release 
from neural cells have been extensively examined, only recently has evidence 
emerged that certain pharmacologically distinct receptors such as the P2Y 
purinergic, M3-mAChR and now PAR-1, are able to positively regulate osmolyte 
efflux.  There are two major implications of these findings.  The first is that the 
ability of receptors to stimulate osmolyte release suggests that the process in 
vivo whereby hypoosmotically-stressed cells restore their volume may be more 
dynamic than previously considered, since these cells are also likely to be 
continuously subjected to neurohumoral regulation.  The second is that the ability 
of these receptors to facilitate osmolyte release under isotonic conditions via 
VSOAC raises the possibility that receptor-mediated release of another 
quantitatively major osmolyte in the brain, namely glutamate, which also 
functions as a neurotransmitter, may constitute a means for intercellular signaling 






ATP modulation of glutamate release from astrocytes under isotonic conditions 
(Jeremic et al., 2001), the present data raises the possibility that additional 
receptors may also share this property. In addition, it should be noted that taurine 
itself has agonist properties at both GABAA and glycine receptors (Hussy et al., 
1997; Hilgier et al., 2005). 
 In summary, the present data emphasizes the importance of receptor-
regulation of osmolyte release through a VSOAC.  Control of neural cell swelling 
is of particular importance to the CNS due to the spatial restrictions of the skull.  
In this case, thrombin via its PAR-1 receptor plays a role in protection of neural 
cells from osmotic insults and regulates volume via a mechanism dependent 
upon intracellular Ca2+ and PKC.  This role for thrombin in osmoregulation within 
the brain adds to the growing list of functions attributed to this protease in CNS 





















































Figure 2.1. Kinetics of basal- and thrombin-stimulated taurine efflux from human 1321N1 astrocytoma cells.  (A) 1321N1 
human astrocytoma cells that had been prelabeled in the presence of [3H]taurine were washed twice with 2 ml of isotonic buffer A 
before incubation in 270 mOsM buffer A in the presence or absence of 1.25 nM thrombin (added at time zero, as indicated by the 
arrow).  Reactions were terminated at the times indicated and taurine efflux measured.  Results are expressed as taurine efflux 
(percentage of total soluble radioactivity) and are the means ± S.E.M. for triplicate replicates.  Data shown are representative of three 
experiments.  (B) Cells were treated as described in (A) with the exception that cells were allowed to incubate for 10 min in hypotonic 











































Figure 2.2. Concentration-response relationship for thrombin-stimulated taurine 
efflux.  Cells that had been prelabeled with [3H]taurine were washed with isotonic buffer 
A and then incubated in 270 mOsM buffer in the presence of thrombin at the 
concentrations indicated.  Reactions were terminated after 20 min and taurine efflux was 
monitored.  Results are expressed as percentage of maximum agonist response 
(obtained at 5 nM thrombin) and are the means ± S.E.M. for three independent 



























































































































































Figure 2.3. Thrombin enhances taurine efflux from 1321N1 astrocytoma through 
its protease activity and via a Proteinase Activated Receptor-1 subtype. (A) Cells 
that had been prelabeled with [3H]taurine were washed in isotonic buffer A and 
incubated for 20 min in 270 mOsM buffer A in the presence or absence of 1.25 nM 
thrombin.  In some experiments thrombin was pretreated with 4 µM PPACK, a protease 
inhibitor.  In (B) cells were incubated for 20 min in the presence of thrombin or synthetic 
peptides specific for PAR-1, PAR-3 and PAR-4 subtypes and efflux monitored. 
Maximally effective concentrations of the synthetic peptides were used. Results are 
expressed as taurine efflux (percentage of total soluble radioactivity) and are the means 
± S.E.M for 4 to 6 independent experiments. **, different from basal control, p<0.01 (by 
repeated measures ANOVA followed by Dunnett’s multiple comparisons test).  In (C) 
primary cultures of rat astrocytes were prelabeled overnight with [3H]taurine, washed in 
isotonic buffer A and then incubated for 20 min in 270 mOsM buffer A in the presence or 
absence of 1.25nM thrombin. Results are expressed as taurine efflux (percentage of 
total soluble radioactivity) and are the means ± S.E.M for 7 independent experiments. **, 





































































Figure 2.4. Basal- and thrombin-stimulated release of taurine as a function of 
osmolarity.  Cells prelabeled with [3H]taurine were first washed in isotonic buffer A and 
then incubated for 20 min in buffer A at the osmolarities indicated in the absence (open 
bars) or presence (filled bars) of 1.25 nM thrombin.  Results are expressed as taurine 
efflux (percentage of total soluble radioactivity) and are the means ± S.E.M. for 4 to 8 
independent experiments, each performed in triplicate. #, different from taurine release 
observed in cells incubated in isotonic buffer A (340 mOsM), p<0.01 (by one-way 
ANOVA followed by Dunnett’s multiple comparison test). **, different from basal release 
(in the absence of thrombin-open bars), p<0.01 (by paired student’s t-test).  Inset-











































































Figure 2.5. Inhibition of basal- and thrombin-stimulated taurine release by anion 
channel blockers.  Cells that had been prelabeled with [3H]taurine were washed in 
isotonic buffer A and then incubated in hypotonic buffer A (270 mOsM) with 100 µM 
dideoxyforskolin (DDF), 100 µM DIDS, 500 µM SITS or 100 µM NPPB in the absence 
(open bars) or presence (filled bars) of 1.25 nM thrombin.  Reactions were terminated 
after 20 min and efflux of taurine monitored.  Results are expressed as taurine efflux 
(percentage of total soluble radioactivity) and are the means ± S.E.M. of 6-8 
independent experiments, each performed in triplicate. * and **, different from control 
basal, p<0.05 and p<0.01 respectively.  #, different from thrombin-stimulated efflux 




































































Figure 2.6. Thrombin elicits an increase in phosphoinositide turnover and in cytoplasmic free calcium. (A)  Cells that had 
been prelabeled for 96 h with [3H]inositol were washed in isotonic Buffer A and then incubated for either 5 or 10 min in hypotonic 
buffer A (270 mOsM) in the presence or absence of thrombin (1.25 nM).  Reactions were terminated by the addition of trichloroacetic 
acid and the accumulation of radiolabeled inositol phosphates was monitored as an index of stimulated phosphoinositide turnover.  
Results are expressed as inositol phosphate release/total soluble radioactivity and are the means ± S.E.M. for five (5 min incubation) 
or four (10 minute incubation) independent experiments. **, different from basal release, p< 0.001 (by paired Student’s t test).  (B) 
Fura-2 loaded cells were resuspended in 270 mOsM buffer A with (  ) or without (  ) extracellular Ca2+ or (   ) pretreated 5 min with 5 
µM thapsigargin in the absence of extracellular Ca2+.  Ca2+ signals were monitored after the addition of thrombin (1.25 nM) at 120 sec 



























































































Figure 2.7. Activation of either PKC, or a rise in intracellular Ca2+, facilitates taurine efflux.  (A) Cells that had been prelabeled 
with [3H]taurine were washed with isotonic buffer A and then incubated in hypotonic buffer A (270 mOsM) with or without PMA (100 
nM), ionomycin (1 µM) or both.  Reactions were terminated after 20 min and taurine efflux monitored.  Results are expressed as 
taurine efflux (percentage of total soluble radioactivity) and are the means ± S.E.M. for 6 independent experiments, each performed 
in triplicate. **, different from control, p<0.01 (by repeated measures ANOVA followed by Dunnett’s multiple comparisons test).  (B) 
Cells were treated as described in (A) but incubated with thrombin (1.25 nM), in the absence or presence of PMA or ionomycin. 
Results are expressed as taurine efflux (percentage of total soluble radioactivity) and are the means ± S.E.M. for four independent 

















































































Figure 2.8. The role of extracellular- and intracellular calcium in thrombin-stimulated taurine efflux.  (A) Cells that had been 
prelabeled with [3H]taurine were washed in isotonic buffer A and then incubated for 20 min in hypotonic buffer A (270 mOsM) in the 
absence (-ext Ca: Ca2+ was omitted and 100 µM EGTA added) or presence of extracellular Ca2+ and with the absence (open bars) or 
presence (filled bars) of 1.25 nM thrombin.  In some experiments, cells were pretreated for 15 min in isotonic buffer A in the presence 
of 50 µM BAPTA-AM prior to the measurement of efflux.  Results are expressed as taurine efflux (percentage of total soluble 
radioactivity) and are the means ± S.E.M. for 3 to 6 independent experiments. Basal- (open bars) and thrombin-stimulated taurine 
release (filled bars) was monitored under all conditions. ***, different from control basal, p<0.001, #, different from thrombin-
stimulated efflux under control conditions, p<0.05 (by one-way ANOVA followed by Dunnett’s multiple comparisons test).  (B) Cells 
were preincubated for 5 min in 270 mOsM buffer A (Ca2+ omitted and 50 µM EGTA added) in either the absence (control) or 
presence of 5 µM thapsigargin.  Thrombin or buffer A was then added and incubations allowed to proceed for an additional 10 min.  
Results are expressed as taurine efflux (percent of total soluble radioactivity) and are the means ± S.E.M. for 5 independent 
experiments. **, different from control basal, p<0.01; #, different from thrombin-stimulated efflux under control conditions, p<0.01 (by 












































































Figure 2.9. Inhibition of thrombin-stimulated taurine efflux by PKC inhibitors in the presence or absence of Ca2+.  (A) Cells 
were pretreated with 10 µM chelerytherine or 1 µM BIM in isotonic buffer A for 15 min before incubation of cells in hypotonic buffer A 
(270 mOsM) in the absence (open bars) or presence (filled bars) of 1.25 nM thrombin.  Reactions were terminated after 20 min and 
taurine efflux monitored.  Results are expressed as taurine efflux (percentage of total soluble radioactivity) and are the means ± 
S.E.M for three independent experiments, each performed in triplicate. *, different from basal control, p<0.05 and #, different from 
thrombin-stimulated efflux under control conditions, p<0.01 (by repeated measures ANOVA followed by Dunnett’s multiple 
comparisons test).  (B) Cells were first preincubated for 15 min in the absence (control) or presence of 10 µM chelerythrine (chel) in 
isotonic buffer A.  The medium was then aspirated and replaced with 270 mOsM buffer A, either Ca2+ containing (control) or with 
Ca2+ omitted and 50 µM EGTA, 5 µM thapsigargin and 10 µM chelerythrine added.  Cells were preincubated for 5 min prior to the 
addition of thrombin (final concentration 1.25 nM) or buffer A, prepared in the same media.  After an additional 10 min, reactions 
were terminated and taurine efflux measured.  Results are expressed as taurine efflux (percentage of total soluble radioactivity) and 
are the means ± S.E.M. for 6 independent experiments. *, different from control basal release, p<0.01; #, different from thrombin-
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RECEPTOR REGULATION OF THE VOLUME-SENSITIVE EFFLUX OF 
TAURINE AND IODIDE FROM HUMAN SH-SY5Y NEUROBLASTOMA CELLS: 





The basal- (swelling-induced) and receptor-stimulated efflux of 125I- and 
taurine have been monitored to determine whether these two osmolytes are 
released from human SH-SY5Y cells under hypotonic conditions via common or 
distinct mechanisms.  Under basal conditions, both 125I- (used as a tracer for Cl-) 
and taurine were released from the cells in a volume-dependent manner.  
Thrombin addition, mediated via the proteinase activated receptor-1 (PAR-1) 
subtype, significantly enhanced the release of both 125I- and taurine (3- to 6-fold) 
and also increased the threshold osmolarity for efflux of these osmolytes (‘set-
point’) from 200 to 290 mOsM.  Inclusion of a variety of broad spectrum anion 
channel blockers and of 4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-
1H-inden-5-yl)oxy]butanoic acid (DCPIB) attenuated the release of both 125I- and 
taurine under basal- and receptor-stimulated conditions.  Basal release of 125I- 
and taurine was independent of Ca2+ or the activity of protein kinase C (PKC).  
However, although PAR-1-stimulated taurine efflux was attenuated by either a 
depletion of intracellular Ca2+ or inhibition of PKC by chelerythrine, the enhanced 
release of 125I- was independent of both parameters.  Stimulated efflux of 125I- 
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following activation of muscarinic cholinergic receptors was also markedly less 
dependent on Ca2+ availability and PKC activity than that observed for taurine 
release.  These results indicate that, although the osmosensitive release of these 
two osmolytes from SH-SY5Y cells may occur via pharmacologically similar 
membrane channels, the receptor-mediated release of 125I- and taurine is 
differentially regulated by PKC activity and Ca2+ availability. 
 
Introduction 
Cell volume is constantly subject to change as a consequence of solute 
accumulation, oxidative metabolism or fluctuations in the osmolarity of the 
extracellular fluid.  To survive, cells need to regulate their volume within relatively 
narrow limits and this homeostatic mechanism is of particular importance to the 
brain due to the restrictions of the skull.  A common cause of brain swelling is 
hyponatremia, a condition that disproportionately impacts the elderly, infants, 
marathon runners and military personnel (Upadhyay et al., 2006).  Hyponatremia 
is associated with a variety of neurological symptoms, such as disorientation, 
mental confusion and seizures (Kimelberg, 2000; Pasantes-Morales et al., 2000, 
2002).  
In response to hypotonic stress, cells swell with a magnitude proportional 
to the reduction in osmolarity.  This is followed by a homeostatic mechanism 
termed regulatory volume decrease (RVD) which involves the extrusion of 
intracellular ions such as K+, Cl- and a number of organic osmolytes, which 
together facilitate the loss of water to normalize cell volume (Pasantes-Morales et 
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al., 2000). Inorganic ions constitute two-thirds of the osmolytes released during 
RVD and the remainder is accounted for by “compatible” organic osmolytes such 
as polyols, methylamines and amino acids.  Of these, taurine, an amino acid 
present in eukaryotic cells at concentrations of up to 40 mM, is considered to be 
an ideal osmolyte due to its metabolic inertness and abundance (Huxtable, 1992; 
Lambert, 2004).  
It is proposed that extrusion of these osmolytes from the cell is mediated 
via a volume-sensitive organic osmolyte and anion channel (VSOAC), which is 
primarily permeable to Cl- but impermeable to cations (for reviews, see Lang et 
al., 1998; Nilius and Droogmans, 2003).  Evidence to support the involvement of 
VSOAC in response to hypotonic stress comes from studies in which RVD, 
volume-sensitive Cl- current and organic osmolyte release can all be blocked by 
broad spectrum anion channel inhibitors, such as DDF or NPPB, and by a highly 
selective agent, DCPIB (Decher et al., 2001; Abdullaev et al., 2006).  Similarities 
in the pharmacological inhibition profile of swelling-activated efflux of organic 
osmolytes and Cl- in response to anion channel blockers has led to the 
suggestion that a common pathway exists for the extrusion of both Cl- and 
organic osmolytes (Jackson and Strange, 1993; Banderali and Roy, 1992; 
Sanchez-Olea et al., 1996; Abdullaev et al., 2006).  However this possibility is at 
variance with results obtained from some non-neural tissues in which Cl- and 
taurine effluxes were found to exhibit differences in kinetics of release, osmotic 
sensitivity and/or degree of inhibition by anion channel blockers, results which 
suggest the existence of separate volume-sensitive channels for Cl- and organic 
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osmolytes (Lambert and Hoffman, 1994; Davis-Amaral et al. 1996; Shennan et 
al., 1996; Stutzin et al., 1999; Shennan and Thomson, 2000; Tomassen et al., 
2004). 
When measured in vitro, the efflux of organic osmolytes is relatively 
insensitive to hypotonic stress often requiring substantial (>25%) reductions in 
osmolarity.  However, recent studies from this and other laboratories have 
demonstrated that the volume-sensitive efflux of organic osmolytes from neural 
preparations can be enhanced following activation of cell-surface receptors.  The 
latter include P2Y purinergic receptors in rat astrocytes (Mongin and Kimelberg, 
2002, 2005), M3 muscarinic cholinergic (mAChR), lysophosphatidic and 
sphingosine 1-phosphate receptors in human SH-SY5Y neuroblastoma cells 
(Loveday et al., 2003; Heacock et al., 2004, 2006) and proteinase-activated 
receptor-1 (PAR-1) in human 1321N1 astrocytoma and rat astrocytes (Cheema 
et al., 2005).  In each case, Ca2+ availability and PKC activity are required for the 
maximum release of organic osmolytes.  
The goals of the present study were two-fold.  First, to determine whether 
the release of 125I- (used as a tracer for Cl-) from hypotonically-stressed SH-SY5Y 
neuroblastoma cells was, like that of taurine, subject to receptor regulation and 
second, to evaluate whether these two osmolytes are released from the cells via 
similar or distinct mechanisms.  The results indicate that the activation of either 
PAR-1 or mAChRs elicits a significant increase in the osmosensitive release of 
both 125I- and taurine and that the efflux of these osmolytes exhibits a similar, if 
not identical, inhibition profile in response to a variety of putative pharmacological 
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inhibitors of VSOAC.  However, the receptor-mediated efflux of 125I- can be 
readily differentiated from that of taurine on the basis of its more limited 
dependence on Ca2+ availability and, to a lesser extent, PKC activity.  Thus, in 
SH-SY5Y cells, although both osmolytes may exit via a common (or 
pharmacologically similar) channel(s), distinct biochemical requirements exist for 
the receptor-stimulated release of 125I- and taurine. 
 
Methods 
Materials. [1,2-3H] Taurine (1.15 TBq/ml) and Na iodide (125I- labeled; 3885 
MBq/ml) were obtained from Amersham Biosciences (Piscataway, NJ). 
Chelerythrine, thapsigargin, toxin B, Y-27632 and niflumic acid were obtained 
from Calbiochem (San Diego, CA). Thrombin, DIDS, NPPB, 1,9-Dideoxyforskolin 
and oxotremorine-M (Oxo-M) were purchased from Sigma-Aldrich (St. Louis, 
MO). DCPIB was obtained from Tocris Biosciences (Ellisville, MO). Thrombin 
receptor activating peptides; TFLLRN, TFRGAP, GYPGKF were purchased from 
BaChem (Torrance, CA). Fura 2/acetoxymethyl ester (Fura-2/AM) was 
purchased from Molecular Probes (Eugene, OR). Dulbecco’s modified Eagle 
medium (DMEM) and 50x penicillin/streptomycin were obtained from Invitrogen 
(Carlsbad, CA). Fetal calf serum was obtained from Cambrex Bio Science 
Walkersville, Inc. (Walkersville, MD). Tissue culture supplies were obtained from 
Corning Glassworks (Corning, NY), Starstedt (Newton, NC) and BD BioSciences 
(Franklin Lakes, NJ). Universol was obtained from Valeant Pharmaceuticals 




Cell culture conditions. 
Human SH-SY5Y neuroblastoma cells (passages 75-90) were grown in tissue 
culture flasks (75 cm2/250 ml) in 20 ml of DMEM supplemented with 10% (v/v) of 
fetal calf serum with 1% penicillin/streptomycin. The osmolarity of the medium 
was 330- 340 mOsM. Cells were grown at 37°C in a humidified atmosphere 
containing 5% CO2. The medium was aspirated and the cells detached from the 
flask with a trypLE express (Biowhittaker, MD) or sterile D1 solution (Heacock et 
al., 2004). Cells were then resuspended in DMEM/10% fetal calf serum with 
penicillin/streptomycin and subcultured into 35 mm, six-well culture plates for 5-6 
days. Experiments were routinely conducted on cells that had reached 70–90% 
confluency.  
 
Measurement of efflux of taurine or 125I-. 
 Osmolyte efflux from SH-SY5Y neuroblastoma cells was monitored essentially  
as previously described (Heacock et al., 2004; Tomassen et al., 2004). In brief, 
cells were prelabeled overnight with 18.5 KBq/ml of [3H]taurine or 92.5 KBq/ml of 
125I- at 37oC.  After prelabeling, the cells were washed 2 or 3 times with 2 ml of 
isotonic buffer A (142 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2, 3.6 mM NaHCO3, 
1mM MgCl2 and 30 mM HEPES, pH 7.4, 1 mg/ml D-glucose; approx. 340 
mOsM). Cells were then allowed to incubate in 2 ml of hypotonic buffer A (295-
195 mOsM; rendered hypotonic by a reduction in NaCl concentration) in the 
absence or presence of thrombin or Oxo-M. In some experiments, buffer A was 
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made hypertonic (370 mOsM) by the addition of NaCl. Osmolarities of buffer A 
were monitored by means of an Osmette precision osmometer (PS Precision 
Systems, Sudbury, MA). At times indicated, aliquots of the extracellular medium 
(200 µl for taurine and 1 ml for 125I-) were removed and radioactivity determined 
after the addition of 6 ml Universol scintillation fluid. The reactions were 
terminated by rapid aspiration of the buffer and cells lysed by the addition of 2 ml 
of ice-cold 6% (wt/vol) trichloroacetic acid for taurine or 1 ml of 0.1 M NaOH for 
125I-. Efflux of taurine or 125I- was calculated as a fractional release, i.e., the 
radioactivity released in the extracellular medium as a percentage of the total 
radioactivity present initially in the cells.  The latter was calculated as the sum of 
radioactivity recovered in the extracellular medium and that remaining in the 
lysate at the end of the assay. For 125I- efflux, radioactivity released at the zero 
time point was subtracted from the observed release of 125I-.  Throughout this 
study, “basal” release of taurine or 125I- is defined as that which occurs at a 
specified osmolarity in the absence of agonists. 
 
Measurement of Phosphoinositide Turnover.  
To monitor phosphoinositide turnover, SH-SY5Y cells that had been prelabeled 
with 148 KBq/ml of [3H]inositol for 96 hr were incubated in hypotonic buffer A 
(230 mOsM) that contained 5 mM LiCl.  The accumulation of radiolabeled inositol 
phosphates present in the trichloroacetic acid cell lysates was determined as 




Measurement of Cytoplasmic Calcium Concentration. 
Cytoplasmic free calcium concentrations, [Ca2+]i, were determined in 
suspensions of SH-SY5Y neuroblastoma cells after preloading cells with the Ca2+ 
indicator, fura-2 AM (Molecular Probes, OR), as previously described (Fisher et 
al., 1989; Cheema et al., 2005).  The fluorometer used was a Shimadzu RF-
5301PC spectrofluorometer (Shimadzu Scientific Instruments, Columbia, MD).  
 
Data analysis. 
Experiments were performed in triplicate and repeated at least three times. 
Values quoted are given as means ± S.E.M. for the number (n) of independent 
experiments indicated. A two-tailed Student’s t-test (paired) was used to evaluate 
differences between two experimental groups (level of significance, p<0.05). 
One-way or repeated measures Analysis of Variance (ANOVA) followed by 
Dunnett’s multiple comparisons test was used for statistical significance of 




Volume-sensitive efflux of taurine and 125I- from SH-SY5Y neuroblastoma 
cells is enhanced by the addition of thrombin.  When SH-SY5Y cells that had 
been prelabeled with [3H]taurine were exposed to hypotonic buffer A (230 mOsM; 
~30% reduction in osmolarity), there was a time-dependent release of the 
radiolabeled amino acid from the cells (Fig. 3.1A).  Although the presence of a 
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functionally coupled thrombin receptor on SH-SY5Y cells has not previously been 
reported, inclusion of thrombin (0.25U/ml, equivalent to 1.25 nM) significantly 
enhanced the rate of release of taurine at all time points examined and increased 
the magnitude of efflux by approximately 7-8 fold over basal (basal release is that 
monitored in the absence of thrombin).  Similarly, exposure of the cells to 
hypotonic buffer A alone also resulted in an increase in 125I- efflux (Fig. 3.1A) and 
this was enhanced by the presence of thrombin (2-3 fold).  Both the rate and 
magnitude of thrombin-stimulated 125I- efflux was greater than that of taurine 
release.  Thus, the net increase in 125I- efflux over basal due to the addition of 
thrombin reached a maximum of 42% of the total radioactivity within 5 min, 
whereas the corresponding value for taurine was 25% (Fig. 3.1B).  Since the 
greatest difference in magnitude of thrombin-stimulated 125I- and taurine release 
was observed in the first 5 min, the efflux of these osmolytes was subsequently 
routinely monitored after 5 min of incubation.   
 
Thrombin enhances the volume-sensitive release of taurine and 125I- via the 
PAR-1 receptor.  To determine whether the ability of thrombin to enhance 
taurine and 125I- release was mediated via the same receptor, three specific 
Protease-Activated Receptor (PAR) peptides were used.  Addition of 100 µM 
TFFLRN, a synthetic peptide specific for the PAR-1 subtype, significantly 
increased the release of both taurine (1226% of basal; Fig 3.2A) and 125I- (278% 
of basal; Fig. 3.2B).  The enhancement of osmolyte release obtained with a PAR-
1-specific peptide was similar in magnitude to that observed for thrombin. 
 114
 
Although inclusion of a 500 µM concentration of the PAR-3 specific peptide 
(TFRGAP) also increased the release of taurine (269% of basal) and 125I- (142% 
of basal), the effect was markedly less than that obtained for the PAR-1 agonist.  
The addition of the PAR-4 peptide, GYPGKF, did not significantly increase 
taurine or 125I- release.  Taken collectively, these data indicate that the ability of 
thrombin to enhance taurine and 125I- release in SH-SY5Y neuroblastoma cells is 
mediated primarily by the PAR-1 receptor subtype.   
 
Comparison of the volume-sensitive efflux of taurine and 125I- at various 
osmolarities.  Because the degree of receptor-mediated facilitation of osmolyte 
release appears to be dependent on the degree of hypoosmotic stress in SH-
SY5Y cells (Heacock et al., 2004; 2006), the ability of thrombin to potentiate the 
release of taurine (Fig. 3.3A) and 125I- (Fig. 3.3B) at different osmolarities was 
examined.  Both basal- and thrombin-stimulated release of taurine and 125I- were 
monitored under conditions of isotonicity (340 mOsM: defined by the osmolarity 
of the DMEM/fetal calf serum medium in which the cells were grown), mild - 
severe hypotonicity (295-195 mOsM) or mild hypertonicity (370 mOsM).  In the 
series of experiments conducted, the basal release of taurine was not 
appreciably enhanced until the osmolarity of the buffer had been reduced to 195 
mOsM (Fig. 3.3A).  In contrast, the addition of thrombin resulted in a significant 
increase in taurine efflux (312% of control) even under mild hypotonic conditions 
(295 mOsM).  Moreover, as the osmolarity of the buffer was reduced, the ability 
of thrombin to enhance taurine efflux over the basal component was further 
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increased.  A similar trend was observed for 125I- efflux for which the basal 
release was not significantly enhanced until the osmolarity of the buffer had been 
reduced to 200 mOsM (Fig. 3.3B).  The addition of thrombin resulted in a 
significant increase in 125I- efflux (183% of control) under mild hypotonic 
conditions (290 mOsM).  The maximum enhancement of both taurine efflux 
(892% of control) and 125I- (319% of control) in the presence of thrombin was 
observed at an osmolarity of approximately 230 mOsM.  In contrast, when cells 
were exposed to mildly hypertonic buffer A (370 mOsM), the addition of thrombin 
did not significantly enhance the release of either taurine or 125I-.  
 
Volume-sensitive efflux of taurine and 125I- efflux from SH-SY5Y 
neuroblastoma is mediated via a VSOAC.  Since VSOAC is considered to be 
primarily a chloride channel, the ability of a variety of broad spectrum chloride 
channel inhibitors to attenuate basal- and thrombin-stimulated taurine (Fig. 3.4A) 
and 125I- release was examined (Fig. 3.4B).  The addition of DIDS, NPPB or DDF 
resulted in a significant inhibition of the basal- and thrombin-stimulated release of 
both taurine and 125I- from SH-SY5Y cells (28-73% and 28-95% for basal- and 
thrombin-stimulated efflux, respectively; Fig. 3.4 A,B).  In general, the anion 
channel blockers, in particular DIDS, were less effective inhibitors of 125I- release 
than that of taurine under both basal- and agonist-stimulated conditions. The 
inclusion of 100 µM niflumic acid, which, at this concentration is purported to 
inhibit Ca2+-activated Cl- channels (Large and Wang, 1996) resulted in a 43% 
inhibition of thrombin-stimulated taurine release, but had no effect on either the 
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thrombin-stimulated 125I- efflux or on the basal release of either osmolyte (Fig. 3.4 
A, B).  
Because these anion channel inhibitors are relatively non-specific, the 
ability of DCPIB, an agent that is considered highly selective for VSOAC (Decher 
et al., 2001; Best et al., 2004; Abdullaev et al., 2006), was also examined for its 
ability to inhibit both taurine and 125I- efflux.  Inclusion of 20 µM DCPIB 
significantly inhibited the basal release of both taurine and 125I- to a similar extent 
(49% and 58% inhibition; Fig. 3.5 A,B, respectively).  Similarly, DCPIB also 
inhibited the thrombin-stimulated taurine and 125I- release (85-87% inhibition).   
 
Thrombin addition elicits an increase in the concentration of intracellular 
calcium in SH-SY5Y cells via a phopholipase C - independent mechanism. 
As previously observed for 1321N1 astrocytoma cells (Cheema et al., 2005), the 
addition of thrombin to fura-2-loaded SH-SY5Y cells resulted in a significant 
increase in [Ca2+]i (from a basal value of 100 nM to a peak value of 250 nM, n = 
8).  Removal of extracellular Ca2+ diminished the thrombin-mediated increase in 
[Ca2+]i from 150 to 75 nM, (n = 8) whereas depletion of intracellular Ca2+ with 
thapsigargin completely abolished the ability of thrombin to increase [Ca2+]i.  The 
thrombin-mediated rise in [Ca2+]i. occurred independently of phospholipase C 
activation since no increase in release of inositol phosphates was observed in 
the presence of thrombin (104 ± 2% of control, n=3).  In contrast, the addition of 
a 100 µM concentration of the muscarinic agonist, Oxo-M, which also elicits a 
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robust increase in [Ca2+]i in these cells (Heacock et al., 2006), resulted in a 
significant increase in inositol phosphate release (250 ± 19% of control, n = 3). 
 
Thrombin-stimulated efflux of taurine, but not that of 125I-, is dependent on 
Ca2+ availability and activation of PKC.  Activation of thrombin receptors on 
1321N1 astrocytoma cells has been reported to elicit an increase in taurine 
release that is dependent on the intracellular concentration of calcium and 
activation of PKC (Cheema et al., 2005).  In agreement with our previous 
observations, the magnitude of thrombin-stimulated taurine release from SH-
SY5Y neuroblastoma cells is also dependent on Ca2+ availability.  However in 
SH-SY5Y cells, removal of extracellular Ca2+ alone is sufficient to inhibit 
thrombin-stimulated taurine release (24% inhibition), while the basal release of 
taurine is unaffected.  Depletion of intracellular Ca2+ stores with 1 µM 
thapsigargin did not further increase the extent of inhibition and no effect on 
basal release of taurine was observed (Fig. 3.6A).  Neither the basal- nor 
thrombin-stimulated efflux of 125I- efflux was attenuated by omission of 
extracellular Ca2+ or depletion of intracellular Ca2+ stores with 1 µM thapsigargin 
(Fig. 3.6B). 
To evaluate a role, if any, for PKC in basal and thrombin-stimulated efflux 
of taurine and 125I-, cells were preincubated with 10 µM chelerythrine prior to 
thrombin challenge under hypotonic conditions.  Although chelerythrine had no 
effect on the basal release of taurine, it significantly attenuated thrombin-
stimulated release (30% inhibition; Fig. 3.7A). In contrast, although a small 
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reduction (9%) in the basal release of 125I- was observed following chelerythrine 
pretreatment, no effect on the magnitude of thrombin-stimulated efflux was 
observed (Fig. 3.7B).  The combination of inhibition of PKC with 10 µM 
chelerythrine, along with depletion of intracellular Ca2+ with 1 µM thapsigargin, 
resulted in a 54% inhibition of thrombin-stimulated taurine release but had no 
effect on basal efflux (Fig. 3.8A).  In contrast, 125I- release elicited by the addition 
of thrombin was not attenuated under these conditions (Fig. 3.8B). 
 
Efflux of taurine and 125I- following the activation of mAChRs is also 
differentially sensitive to depletion of Ca2+ and activation of PKC.  The 
observation that the efflux of taurine and 125I- observed following thrombin 
addition is differentially regulated by Ca2+ and PKC prompted us to examine 
whether this relationship is also observed following the activation of mAChRs.  
As previously observed (Heacock et al., 2006), Oxo-M-stimulated taurine release 
was attenuated by omission of extracellular Ca2+ (60% inhibition; Fig. 3.9A) and 
further in the presence of 1 µM thapsigargin to deplete intracellular Ca2+pools (81 
± 4% inhibition; Fig. 3.9A).  However, Oxo-M-stimulated 125I- efflux was 
unaffected by removal of extracellular Ca2+ and significantly less inhibited than 
taurine release following the additional depletion of intracellular Ca2+ (31 ± 6% 
inhibition; Fig. 3.9B, p<0.005). 
To examine the involvement of PKC, Oxo-M-stimulated taurine release 
was measured after preincubation of the cells with 10 µM chelerythrine.  Basal 
taurine release was unaffected whereas that due to Oxo-M addition was 
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significantly inhibited (73 ± 5% inhibition; Fig. 3.10A).  Chelerythrine also 
significantly inhibited Oxo-M-stimulated 125I- release (47 ± 5% inhibition; Fig. 10B) 
but the degree of inhibition was significantly less than that observed for taurine 
release (p<0.05).  The combination of inhibition of PKC with 10 µM chelerythrine, 
along with depletion of intracellular Ca2+ with 1 µM thapsigargin, resulted in a 94 
± 3% inhibition of Oxo-M-stimulated taurine release whereas stimulated 125I- 
release was inhibited by 64 ± 1% (Fig. 3.11 A,B, p<0.001 vs stimulated taurine 
release).  Thus, a significant fraction (35-40%) of Oxo-M-stimulated 125I- efflux, 
and all of that due to thrombin addition, is independent of both Ca2+ availability 




Previous studies of receptor-regulated osmolyte release from 
hypotonically-stressed neural cells have focused on the efflux of organic 
osmolytes, rather than that of Cl-.  In the present study, we demonstrate that the 
addition of thrombin to SH-SY5Y neuroblastoma cells results in a significant 
enhancement of the volume-sensitive efflux of both 125I- and taurine and that for 
each osmolyte, stimulated release is mediated primarily by the PAR-1 subtype.  
However, receptor-mediated 125I- efflux occurs more rapidly and to a greater 
extent than that of taurine (Fig. 3.1B), an observation that may reflect differences 
in the respective molecular sizes of the two osmolytes.  A similar preferential 
release of 125I- over that of taurine has previously been noted for HeLa and 
Intestinal 407 cells following cell swelling (Stutzin et al., 1999; Tomassen et al., 
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2004).  The threshold osmolarity (‘set-point’) at which the basal release of 
osmolytes occurs was the same for both 125I- and taurine, i.e. approximately 200 
mOsM (Fig. 3.4).  This result is consistent with our previous studies with 
neurotumor cells in which a reduction in osmolarity of >25% was required to elicit 
a significant increase in osmolyte release (Heacock et al., 2004, 2006; Cheema 
et al., 2005).  In contrast, in Intestinal 407 cells, the threshold osmolarity for 
release of 125I- (260 mOsM) is reported to be higher than that of taurine (225 
mOsM; Tomassen et al., 2004).  In the present study, thrombin addition to SH-
SY5Y cells increased the ‘set point’ for the efflux of both 125I- and taurine from 
200 mOsM to 290 mOsM.  Thus receptor activation facilitates the release of both 
inorganic and organic osmolytes and this may constitute a mechanism whereby 
cells can respond to small changes in external osmolarity. 
The possibility that the volume-sensitive release of Cl- and organic 
osmolytes occurs via a common membrane channel (VSOAC) has received 
support primarily on the basis of the similarities of pharmacological inhibition 
profiles obtained in the presence of a variety of non-selective anion channel 
blockers (Banderali and Roy, 1992; Jackson and Strange, 1993; Sanchez-Olea 
et al., 1996; Abdullaev et al., 2006).  However, in some tissues, the existence of 
separate Cl- and taurine efflux pathways has also been proposed (Lambert and 
Hoffman, 1994; Stutzin et al., 1999; Shennan and Thomson, 2000; Tomassen et 
al., 2004).  In addition, the issue of whether Cl- and organic osmolytes are 
released from the cell under conditions of receptor activation via shared or 
distinct pathways has not yet been systematically addressed.  In the present 
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study we observed that the inclusion of three anion channel blockers, namely 
DIDS, NPPB and DDF, inhibited both basal- and receptor-stimulated release of 
125I- and taurine.  Of these, DDF and NPPB were more effective inhibitors than 
DIDS, particularly for stimulated 125I- release.  The sole agent that was able to 
differentiate between taurine and 125I- release was niflumic acid, which, at the 
concentration employed (100 µM), is purported to inhibit Ca2+-activated Cl- 
channels (Large and Wang, 1996).  Although niflumic acid had no effect on the 
basal release of either osmolyte, it significantly inhibited thrombin-stimulated 
release of taurine, but not that of 125I- (Fig. 3.5).  However, the significance of this 
observation remains unclear for two reasons.  First, DCPIB, a highly specific 
inhibitor of VSOAC that is without effect on Ca2+-activated Cl- channels and other 
cation and anion channels (Decher et al., 2001; Best et al., 2004), was an equally 
effective inhibitor of basal-and receptor-stimulated release of both taurine and 
125I- from SH-SY5Y cells (Fig. 3.6).  Second, niflumic acid attenuated thrombin-
stimulated taurine efflux even under Ca2+-depleted conditions, a result 
inconsistent with inhibition of the Ca2+-activated Cl- channel (data not shown).  
Taken collectively, the most parsimonious interpretation of the current data is 
that, following receptor activation, both 125I- and taurine are released from SH-
SY5Y cells via the same (or pharmacologically indistinguishable) VSOAC 
channels. 
 Although the release of 125I- and taurine exhibited a similar 
pharmacological inhibition profile, the receptor-mediated release of these two 
osmolytes could be readily differentiated on the basis of their dependence on 
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Ca2+ availability and PKC activity.  Previously, we and others have demonstrated 
that increases in [Ca2+]i or in PKC activity are not prerequisites for the basal 
(swelling-induced) release of organic osmolytes such as taurine and D-aspartate 
from neurotumor cells, neurons or astrocytes (Moran et al., 1997; Mongin and 
Kimelberg, 2002;  Cardin et al., 2003; Loveday et al., 2003; Cheema et al., 
2005).  Similarly, in the present study, we observed that, at least under mildly 
hypotonic conditions, the basal release of 125I- also appears to be essentially 
independent of Ca2+ availability and PKC activity.  However, PAR-1-mediated 
increases in taurine and 125I- efflux differed in their dependence upon Ca2+ 
availability and PKC activity.  Thus, whereas taurine efflux was attenuated 
following the removal of extra- and intracellular Ca2+, or following inhibition of 
PKC activity with chelerythrine, thrombin-stimulated 125I- efflux was unaffected by 
either treatment.  Under conditions in which both Ca2+ depletion and inhibition of 
PKC activity occurred, stimulated taurine efflux was inhibited by >50% whereas 
125I- release remained unchanged.  Fura-2 fluorimetric studies indicated that the 
addition of thrombin to SH-SY5Y cells resulted in a significant increase in [Ca2+]i 
(100 nM to 250 nM), which was abolished when both extra- and intracellular 
sources of Ca2+ were depleted.  Because the PAR-1-mediated increase in the 
release of 125I- was not attenuated under these conditions, we conclude that the 
efflux of 125I- (but not that of taurine) occurs independently of a rise in [Ca2+]i 
within these cells.  This conclusion is consistent with the Ca2+ insensitivity of 
thrombin-stimulated Cl- currents previously observed in pulmonary artery 
endothelial cells (Manolopoulos et al., 1997).  Further evidence that Ca2+ and 
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PKC differentially modulate the release of these two osmolytes from SH-SY5Y 
cells was obtained following the addition of the muscarinic agonist, Oxo-M.  
Activation of mAChRs on SH-SY5Y cells elicits a large increase in [Ca2+]i (from 
100 to 450 nM), which is sustained due to a continuous influx of extracellular 
Ca2+ (Lambert and Nahorski, 1990; Heacock et al., 2006).  Although omission of 
extracellular Ca2+ and depletion of intracellular Ca2+ with thapsigargin resulted in 
a pronounced inhibition of mAChR-stimulated taurine release (60 and 81% 
respectively), Oxo-M-stimulated 125I- efflux was unaffected by removal of 
extracellular Ca2+ and much less inhibited (31%) by depletion of intracellular Ca2+ 
stores (Fig. 3.9).  Similarly, inhibition of PKC resulted in a significantly greater 
loss of mAChR-stimulated taurine release (73%) than that of 125I- efflux (47%). 
         Two conclusions can be drawn from these results.  The first is that, 
regardless of the receptor activated, the stimulated release of 125I- is less 
dependent than taurine efflux on either Ca2+ availability or PKC activity.  For the 
PAR-1 receptor, stimulated 125I- efflux is fully independent of Ca2+ availability and 
PKC activity whereas for the mAChR, some degree of dependence upon these 
parameters is observed.  The second conclusion is that although Ca2+ and PKC 
are required for maximum receptor activation of taurine efflux from SH-SY5Y 
cells, the degree of dependence is receptor-specific. Thus Ca2+ and PKC appear 
to play a quantitatively more significant role in mAChR stimulation of taurine 
release than that following the activation of either the PAR-1 or lysophospholipid 
receptors (Heacock et al., 2006).  
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 Our observation that Ca2+ availability (and PKC activity) differentially 
regulate the receptor-stimulated release of taurine and 125I- from SH-SY5Y cells 
is consistent with results previously obtained for hepatoma cells (Junankar et al., 
2002).  Osmotic swelling of these cells results in the release of intrinsic ATP, 
which subsequently activates P2Y receptors coupled to an increase in [Ca2+]i.  
However, although this rise in [Ca2+]i is required for the release of taurine, a 
stimulated efflux of 125I- can occur in the absence of an increased intracellular 
Ca2+.  Conceivably, differences in Ca2+ and PKC requirements for taurine and 
125I- efflux in hepatoma and SH-SY5Y cells might reflect the following: (1) the 
receptor-specific activation of distinct signal transduction pathways (Ca2+/PKC-
dependent or –independent) that differentially contribute to the efflux of taurine 
and 125I-, both of which are released through a common membrane channel, (2) 
the presence of separate, but pharmacologically similar, efflux channels for 125I- 
and taurine that differ in their degree of regulation by Ca2+ and PKC or (3) a 
combination of both mechanisms (Fig. 3.12).  In the context of multiple signaling 
pathways, one potential candidate, triggered by thrombin receptors, is rho–
mediated remodeling of the cytoskeleton (Carton et al., 2002; Pederson et al., 
2002).  However, preincubation of SH-SY5Y cells with toxin B, or the rho kinase 
inhibitor Y-27632, had no effect on receptor-stimulated release of taurine or 125I- 
(data not shown).  The possibility that separate efflux channels mediate the 
release of taurine and 125I- in SH-SY5Y cells has previously been suggested for 
non-neural cells (Lambert and Hoffman, 1994; Stutzin et al., 1999).  Regardless 




the volume-dependent release of organic and inorganic osmolytes from SH-
SY5Y cells does not occur by a common mechanism.  This observation may 
ultimately be of relevance to our understanding of the different roles played by 






















Figure 3.1. Time course of basal- and thrombin-stimulated efflux of taurine and 125I- from human SH-SY5Y neuroblastoma 
cells. (A) SH-SY5Y neuroblastoma cells that had been prelabeled in the presence of [3H]taurine or 125I-  were washed two or three 
times respectively with 2 ml of isotonic buffer A. The cells were then incubated in 230 mOsM buffer A in the presence or absence of 
1.25 nM thrombin.  Reactions were terminated at the times indicated and radioactivity measured (basal release, dotted lines; 
thrombin-stimulated release, solid lines).  Unlike taurine, 125I- was not tightly retained by SH-SY5Y cells and the isotonic release of 
this tracer under basal conditions was approximately 50% of that observed at 230 mOsM after a 5 min incubation and 75% at longer 
time intervals (10-15 min). Results are expressed as taurine or 125I- efflux (percentage of total soluble radioactivity) and are the means 













Figure 3.2. Thrombin enhances taurine and 125I- efflux from SH-SY5Y neuroblastoma cells via the PAR-1 subtype.  
Cells that had been prelabeled with (A) [3H]taurine or (B) 125I- were first washed in isotonic buffer A and then incubated for 
5 min in 230 mOsM buffer A in the presence or absence of either thrombin (1.25 nM) or synthetic peptides specific for 
PAR-1 (TFLLRN;100 µM), PAR-3 (TFRGAP; 500 µM) or PAR-4 (GYPGKF;500 M) subtypes.  Results are expressed as 
taurine or 125I- efflux (percentage of total soluble radioactivity) and are the means ± S.E.M for 3 independent experiments. 















Figure 3.3. Basal- and thrombin-stimulated release of taurine and 125I- as a function of osmolarity. Cells prelabeled 
with (A) [3H]taurine or (B) 125I-  were first washed in isotonic buffer A and then incubated for 5 min in buffers at the 
osmolarities indicated in the absence (open bars) or presence (filled bars) of 1.25 nM thrombin. Results are expressed as 
taurine or 125I- efflux (percentage of total soluble radioactivity) and are the means ± S.E.M. for 4 independent experiments.  
#, Different from 125I- release observed in cells incubated in isotonic buffer A (340 mOsM), p< 0.05 (by one-way ANOVA 














Figure 3.4. Inhibition of basal- and thrombin-stimulated efflux of taurine and 125I- by broad spectrum anion 
channel blockers.  Cells that had been prelabeled with (A) [3H]taurine or (B) 125I- were washed in isotonic buffer A and 
then incubated in hypotonic buffer A (230 mOsM) with 200 µM DIDS, 100 µM NPPB, 100 µM dideoxyforskolin (DDF) or 
100 µM niflumic acid, in the absence (open bars) or presence (filled bars) of 1.25 nM thrombin.  Reactions were 
terminated after 5 min and efflux of taurine and 125I- monitored.  Results are expressed as taurine or 125I- efflux (percentage 
of total soluble radioactivity) and are the means ± S.E.M. for 3-5 independent experiments.  #, Different from control basal, 












Figure 3.5.  DCPIB inhibits the basal and thrombin- stimulated efflux of both taurine and 125I- efflux.  Cells 
prelabeled with (A) [3H]taurine or (B) 125I- were first pretreated with 20 µM DCPIB in isotonic buffer A for 10 min before 
incubation in hypotonic buffer A (230 mOsM) containing 20 µM DCPIB in the absence (open bars) or presence (filled bars) 
of 1.25 nM thrombin.  Reactions were terminated after 5 min and efflux of taurine and 125I- monitored.  Results are 
expressed as taurine or 125I- efflux (percentage of total soluble radioactivity) and are the means ± S.E.M. for 4-5 
independent experiments. #, Different from control basal efflux, p< 0.01 (taurine); p<0.001(125I-) and ##, different from 











Figure 3.6. The role of extra- and intracellular Ca2+ in thrombin-stimulated efflux of taurine and 125I-.  (A) Cells that 
had been prelabeled overnight with [3H]taurine were washed in isotonic buffer A and then incubated in hypotonic buffer A 
(230 mOsM) in the absence (-ext Ca: Ca2+ was omitted from buffer and 50 µM EGTA added) or presence of extracellular 
Ca2+.  Reactions were allowed to proceed for 5 min in the absence (open bars) or presence (filled bars) of 1.25 nM 
thrombin.  In some experiments, cells were pretreated for 15 min in isotonic buffer A in the presence of 1 µM thapsigargin 
(Thaps) prior to the 5 min incubation in hypotonic buffer.  Results are expressed as taurine efflux (percentage of total 
soluble radioactivity) and are the means ± S.E.M. for 4 independent experiments. ##, Different from thrombin-stimulated 
efflux under control conditions, p<0.01 (by one-way ANOVA followed by Dunnett’s multiple comparisons test).  (B) Cells 
prelabeled with 125I- were treated as described in (A).  Results are expressed as 125I- efflux (percent of total soluble 










Figure 3.7. Inhibition of the thrombin-stimulated efflux of taurine, but not of 125I-, by chelerythrine. Cells prelabeled 
with (A) [3H]taurine or (B) 125I- were pretreated with 10 µM chelerythrine in isotonic buffer A for 15 min before incubation in 
hypotonic buffer A (230 mOsM) in either the absence (open bars) or presence (filled bars) of 1.25 nM thrombin.  
Reactions were terminated after 5 min and efflux monitored.  Results are expressed as taurine or 125I- efflux (percentage 
of total soluble radioactivity) and are the means ± S.E.M for 4 independent experiments. #, Different from control basal 
efflux p< 0.05 (125I-) and ##, different from thrombin-stimulated efflux under control conditions, p< 0.01 (taurine) (by 













Figure 3.8. Depletion of Ca2+ and inhibition of PKC only attenuates thrombin-stimulated taurine efflux. Cells 
prelabeled with (A) [3H]taurine or (B) 125I- were first preincubated for 15 min in the absence (control) or presence of 10 µM 
chelerythrine and 1 µM thapsigargin (Thaps) in isotonic buffer A.  The medium was then aspirated and replaced with 230 
mOsM buffer A, that either contained Ca2+ (control) or had Ca2+ omitted and 50 µM EGTA, 1 µM thapsigargin and 10 µM 
chelerythrine added.  Reactions were then allowed to proceed for 5 min in the absence (open bars) or presence (closed 
bars) of 1.25 nM thrombin.  Results are expressed as taurine or 125I- efflux (percentage of total soluble radioactivity) and 
are the means ± S.E.M. for 4-7 independent experiments. #, Different from control basal efflux, p<0.05 (125I-) and ##, 










Figure 3.9. The role of extra- and intracellular Ca2+ in Oxo-M-stimulated efflux of taurine and 125I-.  (A) Cells that had 
been prelabeled overnight with [3H]taurine were washed in isotonic buffer A and then incubated in hypotonic buffer A (230 
mOsM) in either the absence (-ext Ca: Ca2+ was omitted from buffer and 50 µM EGTA added) or presence of extracellular 
Ca2+.  Reactions were allowed to proceed for 5 min in the absence (open bars) or presence (filled bars) of 100 µM Oxo-M.  
In some experiments, cells were pretreated for 15 min in isotonic buffer A in the presence of 1 µM thapsigargin (Thaps) 
prior to the 5 min incubation in hypotonic buffer.  Results are expressed as taurine efflux (percentage of total soluble 
radioactivity) and are the means ± S.E.M. for 3 independent experiments. ##, Different from Oxo-M-stimulated efflux 
under control conditions, p< 0.01 (by one-way ANOVA followed by Dunnett’s multiple comparisons test).  (B) Cells 
prelabeled with 125I- were treated as described in (A).  Results are expressed as 125I- efflux (percent of total soluble 
radioactivity), and are the means ± S.E.M. for 5 independent experiments. ##, Different from Oxo-M-stimulated efflux 










Figure 3.10. Inhibition of Oxo-M-stimulated efflux of taurine and 125I- by chelerythrine.  Cells prelabeled with (A) 
[3H]taurine or (B) 125I-  were pretreated with 10 µM chelerythrine in isotonic buffer A for 15 min before incubation in 
hypotonic buffer A (230 mOsM) in the absence (open bars) or presence (filled bars) of 100 µM Oxo-M.  Reactions were 
terminated after 5 min and efflux monitored.  Results are expressed as taurine or 125I- efflux (percentage of total soluble 
radioactivity) and are the means ± S.E.M for 4 independent experiments. #, Different from basal efflux under control 
conditions, p< 0.05 (125I-) and ##, different from thrombin-stimulated efflux under control conditions, p< 0.05 (taurine and 













Figure 3.11. Depletion of Ca2+ and inhibition of PKC abolishes Oxo-M-stimulated taurine efflux and attenuates that 
of 125I-.  Cells prelabeled with [3H]taurine (A) or 125I- (B) were first preincubated for 15 min in the absence (control) or 
presence of 10 µM chelerythrine and 1 µM thapsigargin (Thaps) in isotonic buffer A.  The medium was then aspirated and 
replaced with 230 mOsM buffer A, that either contained Ca2+ (control) or had Ca2+ omitted and 50 µM EGTA, 1 µM 
thapsigargin and 10 µM chelerythrine added.  Reactions were allowed to proceed for 5 min in the absence (open bars) or 
presence (closed bars) of 100 µM Oxo-M. Results are expressed as taurine or 125I- efflux (percentage of total soluble 
radioactivity) and are the means ± S.E.M. for 4 independent experiments. ##, Different from Oxo-M-stimulated efflux 








138 Figure 3.12.  Potential mechanisms that may account for differences in Ca2+ and PKC requirements for receptor-
mediated release of osmolytes in SH-SY5Y cells. (A) PAR-1 and mAChRs, in a receptor-specific manner, can activate 
at least two different signal transduction pathways linked to osmolyte release.  Signal transduction pathway 1 is 
dependent upon Ca2+ availability and PKC activity and is primarily linked to taurine efflux.  Signal transduction pathway 2 
is independent of Ca2+ and PKC activity and is primarily coupled to iodide efflux.  The efflux of both taurine and iodide is 
mediated via a common membrane channel that is permeable to both organic osmolytes and iodide.  The majority of 
taurine efflux elicited by both PAR-1 and mAChRs (and a fraction of iodide release following mAChR activation) is 
mediated by pathway 1.  In contrast, all of the iodide efflux elicited by PAR-1 receptors, and a significant fraction of that 
resulting from mAChR activation, is mediated by pathway 2. (B) The receptor-specific release of taurine and iodide from 
the cell occurs via distinct membrane channels.  Channel 1 is primarily permeable to taurine and is regulated by Ca2+ and 
PKC.  In contrast, Channel 2 primarily mediates the release of iodide and is independent of both Ca2+ and PKC activity.  
Channel 1 mediates the majority of taurine release resulting from activation of both PAR-1 and mAChRs (and a fraction 
of iodide release resulting from mAChR activation) whereas Channel 2 mediates all of the iodide efflux elicited by the 
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CHOLESTEROL REGULATES VOLUME-SENSITIVE OSMOLYTE EFFLUX 






The ability of cholesterol to modulate receptor-mediated increases in the 
volume-dependent release of the organic osmolyte, taurine, has been examined.  
Depletion of cholesterol from SH-SY5Y neuroblastoma by pre-incubation of the 
cells with 5 mM methyl-β-cyclodextrin (CD) for 10 min resulted in a 40-50% 
reduction in cholesterol and an enhancement of the ability of proteinase-activated 
-1 (PAR-1), muscarinic cholinergic (mAChR) and sphingosine 1-phosphate 
receptors to stimulate taurine efflux, when monitored under hypoosmotic 
conditions.  Basal (swelling-induced) release of taurine was also enhanced by 
cholesterol depletion, but less markedly.  Both basal- and receptor-mediated 
increases in taurine efflux were mediated via a volume-sensitive organic 
osmolyte and anion channel in control and cholesterol-depleted cells.  Studies 
with the PAR-1 and mAChR receptor subtypes indicated that the stimulatory 
effect of CD pretreatment could be reversed by incubation of the cells with either 
CD:cholesterol or CD:epicholesterol donor complexes and that cholesterol 
depletion increased agonist efficacy, but not potency.  The ability of cholesterol 
depletion to promote the PAR-1 receptor-mediated stimulation of osmolyte 
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release was most pronounced under conditions of isotonicity or mild hypotonicity.  
In contrast to CD pretreatment, preincubation of the cells with either cholesterol 
oxidase, or sphingomyelinase, conditions under which lipid microdomains are 
also disrupted, had no effect on either basal- or receptor-stimulated taurine 
efflux.  Taken together, the results suggest that cholesterol regulates receptor-
mediated osmolyte release via its effects on the biophysical properties of the 
plasma membrane, rather than its presence in lipid microdomains. 
 
Introduction 
Volume regulation is a fundamental homeostatic mechanism used by cells 
and is of particular importance to the central nervous system because of 
restrictions of the skull.  Even minor increases in brain volume can have adverse 
effects on cell-cell signaling events and more severe brain swelling, as may 
occur during episodes of hyponatremia, and can lead to cerebral anoxia, 
ischemia and ultimately death due to cardiac and respiratory arrest (Pasantes-
Morales et al., 2000).  In response to hypotonic stress, both neural and non-
neural cells regulate their volume through the efflux of K+, Cl- and “compatible” 
organic osmolytes such as taurine, glutamate or myo-inositol.  Loss of these 
osmolytes results in the exit of obligated water thereby restoring cell volume, a 
process known as regulatory volume decrease.  Organic osmolytes and Cl- are 
released from cells via a volume-sensitive organic osmolyte and anion channel 
(VSOAC), a channel that has been extensively characterized both 
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electrophysiologically and pharmacologically, although its molecular structure 
remains unknown (Lang et al., 1998; Nilius and Droogmans, 2003).  
 Given the central role that maintenance of volume plays in the physiology 
of neural cells, mechanisms involved in its regulation assume major significance.  
In this context, we and others have recently demonstrated that the volume-
dependent release of osmolytes from a variety of neural cells can be dramatically 
enhanced following activation of certain G protein-coupled receptors (Mongin and 
Kimelberg, 2002, 2005; Heacock et al., 2004, 2006; Cheema et al., 2005, 2007; 
Ramos-Mandujano et al., 2007).  Receptor activation not only increases the 
extent of osmolyte release, but it also lowers the threshold osmolarity (‘set-point’) 
at which osmolytes are released, thereby permitting cells to respond to small, 
physiologically relevant, reductions in osmolarity.  This observation raises the 
possibility that, in vivo, receptor activation may be a pre-requisite for the efficient 
volume regulation of cells.  Although volume-dependent osmolyte release from 
cells is mediated via a VSOAC under both basal- (swelling-induced) and 
receptor-stimulated conditions (Abdullaev et al., 2006; Cheema et al., 2007), 
separate mechanisms underlie these two responses, as is evident from their 
differential sensitivities to Ca2+ availability and activation of protein kinase C 
(Mongin and Kimelberg, 2005; Heacock et al., 2006).  
 Cholesterol availability represents an additional means whereby the 
activity of VSOAC may be regulated.  In some non-neural cells, depletion of 
cholesterol facilitates the activity of VSOAC in response to hypotonicity, an effect 
that is reversed by increases in the cholesterol content of the cells (Levitan et al., 
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2000; Romanenko et al., 2004; Klausen et al., 2006; Byfield et al., 2006, Lim et 
al., 2006).  As previously observed for receptor activation, cholesterol depletion is 
reported to optimally facilitate basal VSOAC activity under conditions of limited 
reductions in osmolarity.  However, whether cholesterol availability can further 
regulate receptor-stimulated osmolyte release under physiologically relevant 
conditions has yet to be addressed.  In addition, the mechanism(s) underlying 
cholesterol regulation of basal VSOAC activity has not been established.  In 
endothelial cells, cholesterol dependence of VSOAC activity has been attributed 
to changes in membrane fluidity and/or a negative regulation of VSOAC by 
segregation of the channel into membrane lipid domains such as rafts or 
caveolae (Romanenko et al., 2004; Byfield et al., 2006).  In contrast, in other cell 
types, VSOAC activity appears to be dependent upon the integrity of caveolae 
(Trouet et al., 1999, 2001; Ullrich et al., 2006).  Since multiple receptor subtypes, 
and associated signaling proteins have been localized to caveolae and/or lipid 
rafts (Allen et al., 2007), it is conceivable that cholesterol availability may 
differentially influence swelling-induced and receptor-activated VSOAC activity. 
 In the present study, we have addressed the possibility that cholesterol 
availability can regulate receptor-mediated VSOAC activity by monitoring the 
effects of cholesterol depletion and re-addition on volume-dependent taurine 
release from human SH-SY5Y neuroblastoma cells.  We have previously 
demonstrated that these cells possess several pharmacologically distinct, 
receptors that couple to osmolyte efflux, including protease-activated (PAR-1), 
muscarinic cholinergic (mAChR) and sphingosine 1-phosphate (S1P: Heacock et 
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al., 2004, 2006; Cheema et al., 2007).  The results indicate that cholesterol 
depletion, induced by methyl-β-cyclodextrin (CD), synergistically enhances the 
ability of all three receptors to increase taurine efflux above basal levels and that 
this potentiation can be reversed by administration of cholesterol or its 
stereoisomer, epicholesterol.  Cholesterol depletion appears to exert its most 
significant regulatory influence on receptor-stimulated taurine efflux under 
conditions of isotonicity or mild hypotonicity.  Thus, in SH-SY5Y neuroblastoma 
cells, both cholesterol availability and receptor activation may act in concert to 
enable the cells to respond to small changes in osmolarity. 
 
Methods 
Materials. [1,2-3H] Taurine (1.15 TBq/ml) was obtained from Amersham 
Biosciences (Piscataway, NJ). Thrombin, oxotremorine-M, sphingosine 1-
phosphate, methyl-ß-cyclodextrin, cholesterol (5-cholesten-3ß-ol), 
sphingomyelinase from Staphylococcus aureus and cholesterol oxidase were 
purchased from Sigma-Aldrich (St. Louis, MO).  DCPIB was obtained from Tocris 
Biosciences (Ellisville, MO).  Epicholesterol (5-cholesten-3α-ol) was purchased 
from Steraloids (Newport, RI).  Amplex Red Assay kit was from Molecular 
Probes, Inc. (Eugene, OR).  Dulbecco’s modified Eagle medium (DMEM) and 
50x penicillin/streptomycin were obtained from Invitrogen (Carlsbad, CA).  Fetal 
calf serum was obtained from Cambrex Bio Science Walkersville, Inc. 
(Walkersville, MD).  Tissue culture supplies were obtained from Corning 
Glassworks (Corning, NY), Starstedt (Newton, NC) and BD BioSciences 
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(Franklin Lakes, NJ).  Universol was obtained from Valeant Pharmaceuticals 
(Costa Mesa, CA).  
 
Cell culture conditions. 
Human SH-SY5Y neuroblastoma cells (passages 70-89) were grown in tissue 
culture flasks (75 cm2/250 ml) in 20 ml of DMEM supplemented with 10% (v/v) of 
fetal bovine serum with 1% penicillin/streptomycin.  The osmolarity of the 
medium was 330-340 mOsM.  Cells were grown at 37°C in a humidified 
atmosphere containing 5% CO2.  The medium was aspirated and the cells 
detached from the flask with a trypsin-versene mixture (Biowhittaker, MD).  Cells 
were then resuspended in DMEM/10% fetal bovine serum with 
penicillin/streptomycin and subcultured into 35 mm, six-well culture plates for 5-6 
days.  Experiments were routinely conducted on cells that had reached 70–90% 
confluency.  
 
Measurement of taurine efflux. 
Osmolyte efflux from SH-SY5Y neuroblastoma cells was monitored essentially as 
previously described (Heacock et al., 2004; Cheema et al., 2007).  In brief, cells 
were prelabeled to isotopic equilibrium with 18.5 kBq/ml of [3H]taurine at 37oC for 
24 h.  After prelabeling, the cells were washed twice with 2 ml of isotonic buffer A 
(142 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2, 3.6 mM NaHCO3, 1mM MgCl2 and 
30 mM HEPES, pH 7.4, 1 mg/ml D-glucose; approx. 340 mOsM).  Cells were 
then allowed to incubate in 2 ml of hypotonic buffer A (295-200 mOsM; rendered 
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hypotonic by a reduction in NaCl concentration) in the absence or presence of 
the agonists.  In some experiments, buffer A was made hypertonic (370 and 450 
mOsM) by the addition of NaCl.  Osmolarities of buffer A were monitored by 
means of an Osmette precision osmometer (PS Precision Systems, Sudbury, 
MA).  At times indicated, aliquots (200-400 µl) of the extracellular medium were 
removed and radioactivity determined after the addition of 5 ml Universol 
scintillation fluid.  The reactions were terminated by rapid aspiration of the buffer 
and cells lysed by the addition of 2 ml of ice-cold 6% (wt/vol) trichloroacetic acid. 
Taurine efflux was calculated as a fractional release, i.e., the radioactivity 
released in the extracellular media as a percentage of the total radioactivity 
present initially in the cells.  The latter was calculated as the sum of radioactivity 
recovered in the extracellular medium and that remaining in the lysate at the end 
of the assay.  Because SH-SY5Y cells had been labeled to isotopic equilibrium 
with [3H] taurine, measurement of radioactivity in the extracellular medium  
reflects changes in the mass of the osmolyte.  Throughout this study, “basal” 
release of taurine is defined as that which occurs at a specified osmolarity in the 
absence of an agonist. 
 
Modulation of cellular cholesterol content and substitution of cholesterol 
with epicholesterol 
SH-SY5Y neuroblastoma were either depleted of cholesterol by incubation of the 
cells for 10 min at 370C with either 5 mM methyl-ß-cyclodextrin (CD) alone or 
alternatively, enriched with cholesterol by CD complexed with cholesterol 
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dissolved in serum-free media.  Cholesterol was complexed with CD as 
described previously (Romanenko et al., 2004).  Briefly, a small amount of 
cholesterol was dissolved in chloroform: methanol (1:1, by vol) in a glass tube 
and the solvent evaporated. Then, a 5 mM CD solution in serum-free DMEM was 
added to the dried cholesterol.  The tube was then vortexed, sonicated and 
incubated overnight in a shaking bath at 37○C.  CD was complexed with 
cholesterol at a saturating ratio of 1:8 (0.625 mM cholesterol; Christian et al., 
1997).  In preparation for an experiment, cells prelabeled with [3H] taurine were 
first depleted of cholesterol by exposing them to CD for 10 min in a humidified 
CO2 incubator at 37○C.  Cells were then washed with isotonic buffer A and 
exposed to a cholesterol:CD (1:8) donor complex for 1 h and then returned to the 
incubator.  After 1 h, cells were washed once more with isotonic buffer A before 
measurement of taurine efflux.  Control cells were treated in a similar way with 
serum-free DMEM. An epicholesterol: CD (1:8) complex was prepared as 
described for the cholesterol:CD complex above (Romanenko et al., 2002).  
 
Cellular cholesterol content 
The Amplex Red-based cholesterol assay was conducted in a 96-well microplate 
using a 100 µl reaction volume per well.  Cells were lysed with 1X reaction buffer 
containing 0.1 mM potassium phosphate, pH 7.4, 0.05 mM NaCl, 5 mM cholic 
acid and 0.1% Triton X-100. The cells were then sonicated for 20 s before 10 µl 
aliquots of the lysates were diluted into 40 µl of 1X reaction buffer.  The 
cholesterol detection assay was initiated by the addition of 50 µl/well of 300 µM 
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Amplex Red Reagent working solution containing 2 U/ml horse radish 
peroxidase, 2 U/ml cholesterol oxidase and 0.2 U/ml cholesterol esterase.  The 
reaction mixtures were incubated at 37°C for 30 min, and the fluorescence 
intensities were measured using a fluorescence microplate reader equipped with 
a filter set for excitation and emission at 540 ± 10 and 590 ± 10 nm, respectively 
(FLUOstar Optima BMG LabTech, Durham, NC).  The cholesterol values were 
compared to a cholesterol standard curve from (0 – 8 µg/ml).  Protein assay was 
performed with a bicinchoninic acid protein assay reagent kit obtained from 
Pierce (Rockford, IL). Cholesterol values quoted are normalized to the protein 
content of the cell lysates. 
 
Measurement of Phosphoinositide Turnover.  
To monitor phosphoinositide turnover, SH-SY5Y cells that had been prelabeled 
with 111 KBq/ml of [3H]inositol for 48 h were incubated in hypotonic buffer A (230 
mOsM) that contained 5 mM LiCl.  The accumulation of radiolabeled inositol 
phosphates present in the trichloroacetic acid cell lysates was determined as 
previously described (Thompson and Fisher, 1990). 
 
Data Analysis.  
Experiments were performed in triplicate and repeated at least three times. 
Values quoted are given as means ± S.E.M. for the number (n) of independent 
experiments indicated. A two-tailed Student's t test (paired or unpaired) was used 
to evaluate differences between two experimental groups (level of significance, p 
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< 0.05). Ordinary or repeated measures analysis of variance (ANOVA) followed 
by Dunnett's multiple comparisons test was used for statistical significance of 
differences between multiple groups. EC50 values were obtained using Prism 
4.0a (GraphPad Software Inc., San Diego, CA).  
 
Results 
Cholesterol depletion enhances both basal- and thrombin-stimulated 
taurine efflux.  Methyl-β-cyclodextrin (CD), a water-soluble cyclic 
oligosaccharide, provides an effective and reproducible method for extracting 
cholesterol from a variety of cells, thereby disrupting lipid microdomains 
(Christian et al., 1997; Brown and London, 2000).  However, since this approach 
has not previously been employed for SH-SY5Y cells, initial studies were 
directed at determining the optimal conditions for cholesterol extraction while 
limiting the cells to CD exposure, as recommended by Zidovetzki and Levitan 
(2007).  When SH-SY5Y cells were pretreated with increasing concentrations of 
CD (1-5 mM) for 10 min at 37○C, a dose-dependent decrease in total cholesterol 
content was observed (Fig. 4.1A).  More prolonged incubation of the cells with 
CD resulted in cell rounding and a loss of morphology.  In SH-SY5Y cells, total 
cellular cholesterol (predominantly non-esterified) was 17.0 ± 3.0 µg/mg of 
protein (n=10).  A maximum reduction in cholesterol content (43%) was observed 
following pretreatment of the cells with 5 mM CD for 10 min.  Both basal 
(swelling-activated) and thrombin-stimulated taurine efflux monitored under 
hypotonic conditions (230 mOsM), were significantly enhanced by depletion of 
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cholesterol.  A significant effect on basal taurine release was observed at 3 mM 
CD with a maximum effect observed at a 5 mM concentration.  Under the latter 
conditions, efflux increased from 4.5% to 8.7% of the total taurine pool, a net 
increase of 4.2% (Fig 4.1B).  CD pretreatment also significantly potentiated 
thrombin-stimulated taurine release at all concentrations of CD tested (1–5 mM) 
with a maximum observed at CD concentrations >2 mM.  Following pretreatment 
of the cells with 5 mM CD, taurine efflux increased from 46% to 56% of the total 
taurine pool, a net increase in the efflux of 10% (Fig. 4.1C).  In subsequent 
experiments a 10 min pretreatment with 5 mM CD was routinely utilized so that 
changes in both basal- and receptor-stimulated taurine efflux could be readily 
evaluated.  
 
Time-course of volume-dependent taurine efflux following cholesterol 
depletion.  When SH-SY5Y cells that had been prelabeled with [3H]taurine were 
exposed to hypotonic buffer A (230 mOsM; ~30% reduction in osmolarity), there 
was a time-dependent release of the radiolabeled amino acid from the cells, as 
previously reported (Cheema et al., 2007).  This basal release was enhanced by 
~2 fold  (2.8% to 7.0% of the total taurine pool) when the cells were pretreated 
with 5 mM CD for 10 min at 37○C (Fig. 4.2).   Pre-treatment of cells with CD also 
significantly enhanced the ability of thrombin (0.25U/ml, equivalent to 1.25 nM) to 
facilitate taurine efflux at all time points examined (Fig. 4.2).  Since the CD-
mediated increases in the magnitude of both basal-and receptor-stimulated 
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release of taurine were maximal at 5 min of incubation or thereafter, osmolyte 
efflux was subsequently routinely monitored following a 5 min incubation.   
 
Cholesterol depletion facilitates taurine efflux elicited by activation of 
multiple receptors.  We have previously demonstrated that SH-SY5Y cells 
express mAChR, PAR-1 and S1P receptors, the activation of which significantly 
increase taurine release during hypotonic stress (Loveday et al., 2003; Heacock 
et al., 2006; Cheema et al., 2007).  To determine whether the ability of 
cholesterol depletion to enhance taurine release is receptor-specific, the effect of 
CD pretreatment on the ability of all three receptors to stimulate taurine efflux 
was evaluated.  It was observed that CD pretreatment facilitated the ability of 
thrombin, Oxo-M and S1P to enhance the volume-dependent release of taurine 
(net increases in efflux of 13.4%, 14.8% and 19.9% of the total taurine pool, 
respectively).  In contrast, the corresponding value for the net increase in basal 
release of taurine observed following cholesterol depletion was 5.6% (Fig. 4.3).  
Moreover, the increase in receptor-mediated efflux of taurine from cholesterol-
depleted cells was greater than that due to the increase in basal release alone, 
i.e. a synergistic, rather than additive, enhancement of receptor-mediated 
osmolyte efflux was observed for all three receptors (p<0.01; paired Student’s t-
test). Because previous studies of SH-SY5Y cells have extensively characterized 
the coupling of PAR-1 and mAChRs to volume-dependent taurine efflux 
(Heacock et al., 2004, 2006; Cheema et al., 2007), in the current study emphasis 
has been placed on monitoring the effects of cholesterol depletion and repletion 
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on the activity of these receptor subtypes.  In addition, the effects (if any) of CD 
on signal transduction events can readily be assessed by monitoring mAChR-
stimulated phosphoinositide turnover in these cells.  
 
CD pretreatment increases agonist efficacy for taurine efflux but not 
agonist potency.  To determine whether cholesterol depletion enhances agonist 
potency and/or efficacy, dose-response curves for taurine efflux were 
constructed for thrombin and Oxo-M, for both control cells and those pretreated 
with CD.  Cholesterol depletion increased agonist efficacy over the range of 
concentrations of thrombin or Oxo-M tested.  However, agonist potency was 
unaffected by CD pretreatment.  Thus, EC50 values were 105 pM and 60 pM for 
thrombin and 0.9 µM and 1.9 µM for Oxo-M in the absence or presence of CD 
pretreatment, respectively (Fig. 4.4 A, B). 
 
Blockade of VSOAC with DCPIB attenuates the CD-induced facilitation of 
taurine release.  DCPIB, an agent that is considered highly selective for VSOAC 
(Decher et al., 2001; Best et al., 2004; Abdullaev et al., 2006), was examined for 
its ability to inhibit the CD-induced increases in taurine efflux.  Inclusion of 20 µM 
DCPIB significantly inhibited basal taurine efflux monitored under both control 
and CD-pretreated conditions (56% and 67% inhibition, respectively).  Similarly, 
DCPIB also inhibited thrombin-stimulated taurine efflux monitored in either 




Osmolarity dependence of basal- and thrombin-stimulated taurine efflux 
under conditions of cholesterol depletion.  Previously we have demonstrated 
that receptor-mediated enhancement of osmolyte release is dependent on the 
degree of hypo-osmotic stress in SH-SY5Y cells (Heacock et al., 2004, 2006; 
Cheema et al., 2007).  Thus the ability of cholesterol depletion to potentiate 
taurine release at different osmolarities was examined.  SH-SY5Y cells were 
pretreated with 5 mM CD and both basal- and thrombin-stimulated release of 
taurine was monitored under conditions of isotonicity (340 mOsM: defined by the 
osmolarity of the DMEM/fetal calf serum medium in which the cells were grown), 
mild to moderate hypotonicity (295-200 mOsM) or hypertonicity (370-450 
mOsM).  The basal release of taurine was not appreciably increased until the 
osmolarity had been reduced to 200 mOsM.  Although CD pretreatment of cells 
further increased the basal release of taurine when monitored under conditions of 
hypotonicity, this effect only became significant following a 30% decrease in 
osmolarity (a net increase in efflux of 5.9% of the total taurine pool at 230 
mOsM).  As previously reported (Cheema et al., 2007), the addition of thrombin 
to control cells resulted in a significant increase in taurine efflux under either mild 
or moderate hypotonic conditions (Fig. 4.6A).  CD pretreatment of the cells 
further enabled thrombin to enhance taurine efflux under isotonic, as well as mild 
to severe hypotonic, conditions. However, the stimulatory effect of cholesterol 
depletion on PAR-1-mediated taurine release was most marked under conditions 
of either isotonicity (340 mOsM) or mild hypotonicity (295 mOsM.  Thus, although 
little or no increase in taurine efflux was observed following the addition of 
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thrombin to control cells incubated in isotonic buffer A, a significant increase in 
osmolyte release was obtained from CD-pretreated cells under isotonic 
conditions (a net increase in efflux of 5.3% of the total taurine pool).  Similarly, 
cholesterol depletion increased the ability of thrombin to stimulate taurine release 
from 8.2 to 21.5% of the total taurine pool, when monitored at 295 mOsM (Fig. 
4.6A).  When thrombin-stimulated taurine release for cholesterol-depleted cells 
was calculated (as a percentage) relative to control cells, the values were 332%, 
262%, 178% and 139% of control at 340, 295, 250 and 230 mOsM, respectively.  
The ability of cholesterol depletion to enhance thrombin-stimulated taurine efflux 
was reduced under conditions of mild hypertonicity (370 mOsM) and was 
abolished under more severely hypertonic conditions (450 mOsM: Fig. 4.6B). 
 
Enhancement of taurine efflux by CD is reversed by the re-addition of either 
cholesterol or epicholesterol.  The ability of CD pretreatment to facilitate either 
thrombin- or Oxo-M-mediated taurine efflux under hypoosmotic conditions could 
be fully reversed by preincubation of the cells for 1 h in the presence of a 
saturating (1:8) cholesterol: CD complex (0.625 mM cholesterol). In fact, 
following cholesterol administration,  the efflux of taurine monitored under basal-, 
thrombin- and Oxo-M- stimulated conditions was significantly inhibited (61-77%) 
when compared to control values (Fig. 4.7A).  Concurrent measurements of the 
cholesterol content of SH-SY5Y cells revealed that a 65% increase in cholesterol 
content over control cells was observed after the cells were exposed to the 
cholesterol:CD complex (Fig. 4.7B). The addition of a 1:8 cholesterol:CD 
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complex to control cells also resulted in an increase in cholesterol content and a 
reduction in both basal- and thrombin-stimulated taurine release (data not 
shown).  The specificity with which cholesterol administration can reverse the 
stimulatory effects of CD pretreatment was further tested by determining whether 
epicholesterol, a stereoisomer of cholesterol, could substitute for cholesterol.  
Epicholesterol and cholesterol have previously been employed to discriminate 
between effects due to sterol-protein interactions and those due to changes in 
the physical properties of the membrane lipid bilayer (Zidovetzki and Levitan, 
2007).  As observed for cholesterol re-addition, administration of an 
epicholesterol: CD complex (1:8) reversed the stimulatory effects of cholesterol 
depletion and resulted in an inhibition of agonist- stimulated taurine efflux (25-
29%), but did not inhibit basal release.   
 
Alterations in cholesterol content or replacement with epicholesterol do 
not influence the extent of mAChR-stimulated phophoinositide turnover.  In 
some cells, CD pre-treatment results in an attenuation of cell signaling events 
(Burger et al., 2000).  To evaluate the possibility that modulation of cholesterol 
content alters receptor signaling events within SH-SY5Y cells, basal- and 
mAChR-stimulated phosphoinositide turnover was monitored under control, 
cholesterol-depleted and cholesterol- or epicholesterol-supplemented conditions.  
Neither CD-pretreatment (Fig. 4.8A), nor supplementation with either cholesterol 
or epicholesterol, had any significant effect on either basal or mAChR- stimulated 




Pretreatment of SH-SY5Y cells with cholesterol oxidase or 
sphingomyelinase has no effect on basal- or receptor-stimulated taurine 
efflux.  In many cell types, a reduction in cholesterol content can also be 
achieved following incubation of the cells with cholesterol oxidase, an enzyme 
that converts cholesterol into 4-cholesten-3-one, a sterol which exhibits 
membrane fluidity characteristics similar to those of cholesterol (Gimpl et al., 
1997).  Preincubation of SH-SY5Y cells with cholesterol oxidase (1.5 U/ml) for 1h 
had no effect on basal-, mAChR- or PAR-1-stimulated taurine efflux under 
hypotonic conditions (Fig. 4.9A), although the cholesterol content of SH-SY5Y 
cells was reduced by 57% (Fig. 4.9B).  Pretreatment of the cells for 1 h with 
sphingomyelinase (0.5 U/ml: a treatment known to disrupt sphingomyelin, a 
component of lipid rafts) was without effect on either cholesterol content or 
taurine efflux (Fig. 4.9 A, B).  Pre-incubation of the cells with filipin (1-5 µg/ml), 
which forms filipin-cholesterol complexes in membranes, also had no effect on 
either basal- or receptor-stimulated taurine efflux (data not shown). 
 
Discussion 
 Cholesterol availability has previously been reported to modulate the 
activity of several different ion channels (Bolotina et al., 1989; Jennings et al., 
1999; Martens et al., 2000, 2001; Lockwich et al., 2000), in addition to that of 
VSOAC.  In agreement with previous studies of non-neural cells, depletion of 
cholesterol from SH-SY5Y cells by pretreatment with CD under relatively mild 
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conditions (5 mM for 10 min), facilitated the basal release of taurine in response 
to hypotonicity.  However, the more significant observation was that depletion of 
cholesterol resulted in a further potentiation of receptor-stimulated osmolyte 
efflux, such that, following CD pretreatment, a synergistic, rather than additive, 
release of taurine above controls was observed (Fig. 4.3).  The ability of 
cholesterol depletion to enhance receptor-stimulated taurine efflux was observed 
for all three receptors examined (mAChR, PAR-1 and S1P), even though they 
operate via different signal transduction mechanisms.  Although cholesterol 
depletion has been reported to alter ligand binding to cell-surface receptors 
(Burger et al., 2000), CD pretreatment of SH-SY5Y cells increased the efficacy of 
thrombin- or Oxo-M-mediated taurine release, but had no effect on agonist 
potency (Fig. 4.4).  In addition, because cholesterol depletion had no effect on 
the extent of mAChR-stimulated phosphoinositide turnover (Fig. 4.8), this result 
argues against either non-specific effects of CD or increases in second 
messenger production as causes for enhancement of receptor-stimulated taurine 
release.  Taken collectively, the results suggest that the ability of cholesterol 
depletion to potentiate receptor-stimulated osmolyte efflux occurs independently 
of any changes in either ligand binding or monitored signal transduction events 
and that the results are consistent with a modulatory role of the sterol either at 
the VSOAC channel itself, or alternatively, at an associated membrane domain. 
 Further evidence for a role of cholesterol in the regulation of receptor-
stimulated taurine efflux was obtained from experiments in which CD, complexed 
with cholesterol, was used as a donor to restore cholesterol to CD-pretreated 
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cells.  When this approach was employed, it was observed that the CD-mediated 
potentiation of both PAR-1 and mAChR-stimulated taurine release could be 
reversed when the cells were presented with a CD:cholesterol (1:8) complex 
(Fig. 4.7).  Under these conditions, cellular cholesterol concentrations were 
increased by 65% and this was accompanied by a significant inhibition (51-70%) 
of both basal- and receptor-stimulated taurine efflux. Administration of 
epicholesterol, a chiral analog of cholesterol, was similarly able to reverse the 
stimulatory effects of cholesterol depletion on taurine release, and also reduced 
efflux to below control levels.  Since administration of either cholesterol- or 
epicholesterol-CD complexes to SH-SY5Y cells did not result in any change in 
the extent of mAChR–stimulated phosphoinositide turnover, an effect of these 
sterols on signaling events appears unlikely. The more pronounced ability of 
cholesterol (than epicholesterol) to inhibit agonist-stimulated taurine efflux (61-
77% vs. 25-29%) could reflect either a more limited rate of exchange of 
epicholesterol into the cells, or alternatively, differential abilities of cholesterol 
and epicholesterol to form sterol-protein interactions (Zidovetzki and Levitan, 
2007).  Elevated cholesterol concentrations have also been reported to inhibit 
basal VSOAC activity in endothelial and intestinal 407 cells  (Levitan et al., 2000; 
Lim et al., 2006), but not in ascites cells (Klausen et al., 2006).  These results 
indicate that the degree of cholesterol regulation of VSOAC activity may be cell-
type specific. 
 One of the most salient features of volume-dependent osmolyte efflux 
monitored following receptor activation is that the threshold osmolarity for release 
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is significantly reduced, thereby allowing osmolyte release to occur at more 
physiologically relevant osmolarities (Mongin and Kimelberg, 2002; Heacock et 
al., 2004, 2006; Cheema et al., 2007).  A major conclusion to emanate from the 
present study is that cholesterol depletion can further increase this ability of 
receptor activation to facilitate osmolyte effllux and moreover, that the effect is 
most marked under conditions of isotonicity or mild hypotonicity (295 mOsM: a 
13% reduction in osmolarity, Fig. 4.6).  From these results, we conclude that 
cholesterol depletion and receptor activation can act in concert to promote 
osmolyte efflux and, by inference, cell volume regulation under conditions of 
minimal reductions in osmolarity.  A limited degree of facilitation of taurine efflux 
by thrombin in cholesterol-depleted cells was even detected under mildly 
hypertonic conditions (370 mOsM), but not under conditions of more severe 
hypertonicity, a result that indicates that removal of cholesterol permits the 
VSOAC channel to remain partially open under conditions of mild hypertonicity.  
In this context, Levitan et al., (2000) have proposed that cholesterol content 
alters the equilibrium between the closed and open states of the VSOAC, with 
cholesterol depletion favoring the existence of an open channel.  Since VSOAC, 
via the release of glutamate, another organic osmolyte, has also been implicated 
in cell-cell signaling events under isotonic conditions (Mulligan and MacVicar, 
2006), regulation of channel activity by cholesterol availability could be of 
physiological significance under conditions of both isotonicity and hypotonicity.  
Although cholesterol depletion also enhanced the basal release of taurine from 
SH-SY5Y cells in a volume-dependent manner, the stimulatory effect was less 
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marked than that observed for receptor activation and only reached significance 
at an osmolarity of 230 mOsM.  In contrast to previous studies obtained for non-
neural cells in which the stimulatory effects of cholesterol depletion on VSOAC 
activity were abrogated by larger reductions in osmolarity (Levitan et al., 2000; 
Klausen et al., 2006; Lim et al., 2006), cholesterol depletion of SH-SY5Y cells 
was observed to facilitate the basal efflux of taurine even under conditions of a 
40% reduction in osmolarity.  As observed for control cells, inclusion of DCPIB 
attenuated the increases in both basal- and receptor-stimulated efflux of taurine 
from CD-pretreated SH-SY5Y cells. Thus, the increased release of osmolytes 
from cholesterol-depleted cells is also mediated by a VSOAC. 
 The functional relationship between alterations in cholesterol content and 
VSOAC activity remains uncertain. Two major roles for cholesterol in the 
regulation of VSOAC have previously been proposed, i.e. that the channel is 
localized to lipid rafts or caveolae (Trouet et al., 1999, 2000; Ullrich et al., 2006), 
or alternatively, that cholesterol-induced changes in the biophysical properties of 
the membrane result in an altered VSOAC activity (Levitan et al., 2000; 
Romanenko et al., 2004; Byfield et al., 2006).  In SH-SY5Y cells, depletion of 
cholesterol with CD, a treatment documented to disrupt lipid microdomains 
(Brown and London, 2000; Zidovetzki and Levitan, 2007), resulted in an 
enhancement of both basal- and receptor-stimulated taurine efflux.  Although one 
interpretation of this result is that the VSOAC channel is located in a lipid 
microdomain, under a negative constraint, this explanation seems unlikely since 
preincubation of SH-SY5Y cells with either cholesterol oxidase or 
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sphingomyelinase (or filipin), conditions under which lipid rafts are also disrupted 
(Samsonov et al., 2001), did not facilitate the release of osmolytes under either 
basal- or receptor-stimulated conditions (Fig. 4.9).  Changes in the concentration 
of cell cholesterol are also documented to exert a major impact on the physical 
properties of the membrane lipid bilayer, with a reduction resulting in an increase 
in membrane fluidity, whereas elevated concentrations of cholesterol drive the 
fluid membrane bilayer into a more rigid state (Xu and London, 2000).  In SH-
SY5Y cells, the ability of cholesterol depletion to facilitate VSOAC activity, while 
cholesterol replenishment inhibits channel activity, is consistent with the 
possibility that VSOAC is regulated by changes in membrane fluidity.  This 
conclusion is strengthened by the observation that epicholesterol, a chiral analog 
of cholesterol that exhibits similar properties as cholesterol in terms of its effect 
on bulk membrane fluidity (Gimpl et al., 1997), essentially mimicked the ability of 
cholesterol to reverse the stimulation of taurine efflux elicited by cholesterol 
depletion.  In addition, although cholesterol oxidase treatment, like that of CD, 
resulted in a loss of ~50% of cell cholesterol, the oxidation product, namely 4-
cholesten-3-one, exhibits the same membrane fluidity properties as cholesterol 
(Gimpl et al., 1997) and this may account for the absence of change in either the 
basal- or receptor-stimulated osmolyte release.  The results obtained for SH-
SY5Y cells are in agreement with those previously published for endothelial cells  
(Levitan et al., 2000; Romanenko et al., 2004; Byfield et al., 2006) and are 
consistent with a change in membrane fluidity, rather than a localization of the 
channel to a lipid microdomain, being a major determinant of VSOAC activity. 
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 Alterations in cholesterol content within the central nervous system occur 
in conditions associated with genetic deficits in cholesterol synthesis/trafficking, 
such as Niemann-Pick type C, Smith-Lemli-Opitz syndrome or Tangier disease 
(Maxfield and Tabbas, 2005) and also following dietary modification (Foot et al., 
1982) or administration of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors 
(Zipp et al., 2007).  Thus changes in cholesterol content in vivo, could serve an 
important modulatory role for VSOAC and other ion channels.  In this context, it 
is relevant to note that VSOAC activity is markedly reduced in the fibroblasts of 
patients with Niemann-Pick’s disease, a condition in which cholesterol content is 
elevated (Lim et al., 2006).  The present results, obtained for SH-SY5Y 
neuroblastoma cells, are also consistent with the possibility that cholesterol 
availability, acting in concert with receptor activation, provides an additional 











Figure 4.1. Cholesterol depletion enhances both basal- and thrombin-stimulated 
taurine efflux.  (A) SH-SY5Y neuroblastoma cells were pretreated for 10 min at 37○C 
with either serum-free media (control) or with increasing concentrations of CD (1 – 5 
mM) dissolved in serum-free media.  The cells were then washed twice with 2 ml of 
isotonic buffer A and cholesterol content measured by the Amplex Red assay (See 
Methods).  Cholesterol values, calculated as µg/mg of protein, have been normalized to 
the value of cholesterol in control cells (1.0) to account for inter-experimental variation. 
**, Different from control, p<0.01 (by ordinary ANOVA followed by Dunnett’s multiple 
comparisons test).  (B, C) Cells prelabeled with [3H]taurine were treated under similar 
conditions as in (A) and then incubated in 230 mOsM buffer A in the absence (Basal) or 
presence of 1.25 nM thrombin.  Reactions were terminated after 5 min and release of 
taurine monitored.  Results are expressed as taurine efflux (percentage of total soluble 
radioactivity) and are the means ± S.E.M for 3-7 independent experiments. *, Different 
from basal control, p< 0.05; **, different from thrombin control, p<0.01 (by repeated 




















Figure 4.2. Time-course of volume-dependent taurine efflux after cholesterol 
depletion.  SH-SY5Y neuroblastoma cells that had been prelabeled with [3H]taurine 
were pretreated for 10 min at 37○C with serum-free media or 5mM CD dissolved in 
serum-free media.  The cells were then washed twice with 2 ml of isotonic buffer A and 
then incubated in 230 mOsM buffer A in the presence or absence of 1.25 nM thrombin.  
Reactions were terminated at the times indicated and taurine release measured.  
Results are expressed as basal taurine efflux (-○- without CD, -●- with CD) or thrombin-
stimulated taurine efflux (—□— without CD, —■— with CD) (percentage of total soluble 
radioactivity) and are the means ± S.E.M. for 3 independent experiments performed in 
triplicate.  *, Different from basal efflux without CD, p<0.05; **, different from thrombin-
stimulated efflux without CD, p< 0.05 (by repeated measures ANOVA followed by 









Figure 4.3. Cholesterol depletion facilitates taurine efflux elicited by the activation 
of multiple receptors. Cells prelabeled with [3H]taurine were pretreated for 10 min at 
37○C with either serum-free media or 5mM CD.  The cells were then washed twice with 2 
ml of isotonic buffer A and incubated in 230 mOsM buffer A for 5 min in the presence or 
absence of the receptor agonists at the concentrations indicated.  Results are expressed 
as taurine efflux (percentage of total soluble radioactivity) and are the means ± S.E.M for 
3 - 4 independent experiments. *, **, Different from without CD, p< 0.05; p< 0.01 (by 



















Figure 4.4. CD pretreatment increases agonist efficacy for taurine efflux, but not 
agonist potency.  Cells prelabeled with [3H]taurine were pretreated for 10 min at 37○C 
with either serum-free media or 5 mM CD. The cells were then washed twice with 2 ml of 
isotonic buffer A and incubated in 230 mOsM buffer A in the presence or absence of (A) 
thrombin or (B) Oxo-M at the concentrations indicated.  Reactions were terminated after 
5 min and taurine efflux was monitored.  Results are expressed as percentage of total 
soluble radioactivity released and are the means ± S.E.M. for 3-4 independent 
experiments.  Where error bars are not shown, the values fell within the symbol. The 
calculated EC50 values for stimulated taurine efflux for thrombin were 105 pM and 60 pM 
(in the absence and presence of CD, respectively) and 0.9 µM and 1.9 µM for Oxo-M (in 
the absence and presence of CD, respectively).  At all concentrations of either thrombin 
or Oxo-M, taurine release was greater for the CD-pretreated cells than for control cells 
(p<0.05: by ordinary- [thrombin] or repeated measures [Oxo-M] ANOVA followed by 

























Figure 4.5. Blockade of VSOAC with DCPIB attenuates the CD-induced facilitation 
of taurine release.  Cells prelabeled with [3H]taurine were pretreated with 20 µM DCPIB 
in either serum-free media or 5 mM CD for 10 min before incubation in hypotonic buffer 
A (230 mOsM) containing 20 µM DCPIB in the absence (open bars) or presence (black 
bars) of 1.25 nM thrombin.  Reactions were terminated after 5 min and efflux of taurine 
monitored.  Results are expressed as taurine efflux (percentage of total soluble 
radioactivity) and are the means ± S.E.M. for 3 independent experiments, each 
performed in triplicate. **, Different from respective controls, p<0.01; # different from 
basal plus CD, p<0.01; ## different from thrombin alone, p<0.01; † different from 
thrombin plus CD, p< 0.01 (by repeated measures ANOVA followed by Dunnett’s 







Figure 4.6.  Osmolarity dependence of basal- and thrombin-stimulated taurine 
efflux under control and cholesterol-depleted conditions.  Cells prelabeled with 
[3H]taurine were first pretreated for 10 min at 37○C with either serum-free media (open 
symbols) or 5 mM CD (closed symbols).  The cells were then washed twice with 2 ml of 
isotonic buffer A and incubated in (A) hypo-osmolar buffers for 5 min or (B) 
hyperosmolar buffers for 10 min, at the osmolarities indicated in the absence (basal, ○, 
●) or presence (∆, ▲) of 1.25 nM thrombin.  Results are expressed as taurine efflux 
(percentage of total soluble radioactivity) and are the means ± S.E.M. for 3 independent 
experiments, each performed in triplicate.  *, Different from basal, p< 0.05 (by repeated 
measures ANOVA followed by Dunnett’s multiple comparison test); #, different from 
isotonic 340 mOsM, p< 0.01;  ##, different from thrombin-stimulated efflux without CD, 













Figure 4.7. Enhancement of taurine efflux by CD is reversed by the re-addition of 
cholesterol or epicholesterol. Cells that had been prelabeled overnight with [3H]taurine 
were treated with either serum-free media or 5 mM CD for 10 min at 37○C.  The cells 
were washed once with 2 ml of isotonic buffer A and incubated with serum-free media, 
cholesterol: CD (1:8 ratio) or epicholesterol:CD (1:8 ratio) for 1 h.  The cells were 
washed once more with isotonic buffer A before incubation for 5 min with hypotonic 
buffer A (230 mOsM) in the absence (open bars) or presence of thrombin (1.25 nM; 
black bars) or Oxo-M (100 µM; grey bars).  Results are expressed as taurine efflux 
(percentage of total soluble radioactivity) and are the means ± S.E.M. for 3-9 
independent experiments, each performed in triplicate. **, Different from control efflux in 
the absence of CD, p<0.01;  #, different from basal efflux plus CD, p<0.05; ##, different 
from thrombin-stimulated efflux, p<0.05; † different from Oxo-M-stimulated efflux after 
CD, p< 0.01 (by ordinary ANOVA followed by Dunnett’s multiple comparisons test).  (B) 
Cells were treated the same way and cholesterol content measured by Amplex Red kit.  
Results (means ± S.E.M) are normalized as cholesterol: protein ratios from 4 
independent experiments.  *, **, Different from control cells, p< 0.05, p<0.01 (by 





























Figure 4.8. Alterations in cholesterol content or replacement with epicholesterol 
do not modulate mAChR-stimulated phophoinositide turnover.  Cells that had been 
prelabeled for 48 h with [3H]inositol were (A) pretreated with either serum-free media or 5 
mM CD for 10 min or (B) pretreated with serum-free media or CD for 10 min followed by 
incubation with a cholesterol:CD complex (1:8) for 1 h or (C) pretreated with serum-free 
media or CD for 10 min followed by incubation with an epicholesterol:CD complex (1:8) 
for 1 h.  The cells were then washed with isotonic buffer A and incubated for 10 min in 
hypotonic buffer A (230 mOsM) in the presence or absence of Oxo-M (100 µM).  
Reactions were terminated by the addition of trichloroacetic acid and the accumulation of 
radiolabeled inositol phosphates (IP) was monitored as an index of stimulated 
phosphoinositide turnover.  Results are expressed as inositol phosphate (IP) release/ 
total soluble radioactivity in cell lysates (IP/lysate; dpm %) and are the means ± S.E.M. 
for 3 - 4 independent experiments. **, Different from respective controls, p< 0.001 (by 

















Figure 4.9. Pretreatment with cholesterol oxidase or sphingomyelinase has no 
effect on basal- or receptor-stimulated taurine efflux.  Cells that had been prelabeled 
overnight with [3H]taurine were treated with either serum-free media, 0.5 U/ml 
sphingomyelinase or 1 U/ml cholesterol oxidase for 1 h at 37○C.  The cells were then 
washed twice with 2 ml of isotonic buffer A and incubated in hypotonic buffer A (230 
mOsM) for 5 min in the absence (open bars) or presence of either thrombin (1.25 nM; 
black bars) or Oxo-M (100 µM; grey bars).  Results are expressed as taurine efflux 
(percentage of total soluble radioactivity) and are the means ± S.E.M. for 3 - 5 
independent experiments.  (B) Unlabeled cells were treated as above and cholesterol 
content measured by Amplex Red kit.  Results (means ± S.E.M) are normalized as 
cholesterol: protein ratios from 3 independent experiments, each performed in triplicate. 
**, Different from control cells, p<0.05 (by ordinary ANOVA followed by Dunnett’s 
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As the extent of cell swelling in the brain is constrained by the encasing 
skull, pathological conditions that disturb cell volume homeostasis can severely 
compromise neural function and survival. In an attempt to counteract the 
osmolarity disturbance and restore normal cell volume, neural cells initiate 
volume regulatory mechanisms by modifying the concentration of osmotically 
active osmolytes (Mulligan and MacVicar, 2006).  
Although the general characteristics of swelling-induced osmolyte release 
have been extensively studied, only recently has evidence emerged to indicate 
that certain pharmacologically distinct receptors are able enhance the regulatory 
processes.  While previous studies have demonstrated the ability of a number of 
receptors to modulate VSOAC activity and osmolyte efflux from non-neural cells, 
at the initiation of this thesis only two distinct receptor agonists (ATP and Oxo-M) 
had been extensively characterized to enhance the efflux of organic osmolytes 
from astrocytes or neuroblastoma cells. Studies reported in this dissertation 
highlight the potentially important ability of GPCRs to potentiate osmolyte efflux 
through the VSOAC in response to hypo-osmotic stress from neural cells. The 
discovery that thrombin, acting via its PAR-1 receptor, could potentiate the 
release of both inorganic Cl- and the organic osmolyte, taurine, in response to 
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pathological (>30%) or physiological (5-10%) reductions in osmolarity adds to the 
now growing list of receptors known to modulate this response. One notable 
feature in the study using 1321N1 astrocytoma cells (Chapter 2) was that 
thrombin-stimulation was able to substantially enhance osmolyte release even 
under isotonic conditions (340 mOsM; based on the osmolarity of the cell growth 
media). This suggests that the VSOAC that primarily responds to reductions in 
osmolarity is partially open in astrocytoma cells and may contribute to neural cell 
communication between glia and neurons. This is important as previously 
speculated for primary cultures of astrocytes (Mongin and Kimelberg, 2002). 
ATP, via its purinergic receptors, is known to enhance glutamate release even 
under physiological reductions in osmolarity, implicating the role of VSOAC and 
osmolyte efflux in crosstalk between synapses and neuronal excitability (Mongin 
and Kimelberg, 2002; Mulligan and MacVicar, 2006). The observation that 
receptor-stimulation (PAR-1 and mAChR) can lower the threshold osmolarity or 
“set-point” for osmolyte efflux (Chapter 2 and 3), suggests that these receptors 
may be modulating the volume-sensing and regulatory processes such that the 
cells respond immediately to hypo-osmotic stress. Together these data suggest 
that the processes in vivo whereby cells regulate volume may be under neuro-
humoral control and are more dynamic than previously considered.  
Experiments detailed in this thesis suggest that sub-nanomolar 
concentrations of thrombin known to be neuroprotective (Vaughan et al., 1995; 
Striggow et al., 2000) play an important role in potentiating osmoregulatory 
mechanisms in the CNS. Recently a role for thrombin in osmoregulation gained 
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further support from the demonstration that thrombin causes a decrease in the 
expression of the water selective channel, AQP 4, through a protein kinase C- 
dependent mechanism in primary astrocytes (Tang et al., 2007). These studies, 
along with studies in AQP4 knockout mice (Manley et al., 2000; Papadopoulos et 
al., 2004), could collectively suggest that thrombin is involved in the physiological 
as well as the pathological process of cerebral edema. Further studies in PAR-1 
knockout mice may provide a means for investigating thrombin signaling in the 
nervous system and its role in osmoregulation. 
One feature common to all four receptors in SH-SY5Y neuroblastoma 
cells (mAChR, PAR-1, S1P and LPA) now implicated in regulating VSOAC 
activity, is that their activation leads to the release of intracellular stores of Ca2+ 
and PKC activation.  However, no simple relationship exists between the 
magnitude of receptor-mediated increases in [Ca2+]i and the extent of osmolyte 
release. For example, the rank order of efficacy for Ca2+ mobilization (Oxo-M > 
LPA > thrombin > S1P) differs considerably from that of osmolyte release 
(thrombin> S1P > Oxo-M > LPA). One possibility is that each receptor is linked to 
changes in [Ca2+]i via an activation of phospholipase C. However, although 
thrombin enhances phosphoinositide turnover in 1321N1 astrocytoma, this is not 
the case in SH-SY5Y neuroblastoma cells, suggesting that another signaling 
mechanism for calcium mobilization is involved. Thus, although the mechanism 
for a rise in [Ca2+]i remains to be determined, the experiments indicate that 
osmolyte release can be triggered by Ca2+-mobilizing receptors that operate via 
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PLC-coupled (e.g., mAChR) or PLC-independent mechanisms (e.g., thrombin, 
S1P and LPA). 
Experiments in this thesis also provide evidence for the involvement of 
PKC activity in the modulation of receptor-mediated osmolyte release. Thrombin- 
and Oxo-M- stimulated taurine release share this property, as is evident from the 
ability of chelerythrine, a PKC inhibitor, to partially inhibit organic osmolyte efflux 
response. However an interesting observation in this thesis is the differential 
regulation of release of the inorganic osmolyte, Cl-, from the organic osmolyte, 
taurine, by Ca2+ and PKC after PAR-1 or mAChR activation (Chapter 3). In 
contrast to receptor-stimulated taurine efflux that is significantly inhibited by 
removal of Ca2+ and PKC (Fig 3.8 and 3.11), Cl- efflux (125I- used as a tracer) in 
response to receptor stimulation was much less affected. These results could 
have two implications. The first is that the two receptors could activate a 
signaling pathway upstream of Ca2+ or PKC that may preferentially regulate the 
release of Cl- rather than the organic osmolytes. Alternatively, the presence of 
separate VSOAC channels or existence of different isoforms of the channel 
activated by the GPCRs could account for these results. This possibility has been 
previously suggested for cell lines such as hepatoma, HeLa, epithelial and 
mammary tissue (Stutzin et al., 1999; Shennan and Thomson, 2000; Junankar et 
al., 2002). In Chapter 3, the kinetic and pharmacological analysis of the release 
of the two osmolytes (Cl- and taurine) suggests the mediation of a common 
channel, especially considering the data obtained with DCPIB, an inhibitor 
considered to be most specific, yet identified for swelling activated Cl- current 
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(Abdullaev et al., 2006). However caution in interpretation is still warranted due to 
the lack of knowledge of the mechanism of inhibition of these blockers and the 
unknown molecular identity of VSOAC.  
Results obtained in Chapter 4 represent a new line of investigation on the 
role of cholesterol in modulating VSOAC activity. Previous studies suggest that 
VSOAC can be regulated by cholesterol either by changes in the physical 
properties of the membrane (Romanenko et al., 2004), caveolae/lipid rafts 
(Ullrich et al., 2006), or recruitment by cholesterol containing vesicles (Lim et al., 
2006). In this thesis, I provide evidence that cholesterol depletion further 
potentiates the receptor-stimulated taurine efflux in SH-SY5Y neuroblastoma 
cells, mainly due to an influence on the biophysical properties of the membrane. 
Cholesterol is one of the major lipid components of mammalian membranes, 
therefore, an increase in cholesterol content restricts the motion of phospholipids 
resulting in lipid ordering and decrease in membrane fluidity (Xu and London, 
2000). Conversely, a reduction in cholesterol content increases membrane 
fluidity. My studies, which demonstrate a potentiation of the organic osmolyte 
efflux response with decreasing cholesterol content, and an inhibition of taurine 
release with an increased cholesterol content, are consistent with the proposal 
that changes in membrane fluidity regulate the ability of receptor activation to 
enhance osmolyte release. Although compartmentation of signaling proteins in 
lipid rafts or caveolae might provide a mechanism of regulation based on the 
proximity of VSOAC and second messengers, my data suggest that this is not 
the case in SH-SY5Y neuroblastoma cells since monitored cell signaling events, 
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such as phosphoinositide turnover, appeared to be unchanged by cholesterol 
depletion or repletion. Furthermore, my results show no change in PAR-1 or 
mAChR agonist potency by cholesterol depletion suggesting that the effects 
observed with cholesterol cannot be attributed to alterations at the receptor level, 
as previously observed for oxytocin, neurokinin and 5-hydroxytryptamine 
receptors (Burger et al., 2000). 
Methyl-ß-Cyclodextrins (CDs) serve as important tools to remove or 
deliver cholesterol to cells. However it is important to note that the degree of 
cholesterol depletion may differ significantly between cell types even when 
comparable CD concentrations and exposure times are applied. Short (2-10 min) 
exposure and/or low mM concentrations are thought to preferentially remove 
cholesterol from lipid rafts (Zidovetski and Levitan, 2007). Although only a limited 
amount of information is available about the rate of transfer of sterols back into 
cells, substitution of cholesterol with its structural analogs is considered a strong 
tool to discriminate between specific and non-specific effects of cholesterol. 
Epicholesterol differs from cholesterol only in the rotational angle of hydroxyl 
group at position 3 and due to its similar biophysical properties on the 
membrane, this analog mimics the ability of cholesterol to reverse the 
enhancement induced by cholesterol depletion. However, the possibility of a 
change in the cellular distribution of cholesterol, sterol-protein interactions or 
accompanied cytoskeletal changes cannot be excluded as additional factors in 
the modulation of VSOAC function. 
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The central nervous system is particularly enriched in cholesterol.   
Alterations in cholesterol content occur not only in conditions associated with 
disorders of cholesterol metabolism or intracellular cholesterol transport, such as 
Niemann-Pick type C, Smith-Lemli-Opitz syndrome or Tangier disease (Maxfield 
and Tabbas, 2005) but also under conditions of dietary modification (Foot et al., 
1982).  My results raise the possibility that changes in cholesterol content could 
further serve an important modulatory role in the regulation of VSOAC under both 
isotonic and hypotonic conditions. In this context it should be noted that VSOAC 
activity is markedly reduced in fibroblasts of patients with Niemann-Pick C, a 
disease in which cholesterol content is increased (Lim et al., 2006). 
Efforts to understand the mechanisms of regulatory volume decrease 
have yielded multiple factors that contribute to potentiating the osmolyte efflux 
response. This dissertation provides evidence that the activation of PAR-1 and 
mAChRs can enhance osmolyte efflux which is mediated through the VSOAC. 
An increased mobilization of Ca2+ and PKC activity are pre-requisites for the 
release of organic osmolyte but less so for the efflux of Cl-, a result which 
suggests that the release of these two classes of osmolytes is differentially 
regulated. Furthermore, alteration in the membrane fluidity characteristics of the 
plasma membrane can further modulate the receptor-mediated release of 
osmolytes (Fig. 5.1). The novel role of PAR-1 in osmoregulation adds to the 





Relevance and Future Directions 
The relevance of these studies needs to be considered in terms of both 
therapeutic and pathological implications in the brain. Enhancement of VSOAC 
activity may not only potentiate the release of non-perturbing organic osmolyte 
such as taurine, but also the release of glutamate, which at high concentrations 
can be excitotoxic. However, the occurrence of swelling-activated channels in 
non-stimulated cells suggests a fundamental role for this current even under 
physiological conditions. Furthermore, since hypotonic cell swelling is 
accompanied by a reduction in active taurine re-uptake as well as regulation of 
K+ channels, attention also needs to be given to mechanisms that terminate the 
volume-regulatory response. Experiments in this dissertation outline mechanisms 
for response to acute hypotonic exposure, therefore studies investigating 
prolonged as well as gradual hypotonic exposure effects on the expression of 
enzymes, cellular signaling systems and volume-sensitive transporters need to 
be conducted. 
Future studies also need to prove the correlation of the GPCR-stimulated 
osmolyte efflux to RVD by measurement of cell volume. Real time images of 
changes in cell volume may not only contribute to the understanding of the 
kinetics of volume correction but may also provide some evidence for the 
localization of volume shifts between dendritic processes and/or cell nucleus and 
the intracellular dynamics of this regulatory process.   
In spite of more than a 30 year history on the study of cell volume 
regulatory mechanisms, the nature of the primary volume sensor as well as the 
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identity of VSOAC remain elusive. Each of the candidates proposed for the role 
has its pros and cons. Although it is a universal and evolutionary ancient 
structure, variations in volume-sensitive pathways in different cell types has 
made progress difficult in this field. Solving whether or not this diversity in the 
properties of the osmo-dependent anion fluxes reflects the heterogeneity of 
volume-sensitive anion channels in mammalian cells will require the molecular 
identification of the channel(s) involved. 
To accelerate the progress in the field of osmoregulation it seems critical 
to also limit studies to well-characterized established cell models with concurrent 
measurement of Cl- current by patch-clamp, organic osmolyte efflux and volume 
change. Important information may also be obtained using molecular biological 
approaches in genetically characterized species such as Caenorhabditis elegans 
and/or zebrafish (Denton et al., 2005; Yin et al., 2007). Useful information and 
insights may be obtained by experimental techniques such as microarray or 
proteomics. It will also be important to carry out definitive experiments directed at 
establishing whether ClC proteins are candidates for VSOAC. This issue is all the 
more important as several proteins have been assigned as the swelling-activated 
Cl- channel, resulting in confusion in the Cl- channel field for many years (Jentsch 
et al., 2002).  
In addition, it should be noted that although taurine can have agonist 
properties at both GABAA and glycine receptors (Hussy et al., 1997), the role(s) 
of taurine in the brain, besides serving as a volume regulatory osmolyte, is still 
not clear. However, there is an emerging body of data suggesting the importance 
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of organic osmolytes in protein folding and stability (Ignatova and Gierasch, 
2006; Lambert and Draper, 2007) cardiomyopathy and developmental disorders 
(Warskulat et al., 2007). The swelling activated Cl- channels have also been 
suggested to play a role in tumor cell migration and cell cycle progression (Olsen 
et al., 2003), apoptosis (Okada et al., 2006), spermatozoa maturation and fertility 
(Yeung et al., 2006) and aqueous humour secretion (Do and Civan, 2006). 
Changes in cell volume also occur upon ischemic stroke, hypoxic insults, diabetic 
neuropathy and spreading depression which further emphasize the importance of 
studying swelling-activated Cl- and organic osmolyte release pathways (Hoffman 
and Dunham, 1995; Kimelberg et al., 2006). The discovery that sub-nanomolar 
concentrations of thrombin can regulate osmolyte efflux from neural cells also 
lays ground for future experiments to study the role of thrombin in reducing brain 
swelling after intra-cerebral hemorrhage and injury. 
 Understanding the issues regarding the physiological, pathophysiological 
and pharmacological factors that either impair, or enhance volume regulatory 
processes, can help in the design of therapies that alleviate the neurological 










































Figure 5.1. Schematic of mechanisms regulating osmolyte efflux from 
neural cells. In this dissertation (1) PAR-1 and mAChR receptors potentiate 
inorganic and organic osmolyte efflux through the VSOAC. (2) A rise in Ca2+ and 
PKC activity are pre-requisites for this receptor-stimulated osmolyte efflux 
response and can differentially regulate the two osmolytes. (3) Membrane fluidity 
further enhances receptor-stimulated osmolyte release. Dotted lines represent 
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